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Terpenoids, also known as isoprenoids or terpenes, are a large class of natural 
products found in nearly all living organisms (Oldfield and Lin, 2012). Over 60,000 
terpenoid structures have been identified from natural sources making them one of the 
largest classes of natural products known (Köksal et al., 2011; Berthelot et al., 2012). 
Terpenoids are perhaps most familiar to us as major components of essential oils 
produced by various aromatic plants, tree resins such as turpentine, or as cholesterol 
found in animal cell membranes. Essential oils are composed of mixtures of volatile 
compounds which are produced by physical processes such as distillation or pressing 
from the organisms producing them. Due to their volatile nature along with a wide 
variety of scents and flavors terpenoids are important ingredients in the cosmetic and 
flavor industries (Schmidt, 2010). It is the purpose of this thesis to investigate aspects of 
plant terpenoid chemistry relevant to medicine.  
 
History of terpenoid chemistry 
 
 Humankind has for thousands of years made use of plants containing 
terpenoids as medicines, incenses, foods, intoxicants, and even natural rubber. Devices 
and documents that appear to resemble a water distillation apparatus have been dated 
back to ancient Mesopotamia from around 3,000 BCE. The ancient Egyptians adopted 
such primitive distillation practices however the Arabs in the middle ages are often 
credited as the inventors of distillation. Ad-Dimaschki a 13th century Arabian writer 
described the distillation of rose water and early improvements on condensation of the 
vapors. In the 15th century, German physician and scientist Hieronymus Brunschwyk in 
his book Liber de Arte Distillandi (The true art to distill) described the production of 25 
essential oils (Figure 1). It should be noted that many of the products of such early 
distillation practices would not be considered essential oils but rather water or alcohol 
solutions enriched with volatile compounds (Schmidt, 2010). The medicinal use of 
aromatic plants is recorded in ancient herbal texts such as De Materia Medica written 
by the Greek herbalist Pedanius Dioscorides in the first century CE. Resins such as 
myrrh, from Communphora and Balsamodendron species as well as sandalwood oils 
from Santalum species have been used as far back as ancient Egypt for embalming and 
cleansing rituals. Aromatic plants are also featured in both traditional Chinese medicine 
and Ayurvedic medicine (Maffei et al., 2011). Systematic investigations into selection 
criteria of medicinal plants suggest that smell and taste are important characteristics for 
incorporation of a plant into traditional medicine systems (Leonti et al., 2003).  
 
Modern terpenoid chemistry began in the 1800’s. The German chemist Otto 
Wallach who was awarded the Nobel Prize in chemistry in 1910 for his achievements in 
the structure elucidation of monoterpenoids is often regarded as the father of terpenoid 
chemistry. Wallach began researching terpenoids while working under the direction of 
another Nobel Prize laureate, August Kekulé in Bonn, Germany (Christmann, 2010). At 
the time hydrocarbons isolated from plant essential oils with the molecular formula 
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C10H16 which stayed liquid even at low temperatures were known as terpenes, a term 
coined by Kekulé due to their presence in turpentine oil. Compounds with the molecular 
formulas C10H16O or C10H14O containing an alcohol or a ketone respectively and could 
be crystallized or precipitated as solids were known as camphors (Kubeczka, 2010). 
Through the use of distillation techniques, particularly vacuum and fractional 
distillation, Wallach and his contemporaries were able to isolate individual essential oil 
components. By synthesizing terpenoid derivatives which could be crystallized and 
physical properties such as melting point, optical rotation, boiling point etc., 
characterized a systematic way of identifying terpenoids was developed. It was also 
discovered that natural terpenoids could be converted into other natural terpenoids. This 
sort of chemistry made it possible for quality control of natural essential oils and for the 
development of the synthetic fragrance and flavor industry. Furthermore, this research 
revealed that plants within the same genus could produce essential oils of different 
composition and that species taxonomically far apart could produce the same 
compounds (Wallach, 1910).  
 
Figure 1. Inside title page of Hieronymus Brunschwyk’s Liber de Arte Distillandi. 
Image downloaded from National Library of Medicine website 
(http://www.nlm.nih.gov).  
 
In 1887 Wallach proposed that monoterpenoids were constructed from two 




by the work of L. Ruzicka, in Zurich, through the structure elucidation of higher 
terpenes for which he also won the Nobel Prize in 1939 (Kubeczka, 2010). Ruzicka 
described the main terpene chemical classes as monoterpenoids composed of two 
isoprene units, sesquiterpenes three isoprene units (C15), diterpenes four isoprene units 
(C20), and triterpenes six isoprene units (C30) (Ruzicka, 1953). We now know that 
hemiterpenoids made up of a single isoprene unit (C5), tetraterpenes (C40), as well as 
isoprenoid polymers with thousands of units such as rubber are also classes of 
terpenoids (Berthelot et al., 2012). Since the development of chromatographic 
techniques and nuclear magnetic spectroscopy (NMR) in the 2nd half of the 20th century 
the isolation and structure elucidation of thousands of terpenoids has been 
accomplished. Through improvements in analytical techniques such as gas 
chromatography (GC), mass spectrometry (MS), GC and MS in tandem (GC-MS), and 
high performance liquid chromatography (HPLC) identification and quantification of 
terpenoids from natural sources has become routine. 
 





 The isoprene used in the biosynthesis of terpenoids consists of isopentyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). The enzyme isopentyl 
diphosphate isomerase (IDI), also known as IPP isomerase, converts IPP to DMAPP in 
a reversible isomerization reaction, regulating the pool of these 2 metabolites (Figure 3) 
(Berthelot et al., 2012). The mevalonate (MVA) pathway, discovered in the 1950’s, was 
the first biosynthetic pathway elucidated that lead to IPP and DMAPP. The MVA 
pathway was first identified in yeast and mammals (Rodrı́guez-Concepción and 
Boronat, 2002). The MVA pathway is located in the cytosol of most eukaryotes, 
archaebacteria, as well as some gram positive and gram negative bacteria (Oldfield and 
Lin 2012; Berthelot et al., 2012). However in the 1990’s, another pathway the 2-C-
methyl-D-erythritol 4 phosphate (MEP) pathway was discovered. The MEP pathway is 
known to occur in the plastids of terrestrial plants, algae, some protozoa such as malaria 
parasites, and many eubacteria including Escherichia coli (Phillips et al., 2008). Both 
the MVA and MEP pathways leading to IPP and DMAPP are shown in Figure 4.  
 
Terpenoid biosynthesis begins with the condensation of IPP and DMAPP, 
except in the case of the hemiterpenoids. The reaction occurs through a 1’-4 so called 
“head to tail” process beginning with the ionization of DMAPP to remove the 
diphosphate group forming a carbocation intermediate. The carbocation through 
nucleophilic attack with double bond in IPP and removal of H+ forms geranyl 
diphosphate (GPP). Geranyl diphosphate can be further condensed with IPP to farnesyl 
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diphosphate (FPP), and again to geranylgeranyl disphosphate (GGPP) (Figure 5). 
Geranyl diphosphate, FPP, and GGPP are the precursors to the C10 monoterpenoids, C15 
sesquiterpenoids and C20 diterpenoids respectively. Both FPP and GGPP can also be 
condensed in a 1’-2,3 so called “head to head” manner to form C30 triterpenoid and C40 
tetraterpenoid precursors. The C30 is used in plants mainly for the production of sterols 
from squalene while C40 for the production of carotenoids from phytoene (Figure 6) 
(Oldfield and Lin, 2012; Chen et al., 2011). Monoterpenoids, diterpenoids, and 
tetraterpenoids are mainly synthesized by the MEP pathways while sesquiterpenoids 
and triterpenoids are mainly synthesized by the MVA pathway, although there are 
exceptions and cross talk between the 2 pathways occurs (Rodrı́guez-Concepción and 
Boronat, 2002; Maffei et al., 2011). The hemiterpene (C5) isoprene is also 
biosynthesized in plants mainly from DMAPP by loss of diphosphate group. Terpenoids 
and their precursors can also be used to post translationally modify proteins (Oldfield 
and Lin, 2012).   
 
Figure 3. Isopentyl diphosphate isomerase mediated isomerization of IPP and DMAPP. 
 
 
Terpene synthases, also known as terpene cyclases, catalyze the reactions 
which lead to the wide variety of terpenoid structures. Typically terpene synthases 
function by ionizing the respective terpenoid precursor, removing the phosphate groups 
leading to the formation of carbocation intermediates which undergo cyclizations, 
hydride shifts, or other rearrangements. The reaction is terminated by nucleophile 
capture often with water or deprotonation (Figure 7). An interesting aspect of terpene 
synthases is that a single enzyme can sometimes produce multiple terpenoid products 
and enantiomers (Chen et al., 2004; Degenhardt et al., 2009; Chen et al., 2011). 
Terpenoid structures can then be further enzymatically altered by hydroxylation, 
oxidation, reduction, isomerization, further cyclization, or be used as substrates to 
modify other compound classes (Dewick, 2002; Sell, 2010). Cytochrome P450 enzymes 
are an important class of proteins known to further modify terpenoids skeletons after 





Figure 4. MVA and MEP pathways. 1 Acetyl CoA, 2 acetoacetyl-CoA, 3 3-hydroxy-3-
methylglutaryl-CoA, 4 mevalonate, 5 mevalonate-5-phosphate, 6 mevalonate-5-
diphosphate, 7 pyruvate, 8 D-glyceraldehyde 3-phosphate, 9 1-deoxy-D-xylulose 5-
phosphate, 10 2-C-methyl-D-erythritol 4-phosphate, 11 4-(cytidine 5’-diphospho)-2-C-
methyl-D-erythritol, 12 2-C-methyl-D-erythritol 2,4-cyclodiphosphate, 13 (E)-4-
hydroxy-3-methylbut-2-enyl diphosphate. AACT: acetoacetyl-CoA thiolase, HMGS: 3-
hydroxy-3-methylglutaryl-CoA synthase, HMGR: 3-hydroxy-3-methylglutaryl-CoA 
reductase, MVK: mevalonate kinase, PMK: 5-phosphomevalonate kinase, MVD: 
mevalonate-5-diphosphate decarboxylase, DXS: 1-deoxy-D-xylulose 5-phosphate 
synthase, DXR: 1-deoxy-D-xylulose 5-phosphate reductoisomerase, MCT: 2-C-methyl-
D-erythritol 4-phosphate cytidylyltransferase, CMK: 4-(cytidine 5’-diphospho)-2-C-
methyl-D-erythritol kinase, MDS: 2-C-methyl-D-erythritol 2,4-cyclodiphosphate 
synthase, HDS: (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase, HDR: (E)-4-




Terpenoid secondary metabolites are often produced and secreted by 
specialized plant cells in anatomical structures such as glandular trichomes, secretory 
cavities, and resin ducts. Glandular trichomes are made up of groups of cells which 
form an outgrowth of the epidermis. The morphology of glandular trichomes can vary 
considerably (Figure 8) (McCaskill and Croteau, 1998). Glandular trichomes can be 
divided into two groups peltate and capitate. Peltate trichomes contain a basal cell on 
the epidermis, a stalk or neck cell, and 4-16 cells on the head which secrete terpenoids 
into a large subcuticular space. Capitate trichomes contain a smaller subcuticular space 
and typically 1-4 secreting cells (Franz and Novak, 2010). Citrus fruits secrete essential 
oils into secretory cavities surrounded by isolated cells located beneath the epicarp. 
Similar secretory cavities are found in eucalyptus leaves which are located beneath the 
epidermis (Schmidt, 2010). Pine trees produce terpenoids in layers of cells found within 
the intercellular space of their bark which can be excreted through resin ducts (Keeling 
and Bohlmann, 2006).  
 
Figure 5. Biosynthesis of important terpenoid precursors.  
 
Roles in plant physiology 
  
Certain terpenoids are ubiquitous in plants having essential functions in their 
physiology and are thus often considered part of primary metabolism. Protein 
prenylation by C15 and C20 units is important for transferring and anchoring of cytosol 
proteins to membranes. Carotenoids make up part of the photosynthetic apparatus and 
are important plant pigments. Chlorophylls contain a diterpene side chain derived from 
phytol (Figure 6). Ubiquinones, which are part of the mitochondrial electron transport 
chain and plastoquinone in the photosynthetic electron carrier chain, both contain 
polyprenyl isoprenoid units (Lohr et al., 2012). Sterols are important constituents of 
plant cell membranes and are required for various cellular processes including cell 
division, elongation, and polarity (Figure 6). Although the mechanisms of plant sterols 
function remain largely unknown. Plant sterols are also precursors to the steroid 
hormones, brassinosteroids which are involved in plant growth and development 
(Figure 6) (Boutte and Grebe, 2009). Another important group of plant hormones are 
the diterpenoid carboxylic acids known as gibberellins which act as endogenous plant 




Figure 6. Examples from terpenoid classes. 
 
 
Chemical ecology  
 
 The majority of terpenoid chemical diversity found in nature is the result of 
secondary metabolism. Plants produce terpenoids and other volatile compounds to 
interact with the surrounding environment. Volatile terpenoids from flowering plants 
can serve as important environmental cues to attract or deter pollinators. Allelopathic 
effects from a terpenoid producing plant on other plants in the environment such as 
growth inhibition or inhibition of seed germination are also known (Maffei et al., 2011). 
Terpenoids and other plant volatiles can act as defense compounds against herbivores 
by either direct action against the attacking organism or by attracting natural predators 
of herbivores (Lucas-Barbosa et al., 2011).  
 
Examples of direct terpenoid defenses against insects include the triterpene 
glycosides (eg. cardenolides) found in the latex of the milkweed Asclepias curassavica. 
The larvae of Trichoplusia ni (Lepidoptera) after feeding on A. curassavica have 
spasms resulting in immobility, taking around 3 days to recover. Aradopsis thaliana 
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genetically modified to produce large amounts of the monoterpene alcohol linalool are 
more resistant to Myzus persicae (aphids) then non-engineered plants which produce 
very low levels of linalool (Gershenzon and Dudareva, 2007). Conifer resins which 
often contain mixtures of monoterpenoids, sesquiterpenoids, and diterpenoids have been 
shown to have important roles in defending trees against bark beetles and pathogenic 
fungi (Langenheim, 1994; Keeling and Bohlmann, 2006). Saponins (triterpenoid 
glycosides) can act as detergents disrupting fungal cell membranes leading to toxicity. 
Avena strigosa an oat species which normally produces saponins has mutant varieties 
which do not produce saponins. Such plants are significantly more susceptible to fungal 
pathogens (Gershenzon and Dudareva, 2007).   
 
Figure 7. Generalized scheme showing typical reaction mechanisms of monoterpene 





 Due to the historical use of terpenoids in medicine and the evolutionary fine 
tuning of their interactions in natural systems it is no surprise that so many biological 
activities have been reported. Since there are hundreds of studies dealing with the 
biological activity of terpenoids the aim of the following sections is not to provide a 
comprehensive survey of their activity but rather to provide an overview of biological 




chapters. Throughout the rest of this thesis the focus will be on monoterpenoids, 
sesquiterpenoids, and diterpenoids. Tripterpenoids and carotenoids are excluded 
because they are not discussed or studied in subsequent chapters. The term essential oil 
will be used to refer to essential oils dominated by monoterpenoid and sesquiterpenoid 
constituents while those containing mostly phenylpropanoids or other compounds will 
not be discussed. One common chemical feature of many but not all terpenoids is their 
lipophilic nature. Due to their hydrophobic nature it is often assumed that the biological 
activity of certain terpenoids is a result of their tendency to partition into cellular 
membranes and either disrupt membrane integrity or interact with membrane bound 
proteins (Edris, 2007; Maffei et al., 2011; Solórzano-Santos et al., 2012).  
 
Figure 8. Scanning electron microscope photos of trichomes on floret surfaces of 
Tanacetum parthenium (left) and Inula britannica (right). Image generously donated by 
Dr. Slađana Todorović from Institute for Biological Research “Siniša Stanković”, 





 One of the most commonly reported biological activities of terpenoids and 
especially those found in essential oils is their in-vitro antimicrobial activity. Thymol 
and carvacrol, phenolic monoterpenoids commonly found in Thymus vulgaris and 
Origanum vulgare essential oils as well as menthol found in peppermint oils are among 
some of the best studied antimicrobial monoterpenoids (Pauli and Schilcher, 2010; 
Solórzano-Santos et al., 2012). Due to the fact that essential oils occur in mixtures and 
their chemical composition can vary so can their antimicrobial effects. This makes 
clinical trials and pharmaceutical research into essential oils difficult. For example 
rosemary oil’s minimum inhibitory concentration (MIC) against Staphylococcus aureus 
in nine in-vitro studies ranged between 20-50,000 μg/mL (Pauli and Schilcher, 2010). 
Many diterpenoids also exhibit antibacterial and antifungal activities (Hanson, 2007). 
Antiviral effects of monoterpenoids, sesquiterpenoids, and diterpenoids have also been 
reported (Sun et al., 2003; Wang et al., 2005; Buchbauer, 2010).  
 
 One reason why so many essential oils have in-vitro antimicrobial activity is 
likely due to their non-specific membrane disrupting properties. In-vitro antimicrobial 
data of terpenoids must therefore be interpreted carefully (Maffei et al., 2011). 
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Furthermore weak or strong in-vitro antibacterial data of essential oils does not always 
correlate well with in-vivo results complicating the interpretation of in-vitro data even 
further (Pauli and Schilcher, 2010). While the complex chemical profile of essential oils 
and weak to moderate antimicrobial activity makes them unlikely candidates for 
systemic treatment of infections, essential oils do have uses as topical and 
gastrointestinal antimicrobial agents as well as antiseptics (Maffei et al., 2011). Clinical 
data regarding the antimicrobial activity of essential oils is unfortunately scarce. 
Regarding topical application of essential oils studies have shown positive effects 
against Propionibacterium acnes (acne) infections from treatment with Ocimum 
gratissimum (rich in thymol) and tea tree oil (Melaleuca alternifolia). A number of 
studies have also shown promising results against topical fungal infections from various 
essential oils. However the best clinically studied use of topically administered essential 
oils is against infectious bacteria of the oral cavity. The commercial mouthrinse 
Listerine contains 1,8-cineole (cineol), menthol, and thymol as active ingredients 
(Harris, 2010).       
 
 Artemisinin, a sesquiterpene lactone found in Artemisia annua (Asteraceae) is 
an example of a potent antimicrobial terpenoid with specific activity against the malaria 
parasite, Plasmodium falciparum (Figure 9). Artemisinin and its analogues can kill most 
stages of the parasites life cycle and are currently the main treatments against malaria 
worldwide (White, 2008). The endoperoxide functionality is necessary for artemisinin’s 
antimalarial activity. Artemisinin’s mechanism of action is not entirely understood 
although there is evidence that once inside the parasite the endoperoxide can be cleaved 
by an iron source, such as Fe2+. This reaction leads to the formation of radical ion 
intermediates which bind to various proteins one of which is the sarco-endoplasmic 
reticulum Ca2+-ATPase (SERCA) thereby killing the organism (O’Neill, 2010).    
 
Inflammation and pain 
 
 Many plants containing terpenoids are used in traditional medicine for their 
anti-inflammatory and pain relieving properties. The Asteraceae family contains many 
species used traditionally against inflammatory conditions which produce sesquiterpene 
lactones. One well known example is parthenolide from Tanacetum parthenium 
commonly known as feverfew (Figure 9). The pro-inflammatory transcription factor, 
nuclear factor kappa B (NF-ΚB) is inhibited by sesquiterpene lactones which may 
explain their mechanism of action (Salminen et al., 2008). Many essential oils have 
been evaluated for anti-inflammatory and analgesic activity in a variety of cellular and 
animal models (Buchbauer, 2010). Small clinical trials performed with essential oils 
have demonstrated positive effects against dysmenorrhea (menstrual pain), infantile 
colic, traumatic or surgical joint related pain, headaches, postherpetic neuralgia, and 
irritable bowel syndrome (Harris, 2010). Important anti-inflammatory diterpenoids 
include triptolide found in the traditional Chinese medicinal plant Tripterygium 
wilfordii (Figure 9). Traditionally the plant is used in the treatment of autoimmune 
conditions. Triptolide may also exert its effects via NF-ΚB mediated mechanisms 
(Salminen et al., 2008). The labdane diterpenoid, andrographolide from Andrographis 
panuculata, exhibits anti-inflammatory effects through inhibition of pro-inflammatory 




2007). Abietane diterpenoids carnosic acid and carnosol found in Rosmarinus officinalis 
(rosemary) and Salvia officinalis (sage) also have anti-inflammatory properties. They 
have been shown to activate the peroxisome proliferator-activated receptor gamma 
(PPARγ) (Rau et al., 2006) as well as suppress pro-inflammatory responses of human 
polymorphonuclear leukocytes (Peockel et al., 2008).          
 
 Other potential protein targets of terpenoids are the transient receptor potential 
channels (TRP) also known as vanilloid or capsaicin receptors. These membrane bound 
receptors are known to be involved in sensing hot or cold temperatures and other 
noxious stimuli. Compounds such as (-)-menthol and camphor exhibit their cooling 
sensations by interacting with TRP’s (Maffei et al., 2011).  The TRP vanilloid-3 
(TRPV3) is known to be involved in skin inflammation and peripheral nerve injuries. 
Camphor and cineol not only activate the TRPV3 but desensitize the receptor after long 
term exposure which may explain their mechanism as topical analgesics (Sherkheli et 
al., 2009). Sesquiterpene dialdehyes which are pungent ingredients in certain spices also 
activate vanilloid receptors (Szallasi et al., 1998). The cannabinoid receptors, CB1 and 
CB2 are G protein coupled receptors. They are the primary targets of cannabinoids, part 
terpenoid and part polyketide compounds found in Cannabis sativa L (cannabis). The 
CB1 receptor is located primarily on central and peripheral neurons while the CB2 
receptor is located primary on immune cells. Many of the pain relieving, anti-
inflammatory, and psyschoactive effects of cannabinoids are mediated through the CB1 
and CB2 receptors (Pertwee, 2009). Interestingly the dietary sesquiterpenoid, β-
caryophyllene is a potent and selective CB2 receptor agonist with anti-inflammatory 
properties. Many herbs and spices including cannabis, cinnamon, and black pepper 
contain significant amounts of β-caryophyllene (Gertsch, 2008).  
 
Inflammation and pain 
 
 Many plants containing terpenoids are used in traditional medicine for their 
anti-inflammatory and pain relieving properties. The Asteraceae family contains many 
species used traditionally against inflammatory conditions which produce sesquiterpene 
lactones. One well known example is parthenolide from Tanacetum parthenium 
commonly known as feverfew (Figure 9). The pro-inflammatory transcription factor, 
nuclear factor kappa B (NF-ΚB) is inhibited by sesquiterpene lactones which may 
explain their mechanism of action (Salminen et al., 2008). Many essential oils have 
been evaluated for anti-inflammatory and analgesic activity in a variety of cellular and 
animal models (Buchbauer, 2010). Small clinical trials performed with essential oils 
have demonstrated positive effects against dysmenorrhea (menstrual pain), infantile 
colic, traumatic or surgical joint related pain, headaches, postherpetic neuralgia, and 
irritable bowel syndrome (Harris, 2010). Important anti-inflammatory diterpenoids 
include triptolide found in the traditional Chinese medicinal plant Tripterygium 
wilfordii (Figure 9). Traditionally the plant is used in the treatment of autoimmune 
conditions. Triptolide may also exert its effects via NF-ΚB mediated mechanisms 
(Salminen et al., 2008). The labdane diterpenoid, andrographolide from Andrographis 
panuculata, exhibits anti-inflammatory effects through inhibition of pro-inflammatory 
mediators tumor necrosis factor α (TNF-α) and interleukin-12 (Figure 9) (Hanson, 
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2007). Abietane diterpenoids carnosic acid and carnosol found in Rosmarinus officinalis 
(rosemary) and Salvia officinalis (sage) also have anti-inflammatory properties. They 
have been shown to activate the peroxisome proliferator-activated receptor gamma 
(PPARγ) (Rau et al., 2006) as well as suppress pro-inflammatory responses of human 
polymorphonuclear leukocytes (Peockel et al., 2008).          
 
Figure 9. Structures of biologically active terpenoids. 
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terpenoid and part polyketide compounds found in Cannabis sativa L (cannabis). The 
CB1 receptor is located primarily on central and peripheral neurons while the CB2 
receptor is located primary on immune cells. Many of the pain relieving, anti-
inflammatory, and psyschoactive effects of cannabinoids are mediated through the CB1 
and CB2 receptors (Pertwee, 2009). Interestingly the dietary sesquiterpenoid, β-
caryophyllene is a potent and selective CB2 receptor agonist with anti-inflammatory 
properties. Many herbs and spices including cannabis, cinnamon, and black pepper 





Cytotoxic, antitumor, and anticancer  
 
 In the following section cytotoxic compounds will refer to compounds which 
inhibit cancer cells in-vitro, antitumor to those which inhibit tumor growth in-vivo, and 
anticancer to those being used to treat cancer in humans. An important anticancer 
diterpene is taxol, also known as paclitaxel isolated from the bark of Taxus species 
(Figure 9). Taxol is used in the treatment of a variety of cancers such as ovarian, breast, 
and lung cancer (Wang et al., 2005). The anticancer effects of taxol are due to its ability 
to promote polymerization of tubulin into stable microtubules, which thereby prevent 
mitosis. Structure activity relationships of taxols anticancer properties revealed that the 
oxetane ring and aromatic substituents are important for the drugs activity (Kingston, 
1994). Many other diterpenoids also exhibit cytotoxic or antitumor properties (Hanson, 
2007). Interestingly many of the same diterpenoids mentioned above as having anti-
inflammatory activity also have cytotoxic and antitumor activities. Andrographolide has 
antitumor properties which may also be mediated by inhibition of NF-ΚB (Gunn et al., 
2011; Kuttan et al., 2011). Carnosic acid and carnosol have cytotoxic and antitumor 
properties (Johnson, 2011; Ngo et al., 2011).  
 
Many sesquiterpenoids have been reported to have cytotoxic activity 
(Modzelewska et al., 2005). Sesquiterpene lactones are among the most well studied 
cytotoxic sesquiterpenoids. Extensive structure activity relationships have demonstrated 
that the α-methylene-γ-lactone moiety is often, although not always necessary for 
cytotoxicity. Through a Michael addition reaction the α-methylene-γ-lactone 
functionality can act as a nucleophile reacting with cysteine residues on proteins 
forming a protein adduct. As with anti-inflammatory activity an important target protein 
for sesquiterpene lactones cytotoxic activity is NF-ΚB. Parthenolide is an example of an 
antitumor sesquiterpene lactone containing the α-methylene-γ-lactone (Ghantous et al., 
2010). However it is important to note that the α-methylene-γ-lactone group is also 
responsible for certain sesquiterpene lactones causing contact dermatitis (Lepoittevin et 
al., 2009) and toxicity in mammals (Robles et al., 1995). Thapsigargin, from Thapsia 
garganica and Thapsia gymnesica is an example of a sesquiterpene lactone that does 
not contain an unsaturated lactone yet still possesses antitumor activity (Figure 9). The 
main mechanism of inducing apoptosis by thapsigargin is inhibition of SERCA which 
causes an increase in cytoplasmic Ca2+ leading to cell death (Drew et al., 2009). 
Artemisinin also lacks the unsaturated lactone functionality yet also exhibits anti-tumor 
activity through a similar mechanism as against malaria. Interestingly parthenolide, 
thapsigargin, and artemisinin all seem to exhibit selectively towards cancer cells in-vivo. 
Analogues of all 3 compounds are being developed as anti-cancer drugs (Ghantous et 
al., 2010).  
 
Monoterpenoids such as limonene and its main metabolite in humans, perillyl 
alcohol exhibit antitumor activities (Figure 9). Other monoterpenoid alcohols such as 
geraniol, linalool, carveol prevent tumor formation in chemically induced tumor animal 
models. Many essential oils have also been tested for cytotoxic and antitumor properties 
(Buchbauer, 2010). Despite much research in-vitro and in animals, clinical trials with 
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monoterpenoids are scarce. Perillyl alcohol has been tested in phase II clinical trials 
however no anti-cancer effects were observed in advanced ovarian, colorectal, or breast 
cancer. A reduction in tumor size was noted in a trial with recurrent malignant gliomas 
(Harris, 2010). A phase I and II trial to assess anticancer potential of limonene 
demonstrated that limonene was well tolerated however was only able to exhibit a 
partial response in one patient. The researchers note however that the dose which was 
the maximum tolerated dose for each patient may not be appropriate and suggested 
further research (Vigushin et al., 1998).  
 
Central nervous system 
 
 The most obvious effect of terpenoids can have on the central nervous system 
(CNS) is odor perception. Why exactly humans maintain the evolutionary traits which 
allow us to sense and discriminate so many volatile terpenoids is not entirely clear. 
Terpenoids are not directly linked to the nutritional value of a plant when compared to 
other plant volatiles derived from essential nutrients such as fatty acids or carotenoids. 
The antimicrobial effects of many spices containing terpenoids suggest that cultural 
preferences for certain flavors may have developed throughout history due to health 
promoting or food preservation benefits (Goff and Klee, 2006). Olfactory receptors are 
located primarily on neurons in nasal cavities. About 380 genes encode for human 
olfactory receptors. Another, approximately 400 non-functional pseudogenes can be 
found in the human genome suggesting that olfactory genes were lost throughout 
primate evolution (Niimura and Nei, 2003; Schmiedeberg, 2007). In contrast with other 
senses, olfactory information can bypass the thalamus and directly link with areas of the 
brain involved in emotion and memory such as the amygdala, frontal cortex, 
hypothalamus, and hippocampus (Kandal et al., 2000). Furthermore due to their 
lipophilic nature terpenoids are able to pass the blood brain barrier (BBB) and interact 
directly with the brain. Both mechanisms are important because odorous terpenoids can 
have a direct pharmacological action in the brain, such as interaction with a neural 
receptor, and a psychological component through the olfactory system (Heuberger, 
2010).  
 
 Essential oils used commonly in folk medicine and pure monoterpenoids have 
been demonstrated to cause sedative and stimulating effects in mice (Buchbauer et al., 
1993). Psychopharmacological effects of essential oils and pure monoterpenoids in 
animals include anxiolytic, anticonvulsant, antidepressant, and hypnotic effects (Nunes 
et al., 2010). Mechanisms of action have been investigated. Lemon oil vapor increases 
metabolism of dopamine in the hippocampus and serotonin in the prefrontal cortex and 
striatum which may explain its anxiolytic and antidepressant effects in mice (Komiya et 
al., 2006). The anticonvulsant effects of linalool may be mediated by interactions with 
NMDA receptors (Brum et al., 2001). The effects of essential oils and pure fragrances 
on human cognition have also been investigated. Examples of higher cognitive 
functions studied include alertness and attention as well as learning and memory. 
Unfortunately most studies do not report chemical composition of the essential oil under 
investigation and dose response curves are not established. Therefore it is difficult to 
draw clear relationships between essential oils and their effects on higher cognitive 





 Terpenoids can also have profound effects on human consciousness. Salvia 
divinorum is used by Mazatec traditional healers for divination. The plant is often 
chewed or smoked to produce hallucinations necessary for their healing rituals. The 
main active ingredient is salvinorin A, a neoclerodane diterpenoid (Figure 9). Salvinorin 
A is one of the most potent non-nitrogenous natural hallucinogens known with doses as 
little as 200-500 μg inducing hallucinatory experiences. The psychoactive effects of 
salvinorin A are due to its ability to act as a selective Κ-opioid receptor agonist 
(Vortherms and Roth, 2006). The cannabinoid, ∆9-tetrahydrocannabinol (THC) is the 
primary psychoactive ingredient in cannabis (Figure 9). The psychoactive effects of 
THC are mediated mainly through the CB1 receptor (Pertwee, 2009). Clinical studies 
demonstrate potential of cannabinoids and cannabis in treating chronic neuropathic 
pain, as appetite stimulants in cancer patients undergoing chemotherapy as well as 
AIDS patients, and treatment of multiple sclerosis (Amar, 2006; Hazekamp and 
Grotenhermen, 2010).    
 
Thesis outline and goals 
 
 Throughout this discussion a number of issues become apparent with regards 
to complications in the development of terpenoids and plants containing them as drugs. 
One major issue is that plants and products derived from them such as essential oils or 
extracts are often of variable or unknown chemical composition. Another issue concerns 
administration forms of volatile terpenoids. Often protocols for administering essential 
oils vary between studies and controlled dosing is difficult. Finally for many terpenoids 
the mechanisms of action and structure activity relationships are still unknown. 
Therefore the major goals of this thesis are: 
1. Investigate vaporization as an administration form for volatile terpenoids 
in various medicinal plants.  
2. Determine if plants can be standardized to produce reproducible levels of 
active components in order to improve clinical research.  
3. Isolate and study the biological activity of medically interesting 
sesquiterpenoids and diterpenoids.  
 
In chapter 2 a device designed to administer plant volatile compounds called a 
vaporizer was investigated. Some common terpenoid producing plants with medicinal 
properties were selected and tested in the device.  The essential oil content and 
terpenoid content of the vapor was analyzed with GC and GC-MS. In chapter 3, 
cannabis was used as a model plant to test the vaporizer in more detail, compare it with 
cannabis smoke, and test whether any components in the smoke or vapor altered the 
CB1 binding of THC in-vitro. In order to determine if plants producing terpenoids can 
be standardized for their chemical content cannabis was again chosen as a model plant. 
In chapter 4 a number of cannabis varieties grown in multiple batches under the same 
environmental conditions were analyzed with GC-FID and GC-MS. Multivariant data 
analysis was used to chemically classify the varieties. The reproducibility of the 
chemical profiles was determined. The plants studied in chapters 5-7 were investigated 
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as part of a larger projet to further study their biological activity and their biosynthesis 
called the Terpmed project (EU grant number 227448). Chapter 5 focuses on the 
isolation and biological activity of sesquiterpenoids from T. parthenium. The isolated 
compounds were tested as activators of a biological pathway emerging as a potential 
drug target for neurodegenerative disease, the nuclear factor E2-related factor 2 / Kelch-
like ECH-associated protein 1 pathway. This same pathway is investigated for 
diterpenoids isolated from S. officinalis in chapter 7. In chapter 6 sesquiterpene lactones 
isolated from Inula britannica were studied for their cytotoxic activity in drug 
susceptible cancer cell lines and multi drug resistant cancer cell lines. Finally chapter 8 
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In order to improve the ability to study the pharmacology of essential oils 
reproducible administration forms are needed. Vaporizers are devices that heat up plant 
material in order to release their volatile components from plant matrix for inhalation. 
In this study we analyzed the vapor produced by a vaporizing device from a selection of 
common herbs using gas chromatography. Lavandula angustifolia, Thymus vulgaris, 
Matricaria recutita, Salvia officinalis, Eucalyptus globulus, and Melissa officinalis were 
selected as model plants for this study because of their well studied essential oils. 
Lavandula. angustifolia, T. vulgaris, M. recutita, and S. officinalis all produced 
detectable (>0.1 mg/g) levels of essential oil components in the vapor. Levels of 
compounds increased with temperature. These results suggest that vaporizing devices 






Many medicinal and food plants contain volatile compounds commonly known 
as essential oils. Essential oils have many practical uses ranging from herbal medicines 
to cosmetics and foodstuffs. Aromatherapy involves inhaling volatile compounds either 
from whole plant preparations or pure essential oils for therapeutic effects or relaxation 
(Lahlou, 2004a; Lahlou, 2004b). Potential therapeutic effects of inhaled essential oils 
include antimicrobial, antiviral, anti-carcinogenic, sedative, analgesic, anxiolytic, and 
anti-inflammatory effects (Edris, 2007). Despite a long history of using essential oils the 
molecular mechanisms of action and therapeutic efficacy of many plant volatiles are 
largely unknown (Maffei et al., 2011). Although some clinical trials have been 
performed on essential oils administered in an aromatherapy setting, most have weak 
experimental designs and thus the effectiveness of such approaches is questionable 
(Yim et al., 2009; Cooke and Ernst, 2000). 
 
One approach to improve research into essentials oils is to use methodology 
that allows for controlled dosing and manipulation of the essential oil or herb under 
study. Safe and effective methods for administering essential oils may be possible with 
the use of vaporizing devices. Vaporizers are devices that heat plant material below 
combustion temperatures in order to volatilize plant compounds for inhalation, ideally 
without generating carcinogenic polynuclear aromatic hydrocarbons (PAH) associated 
with smoked plant material. The Volcano® is a sophisticated vaporizing device that 
utilizes a temperature controlled heat flow to fill a plastic bag with plant vapors. After 
filling the bag it is removed from the heat source and connected to a mouthpiece for 
inhalation. Vaporizer technology has been employed for the inhalation of cannabinoids, 
the main compounds found in Cannabis sativa in a clinical setting (Abrams et al., 
2007).  
 
The purpose of this study is to examine whether or not the volcano can 
reproducibly volatilize essential oil components found in 6 common medicinal plants. 
Gas chromatography with flame ionization detection (GC-FID) and mass spectrometry 
(GC-MS) was used to analyze the major components found in the essential oil and 
vapor of common herbs with well-known essential oils. Lavandula angustifolia 
(lavender), Thymus vulgaris (thyme), Matricaria recutita (chamomile), Salvia 
officinalis (sage), Eucalyptus globulus, and Melissa officinalis (lemon balm) were 
chosen for this study. 
 
 Thymus vulgaris is a popular herb used in cooking as well as industry. The 
essential oil has many interesting biological properties including antimicrobial, 
antifungal, and antioxidant activity. Monoterpenoids make up the majority of T. 
vulgaris essential oil with thymol being the major component as well as carvacrol, p-
cymene, and γ-terpinene (Dawidowicz et al., 2008). Both thymol and carvacrol have 
been shown to be antimicrobial against oral bacteria. When utilized in combination they 
display a synergistic enhancement of antimicrobial activity (Didry et al., 1994).  
 




foods and cosmetics as well as for its medicinal properties. Linalool is a major 
component of L. angustifolia essential oil along with eucalyptol and camphor (Da Porto 
et al., 2009). There is some clinical evidence that administration of L. angustifolia 
essential oil by aromatherapy has a significant relaxation effect (Shiina et al., 2008). 
Linalool has been shown to exhibit anticonvulsant properties (Silva Brum et al., 2001). 
Anti-inflammatory and analgesic effects have also been demonstrated in mice after 
administration of L. angustifolia essential oil (Hajhashemi et al., 2003). Anxiolytic 
effects have also been observed after the inhalation of L. angustifolia essential oils in 
rats (Shaw et al., 2007). The essential oil of S. officinalis has been shown to inhibit 
human acetylcholinesterase (AChE) and butyrylcholine esterase (BuChE) (Savelev et 
al., 2004). In a double blind clinical trial daily administration of a S. officinalis tincture 
significantly reduced cognitive impairment in patients with Alzheimer’s disease which 
may be mediated by AChE or BuChE activity (Akhondzadeh and Abbasi, 2006).  
 
Matricaria recutita is a popular herb used for a variety of minor ailments such 
as indigestion, inflammation, and for its antimicrobial action. The oil is composed of 
mostly sesquiterpenoids such as α-bisabolol, oxides of α-bisabolol, and chamazulene 
(Ganzera et al., 2006). Matricaria recutita may be helpful to women delivering birth for 
pain relief, as well as for relaxing and sedative effects (McKay and Blumberg, 2006). 
Eucalyptus globulus essential oil is mainly composed of eucalyptol a monoterpenoid 
and has been traditionally used for treatment of respiratory illnesses. The oil has 
analgesic, anti-inflammatory, and antimicrobial effects (Silva et al., 2003; Cermelli et 
al., 2008). Melissa officinalis essential oil contains the monoterpenoids citral and 
citronellal, as well as the biologically active sesquiterpenoid β-caryophyllene. The herb 
is often used for the treatment of digestive ailments and for its relaxing properties 
(Sadraei et al., 2003).  
 
Materials and Methods 
 
Chemicals and reagents 
 
All organic solvents were of analytical reagent grade and purchased from 
Biosolve BV (Valkenswaard, The Netherlands). Camphor, carvacrol, 1,8-cineol 
(eucalyptol), (+)-borneol, (-)-linalool, α-humulene (humulene), α-bisabolol, β-pinene 
and thymoquinone were purchased from Sigma Aldrich (Steinheim, Germany). β-
Caryophyllene (caryophyllene) ≥ 80% purity was purchased from SAFC Supply 
Solutions (Saint Louis MO, USA). Chamazulen, thymol and geraniol were purchased 
from Chromadex (Boulder CO, USA). Stock solutions of each compound were made in 
ethanol and stored in -20 °C.  
 
Plant materials  
 
Thymus vulgaris, L. angustifolia, M. recutita, E. globulus and M. officinalis 
were purchased from A.J. Van Der Pigge Drogisterij (Haarlem, The Netherlands). 
Salvia officinalis and an additional sample of M. officinalis were purchased from Jacob 
Hooy (Limmen, The Netherlands). Lavandula angustifolia and M. recutita were 
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supplied as dried mostly flower top material. Thymus vulgaris, E. globulus and M. 
officinalis were supplied as dried leaf material. Salvia officinalis was supplied as a 
mixture of dried leaves, flower material and stems.  
 
The volcano vaporizer and vapor collection  
 
The volcano was purchased from Storz & Bickel GmbH & Co (Tuttlingen, 
Germany). The device was used in a manner similar to that described in the manual 
provided by the manufacturer. In order to assess the effect of temperature on 
vaporization 3 different temperature settings were used 100, 150 and 200 °C. One gram 
of plant material was heated on the volcano vaporizer per sample until the bag was full, 
which took approximately 45 seconds. Once the bag was full it was removed from the 
heat flow. Vapors were collected immediately by placing the volcano mouth piece onto 
the bag and attaching it to a plastic filter holder which held a glass fiber filter (44 mm in 
diameter). Vapor was gradually sucked onto the glass fiber filter under vacuum. Each 
sample was performed in triplicate at each temperature setting with a new g of plant 
material and fresh glass fiber filter. Between each vapor collection volcano parts 
exposed to vapor and plant material were ultrasonicated for 30 seconds in EtOH, rinsed 
with EtOH and dried under a stream of air. The bag was also filled with hot air and 
emptied 3 times to ensure that no residual vapors remained from previous plant 
samples. Vapor samples were extracted by placing glass fiber filters into 15 ml falcon 
tubes and extracting the filter two times with 5 ml ethanol with 15 min of gentle shaking 
during each extraction. Both ethanol extracts were pooled to a volume total volume of 
10 ml. Samples were then centrifuged for 5 min at 2000 rpm. Supernatant was 
transferred to a glass vial for GC-MS and GC-FID analysis.  
 
Determination of plant essential oil content  
 
In order to determine the total essential oil content of each plant 20 g of plant 
material was steam distilled in a Clevenger apparatus for 3 h. Plant essential oils yields 
were determined in samples with a volume ≥ 100 μl. Essential oils were diluted in EtOH 
or hexane to various concentrations and analyzed by GC-FID and GC-MS. The density 
of each essential oil was measured by weighing 10 μl of oil on an analytical balance 
(0.01 mg). Dilutions in ethanol for thymol, linalool, eucalyptol, and geraniol ranging 
from 0.05 mg/ml to 1 mg/ml and dilutions for chamazulen, carvacrol, camphor, and α-
humulene ranging from 0.1 mg/ml to 1 mg/ml were used for quantitative analysis on the 
GC-FID. Reproducibility of the GC-FID was determined by injecting a L. angustifolia 
vapor sample (200 °C) 3 times and calculating % relative standard deviation (%RSD) of 
eucalyptol, linalool, and geraniol.  
 
Gas chromatographic analysis  
 
An Agilent gas chromatograph 6890 series with an FID detector was used for 
quantitative essential oil and vapor analysis (Agilent Technologies Inc., Santa Clara, 
CA, USA). The instrument was equipped with a 7683 series injector and autosampler, 
plus a 6890 series integrator. A Varian VA-5ms (5% phenyl polysiloxane) column with 




samples (Varian Inc., Walnut Creek, CA, USA). Injection volume was 2 μl and split 
ratio was 1:20. Temperature program was the following: injector 180 °C, FID detector 
190 °C, oven start 60 °C, oven rise 3 °C/min, oven final 180 °C, final temperature hold 
5 min and total run time was 45 min per sample.  
 
A Varian 3800 GC equipped with an 8200 autosampler and a Saturn 2000 
GC/MS ion trap mass detector was used for identification of essential oil and vapor 
components. The column was a DB-5ms with a length of 30 m, an I.D. of 0.25 mm and 
a film thickness of 0.25 µm. The split ratio was 1:20. Temperature program was the 
following; injector 230 °C, oven start 60 °C, oven rise 3 °C/min, oven final 240 °C, 
final temperature hold 5 min and total run time was 65 min. The ion trap temperature 
was 220 °C, the manifold 60 °C and the transfer line was 275 °C. Varian MS 
workstation version 6.9.1 software was used for instrument control and data analysis.  
 
Table 1: Essential oil yield and % composition. 
Plant 
 yield  
(% v/w) Essential oil components 
Thymus vulgaris   1.5 thymol (66%), cymene (12%), γ-terpinene (8%), 
carvacrol (3%), β-caryophyllene (1%) 
Lavandula 
angustifolia  
3.5 linalool (43%), eucalyptol (28%), geraniol (11%), 
γ-terpineol (5%), camphor (4%) 
Salvia officinalis  1.5 camphor (29%), thujone (29%), eucalyptol 
(12%), camphene (8%), humulene (2%) 
Matricaria recutita < 1 bisabolol oxide A (77%), bisabolol oxide B 
(11%), α-bisabolol (8%), chamazulene (< 1%)  
Eucalyptus globulus  1.7 eucalyptol (74%), α-pinene (10%) 
Melissa officinalis   < 1 citronellal (5%), β-caryophyllene (10%), 
caryophyllene oxide (32%) 
 
Results and Discussion 
 
Essential oil and vapor components were identified on the basis of their mass 
spectrum and retention time comparison with authentic standards. Table 1 shows the 
yield of essential oils from each plant as well as the major components identified. The 
approximate percentage composition of essential oil components is based on peak area 
comparison in the FID detector. Standard curves were linear in the ranges analyzed 
(Table 2). The %RSD for eucalyptol, linalool, and geraniol from a L. angustifolia 
vapour sample (200 °C) after 3 injections was 2.1%, 1.0%, and 1.0% respectively 
suggesting that the GC-FID was reproducible for analysis of essential oil components. 
Identified essential oil components present in the vapor at levels > 0.1 mg/g were 








Table 2. Response factor and r2 value for standard curves.  
Compound Response factor r2 
thymol 201550 0.996 
eucalyptol 183907 0.999 
linalool 200260 0.999 
geraniol 191963 1.000 
carvacrol 209572 0.998 
camphor 198536 0.999 
α-humulene 228170 1.000 
chamazulene 174133 0.987 
 
Figure 1. Quantitative analysis (mg/g of plant material) of major vapor and essential oil 
(EO) components.  
 
 
Thymus vulgaris, L. angustifolia, S. officinalis, and M. recutita all had major 
components of their essential oils enter the vapor with levels increasing with 
temperature (Figure 1). A representative GC-MS chromatogram comparing L. 
angustifolia vapor with its essential oil shows the 5 major components present in the 
essential oil are also present in the vapor at 200 °C (Figure 2). Although qualitatively 
similar the vapor samples differed both in absolute and relative quantitative terms from 
the total essential oil content. Lavandula angustifolia essential oil had eucalyptol as the 
2nd major component while in the vapor at 200 °C geraniol is the 2nd major component. 




vapor than in the essential oil. The same was true for geraniol in L. angustifolia. Such 
quantitative variation could result from differences in efficiency of steam distillation 
versus the vaporizing technique or from chemical conversions of the essential oil 
components. Some compounds volatilized very efficiently from their plant matrix in the 
vaporizer. At 200 °C, 73% of the total thymol found in the essential oil of T. vulgaris 
was detected in the vapor and in L. angustifolia 43% of the linalool. No compound 
varied by more than 2 mg/g in vapor samples indicating that the volcano is capable of 
reproducibly delivering essential oil compounds.  
 
Figure 2. GC-MS trace Lavandula angustifolia essential oil (top) compared to vapor 






No essential oil components were detected at a concentration above 0.1 mg/g 
in vapor samples of E. globulus and M. officinalis on the GC-FID detector. Melissa 
officinalis had a low yield of essential oil (< 1%), which could explain why no 
components were detected in the vapor. A second batch of M. officinalis was purchased 
from a separate herb supplier and analyzed in the same manner. No essential oil 
components were detected in the vapor and the essential oil yield was again < 1%. This 
suggests that the lack of compounds detected was due to low amounts of terpenoids in 
the M. officinalis analyzed. Eucalyptus globulus had a higher yield of essential oil 
(1.7%) when compared to M. officinalis but no compounds were detected in vapor 
samples. An experiment was attempted where E. globulus leaves were soaked in water 
for 0.5 h and then vaporized in the same manner as the dry leaves but still no 
compounds were detected. Terpenoids in E. globulus are produced in secretory cavities 
beneath the epidermis (McCaskill and Croteau, 1998). This result suggests that the 
vaporizer is less efficient for volatiles from plants which are stored in secretory cavities 
as opposed to trichomes.  
 
Overall these results demonstrate that volatile terpenoid components of 
aromatic plants can be produced by a vaporizing device. It is difficult to speculate 
whether or not the doses observed in the herb vapors would be enough to induce a 
clinical effect because so few well controlled clinical studies on monoterpenoids have 
been conducted. However, following oral administration of an equivalent of 1.08 mg 
thymol detectable levels of thymol metabolites were observed in human urine and blood 
(Kohlert et al., 2002). A pilot clinical trial conducted on dementia patients with orally 
administered Salvia lavandulaefolia (50 μl) 1-3 times daily was enough to produce 
significant improvements in cognition and inhibition of AChE in-vivo (Perry et al., 
2003). Another recent study observed that different essential oils were capable of 
maintaining their antimicrobial activity in the vapor phase (Nedorostova et al., 2011). 
Based on such literature reports it is possible that the levels of terpenoid components 
produced by the vaporizer in this study are within a range that may be appropriate for 
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Cannabinoid Receptor 1 Binding Activity and Quantitative Analysis 
of Cannabis sativa L. Smoke and Vapor 
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Cannabis sativa L. (cannabis) extracts, vapor produced by the Volcano 
vaporizer, and smoke made from burning cannabis joints were analyzed by GC-
hydrogen flame ionization detector (FID), GC-MS and HPLC. Three different 
medicinal cannabis varieties were investigated Bedrocan®, Bedrobinol®, and Bediol®. 
Cannabinoids plus other components such as terpenoids and pyrolytic by-products were 
identified and quantified in all samples. Cannabis vapor and smoke was tested for 
cannabinoid receptor 1 (CB1) binding activity and compared to pure ∆9-
tetrahydrocannabinol (∆9-THC). The top five major compounds in Bedrocan extracts 
were ∆9-THC, cannabigerol (CBG), terpinolene, myrcene, and cis-ocimene in 
Bedrobinol ∆9-THC, myrcene, CBG, cannabichromene (CBC), and camphene in Bediol 
cannabidiol (CBD), ∆9-THC, myrcene, CBC, and CBG. The major components in 
Bedrocan vapor (>1.0 mg/g) were ∆9-THC, terpinolene, myrcene, CBG, cis-ocimene 
and CBD in Bedrobinol ∆9-THC, myrcene and CBD in Bediol CBD, ∆9-THC, myrcene, 
CBC and terpinolene. The major components in Bedrocan smoke (>1.0 mg/g) were ∆9-
THC, cannabinol (CBN), terpinolene, CBG, myrcene and cis-ocimene in Bedrobinol 
∆9-THC, CBN and myrcene in Bediol CBD, ∆9-THC, CBN, myrcene, CBC and 
terpinolene. There was no statistically significant difference between CB1 binding of 
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More than 400 chemicals have been identified in Cannabis sativa L. 
(cannabis), of which 70 are a group of terpenophenolic compounds known as 
cannabinoids (Turner et al., 1980; ElSohly and Slade, 2005). ∆9-Tetrahydrocannabinol 
(∆9-THC) is the main cannabinoid and is primarily responsible for the psychoactive and 
medicinal effects of cannabis. ∆9-THC exhibits many of its effects by interacting with 
two G-protein coupled receptors known as the cannabinoid receptor 1 (CB1) and the 
cannabinoid receptor 2 (CB2) (Costa, 2007). A variety of compounds both endogenous 
to the human body and synthetic, can interact with the CB receptors including fatty acid 
amides, fatty acid esters, aminoalkylindoles and diarylpyrazoles (Howlett, 1995).  
 
Despite the illegality of cannabis in most nations a renewed interest in the 
medicinal properties of cannabis has resulted in the development of a number of 
cannabinoid based medicines. Oral ∆9-THC (Marinol®) and nabilone (Cesamet®) a 
synthetic analogue of ∆9-THC have been available since the 1980’s as prescription 
medicine for treatment of nausea and appetite stimulation for patients undergoing 
chemotherapy or for AIDS wasting syndrome. More recently Sativex® a cannabinoid 
based oral mucosal spray containing ∆9-THC and cannabidiol (CBD) has become 
available in some countries for relief of neuropathic pain in multiple sclerosis (Pertwee, 
2009). In the Netherlands cannabis can be legally prescribed by medical doctors for 
treatment of nausea (caused by chemotherapy and radiotherapy), for chronic pain, 
Tourette’s syndrome and multiple sclerosis. Since March 2005, Bedrocan BV (The 
Netherlands) has been contracted by the Dutch Ministry of Health, Welfare and Sport 
for the growth and production of medicinal cannabis.  
 
Cannabis is traditionally consumed by smoking, eating, or drinking in the form 
of a tea preparation. Heating the plant material plays an important role as this 
decarboxylates the naturally occurring non-psycho-active tetrahydrocannabinolic acid 
(THCA) into the psycho-active neutral cannabinoid ∆9-THC (Russo, 2007). A relatively 
new method of administration is to heat cannabis plant material at a temperature high 
enough to volatilize the active compounds without reaching temperatures which could 
cause combustion of the plant material. This technique is known as vaporizing and 
shows promise as a safe alternative to smoking while maintaining pharmacokinetic 
advantages of pulmonary administration (Abrams et al., 2007).  
 
The identification of components in cannabis smoke condensate has been 
extensively studied (Fentiman et al., 1973; Adams and Jones, 1973; Jones and Foote, 
1975; Lee et al., 1976; Maskarinec et al., 1976; Kettenes-Van Den Bosch and Salemink, 
1977; Novotný et al., 1982; Hiller et al., 1984; Van der Kooy et al., 2008; Van der Kooy 
et al., 2009). An excellent review on cannabis smoke condensate, its constituents and 
some biological effects is available (ElSohly, 2006). Recently, research has been 
undertaken to determine the safety and effectiveness of vaporization for the 
administration of cannabis and cannabinoids. Effectiveness in human subjects has been 
demonstrated (Abrams et al., 2007), the suppression of pyrolytic by-products has been 
shown (Gieringer et al., 2004), vaporization parameters of pure ∆9-THC have been 




temperatures on ∆9-THC levels has been studied (Pomahacova et al., 2009). However 
one shortcoming of the above studies is that other components delivered by cannabis 
smoke or vapor such as terpenoids were not investigated.      
 
Therefore in order to continue to evaluate the effectiveness of vaporization 
versus smoking our research focused on the identification and quantification of the 
components of cannabis smoke and vapor as well as CB1 binding activity of the 
collected samples. The goal of the CB activity test was to observe whether or not levels 
of ∆9-THC in cannabis smoke and vapor was equivalent to CB1 binding activity of pure 
∆9-THC.  
 
Materials and Methods 
 
Plant Material  
 
The plant material was obtained from Bedrocan BV (Groningen, The 
Netherlands) under the opium regulation register number 105815 CO/w. It consisted of 
mature flower tops of three cannabis varieties Bedrocan (dried), Bedrobinol (dried) and 
Bediol (granular, dried). According to the producer Bedrocan contains 18% ∆9-THC and 
<1% CBD, Bedrobinol contains 11% ∆9-THC and <1% CBD, and Bediol contains 6% 
∆9-THC and 7% CBD. Upon receiving the plant material it was stored at 4° C in the 
dark until use.   
 
Chemicals   
 
All reference terpenoids were purchased from Sigma-Aldrich (Steinheim, 
Germany), Fluka (Steinheim, Germany) or Chromadex (California, USA) and included 
α-thujene, camphene, sabinene, 1-8-cineol, terpinene-4-ol, 1-4-cineol, α-humulene, 
camphor, α-bisabolol, β-pinene, linalool, myrcene, terpineol, α-pinene, γ-terpineol, 
limonene, caryophyllene-oxide, (-)-carvacrol, ∆3-carene, p-cymene, terpinolene, 
citronellal, geranyl acetate, pulegone, citral, α-terpinene, α-fenchyl alcohol, calamanene, 
γ-cadinene, bornyl acetate, cis-trans-ocimene, α-cedrene, α-phellandrene, nerol, β-
phellendrene, nerolodol, piperitonoxide, β-caryophyllene and geraniol. The cannabinoid 
references for ∆9-THC, THCA, ∆8-tetrahydrocannabinol (∆8-THC), CBD, cannabigerol 
(CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), and cannabinol 
(CBN) were purified and quantified as previously described (Hazekamp et al., 2004a; 
Hazekamp et al., 2004b) by PRISNA BV (Leiden, The Netherlands). All cannabinoids 
references were >98% pure. Organic solvents used for extraction and sample 
preparation were of analytical reagent (AR) grade. Solvents used for HPLC were of 
HPLC grade.  
 
Sample Preparation  
 
Cannabis plant material was extracted using previous validated methodology 
(Hazekamp, 2007). Extracts from each cannabis variety were prepared in triplicate. One 
gram of plant material was transferred to 50 ml falcon tubes for extraction. The amount 
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of ethanol was brought to 40 ml and the falcon tubes were placed on a shaker for 15 min 
at 300 rpm. After shaking the samples were centrifuged at 2500 rpm for 5 min and the 
supernatant was collected in a 100 ml volumetric flask. The same procedure was 
repeated two more times with 25 ml ethanol. The final volume of ethanol was made up 
to 100 ml and samples were filtered through a 25 mm PTFE membrane syringe filter 
(0.45 µm). 
 
For the smoke experiments the procedure described by Van der Kooy et al., 
(2009) was followed. Each cannabis joint was separately weighed (1 g/joint) and 
numbered. For each sample 2 joints were prepared. The puff frequency was one puff 
(lasting 3 sec) every 30 sec while the puff volume was 35 ml. The smoke was collected 
in two gas traps connected in series containing each 50 ml of a 1:1 mixture of ethanol 
and hexane. The final volume for each sample was 100 ml. A total of 3 samples were 
collected for each variety.  
 
For the vapor collection the procedures described by Pomahacova et al., 2009 
were followed. The Volcano® was obtained from Storz & Bickel GmbH & Co. 
(Tuttlingen, Germany) and was used according to the manual as provided by the 
manufacturer. The volume of the plastic bag used was 8 L. For each vaporization 250 
mg of plant material was used. This process was repeated with 5 (total) separate 250 mg 
portions per sample (1.25 g cannabis material/sample). Samples were prepared in 
triplicate for each of the cannabis varieties. At the start of each experiment the Volcano 
was preheated until the indicator light showed that the target temperature of 200 °C was 
reached. The bag, connected to the filling chamber, was then immediately placed onto 
the Volcano and the ventilation was started. When the bag was completely inflated, 
ventilation was stopped and the bag was removed and reattached to a tube connected to 
the solvent trap (ethanol: n-hexane 1:1, 100 ml). Using a pump connected to the solvent 
system via a tube, the smoke was collected into the solvents. All resulting samples were 
analyzed with GC-FID, GC-MS, and HPLC.           
                                                                   
GC-FID Analysis  
 
An Agilent GC 6890 series equipped with a 7683 autosampler and injector was 
used for quantification. The column used for separation was a VA5ms (0.25 mm x 30 
m, film thickness 0.25 µm, Varian, Walnut Creek, CA, USA). The injector temperature 
was set to 230 °C with an injection volume of 4 µl, a split ratio of 10 and a N2 flow of 2 
ml/min. The oven temperature program began at 60 °C with a ramp rate of 3 °C/min. 
The final temperature was 240 °C which was held for 5 min making a total run time of 
65 min/sample. The FID detector temperature was 250 °C. Five point standard curves of 
myrcene, α-humulene and ∆9-THC (0.01-1.0 mg/ml) diluted in ethanol were measured 
for quantification. All samples were analyzed undiluted and reference compounds were 
run at a concentration of 1 mg/ml.   
 
GC-MS Analysis  
 
The GC-MS analyses for compound identification were performed on a Varian 




The injection volume was 3 µl with a split ratio of 20. The column used for separation 
was a DB5ms. (0.25 mm x 30 m, film thickness 0.25 µm, J&W Scientific, Folsom, CA, 
USA). The oven temperature program was the same as GC-FID. The transfer line 
temperature was 275 °C, manifold temperature 60 °C, and ion trap temperature 220 °C. 
Electron impact was used at an ionization mode of 70 eV and a scan range of 41-500 
amu. All samples were analyzed undiluted and reference compounds were analyzed at a 
concentration of 1 mg/ml. The NIST library (Standard Reference Data Program of the 
National Institute of Standards and Technology) was used to aid in compound 
identification when no reference standard was available.  
 
HPLC Analysis  
 
The quantification of acidic and neutral cannabinoids was performed on an 
Agilent 1200 HPLC system equipped with an autosampler and injector and a 
photodiode array detector. The column used for separation was a GraceVydac 
(Deerfield, IL, USA) (250 x 4.6 mm 5 µM C18) equipped with a guard column 
containing the same material as the column (All-guard 7.5 x 4.6 mm 5 µM C18). The 
mobile phase consisted of solvent A (50% MeOH and 0.1% formic acid) and solvent B 
(100% MeOH and 0.1 % formic acid). The gradient employed started with 70% solvent 
A at time 0 and increased to 100% solvent B in 25 min. At 26 min the system was 
returned to 70% solvent A and 4 min was allowed for re-equalibration. The total run 
time was 30 min/sample. The flow rate was 1.5 ml/min and the detection wave length 
was 228 nm. Quantitative HPLC analysis of all samples was performed based 
previously validated methodology (Hazekamp, 2007). 
 
CB1 Radioactive Displacement Assay  
 
The CB1 receptor containing membranes (0.63 pmol/mg membrane protein; 
16.4 mg/ml protein concentration) from Sf9 cells coexpressed with Gαi3β1γ2 were 
purchased from PerkinElmer (Boston, MA, USA). The radioactive ligand CP-55,940, 
[Side chain-2,3,4(N)-3H] was purchased from PerkinElmer. The CB1 containing 
membranes were diluted at a ratio of 1:200 with assay buffer (20 mM Hepes, 5 nM 
MgCl2, 1 mM ethylene-diamine-tetra-acetic acid (EDTA), 0.3% bovine serum albumin 
(BSA), pH 7.4). Receptor solutions were used on the same day and all buffers were 
freshly prepared. The total assay volume was 550 µl of which 500 µl was the receptor 
solution, 25 µl the radioactive ligand (0.5 nM final concentration) and 25 µl the sample. 
All vapor and smoke samples were diluted to a final concentration of 10 nM ∆9-THC in 
the final assay solution and were assayed in triplicate. Samples containing 10 nM of 
pure ∆9-THC were also assayed (n=6). To determine non-specific binding CP-55,940 
was assayed at final concentration of 10 µM (n=6). Blank samples were assayed to 
determine total binding of the radioactive ligand (n=6). All samples including controls 
∆9-THC, CP-55,940, and blanks contained ≤0.3% ethanol in the final assay solution.   
 
The radioactive displacement assay was performed according to the 
recommended assay conditions of PerkinElmer with an incubation time of 1 hour at 30 
°C. After incubation samples were filtered with a Brandel harvester (Gaithersburg, MD, 
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USA) over GF/C filters. The harvester can handle 24 filters at a time. After filtration the 
filters were collected in plastic scintillation vials to which 3 ml scintillation fluid was 
added. The scintillation fluid (brand: ‘emulsifier safe’) contained ethoxylated phenol. 
After adding the scintillation fluid and a brief vortex the samples were counted in a 
PerkinElmer scintillation counter (Tri-carb 2900TR). A student t-test (two tailed; two 
sample unequal variance) was performed in order to compare statistical significance 
between pure ∆9-THC and group of samples (variety and smoke or vapor). A p-value 
<0.05 was considered significant.  
 
Results and Discussion 
 
HPLC quantification  
 
The results of HPLC quantification of THCA and ∆9-THC are shown in Table 
1. The amount of THCA in the extracted cannabis plant material was used to calculate 
the total theoretical amount of ∆9-THC in the ethanol extracts taking into account the 
difference in molecular weight (∆9-THC% = THCA% x (314.47 / 358.48)). ∆9-THC 
levels for Bedrocan were higher than claimed by the producer (21.7%). This difference 
could be due to the fact that Bedrocan material was supplied as intact dried flower buds 
rather then granulated as it is normally supplied to pharmacies. Granulating the plant 
material causes some trichomes which contain the most cannabinoids to fall off. As 
expected the amount of ∆9-THC in the vapor and smoke declined with the original 
content of ∆9-THC in the plant varieties. The smoke and vapor samples showed an 
inverse relationship between ∆9-THC volatization efficiency compared to original ∆9-
THC content with the Bediol variety having the highest efficiency. ∆9-THC volatization 
efficiency was higher for each variety when vaporized compared to smoked. The 
absolute quantities of ∆9-THC in the smoke samples of the Bedrocan variety confirms 
earlier reports (Pomahacova et al., 2009) which found ∆9-THC levels of around 40 mg/g 
in the smoke samples. ∆9-THC levels in vaporized samples cannot be directly compared 
with previous research as differences in sample weights vaporized causes differences in 
∆9-THC levels (Pomahacova et al., 2009).  
 
GC Identification and Quantification  
 
All components identified and quantified by GC-FID and GC-MS are shown in 
tables 2-4. A representative chromatogram for a Bedrocan extract, smoke and vapor 
sample is shown in figure 1. Compound identification was based on mass spectra, 
retention times compared with authentic standards and retention indexes reported in 
literature (Ross and ElSohly, 1996; Adams, 1989). Mono-terpenoids were quantified 
using a linear calibration curve for myrcene (y=6945.1x; r2=0.997), sesquiterpenoids 
with α-humulene (y=7529.5x; r2=0.998), and cannabinoids with ∆9-THC (y=5873.4x; 
r2=0.999). The % difference in response coefficients between the above three 
compounds classes was 12.4%. Putative identification of pyrolytic by-products using a 
NIST library (2005) is reported in smoke samples. These compounds did not fit into the 
above 3 compound groups therefore they were quantified using the standard compound 
that was most similar in mass as response coefficients in FID detectors are mass 




data represents a normalized quantitation. A number of compounds had fragmentation 
patterns that were typical of cannabinoids or sesquiterpenoids but identification could 
not be confirmed based on available data. For such compounds mass ions were reported 
and they were labeled as unknown sesquiterpenoids or cannabinoids.  
 
Table 1. HPLC Quantification of THC and THCA in the three cannabis varieties 











Extract  Bedrocan 217.0a) 2.4 - 240.9 2.5 
 Bedrobinol 103.0 a) 3.5 - 114.8 3.5 
 Bediol 62.0 a) 1.4 - 66.9 1.3 
Vapor  Bedrocan 47.7 5.7 22.0% 2.3 17.4 
 Bedrobinol 36.3 10.9 35.2% 2.2 6.3 
 Bediol 24.5 22.2 39.5% 1.2 19.9 
Smoke  Bedrocan 34.6 33.4 15.9%    NDb) -- 
 Bedrobinol 26.3 6.4 25.5% ND -- 
 Bediol 18.5 12.4 29.8% ND -- 
a) THC equivalents based on the amount of THCA in the samples. b) ND = not 
detected. 
 
Table 2 lists all the components which were identified and quantified in the 
cannabis extracts. No acidic cannabinoids were observed as expected because the high 
temperature used in GC decarboxylates them into their neutral forms. The concentration 
of ∆9-THC determined by GC confirms the results obtained by HPLC. No CBN, a ∆9-
THC degradation product, was detected in any of the initial sample extracts. The top 
five major compounds in Bedrocan extracts were ∆9-THC, CBG, terpinolene, myrcene, 
and cis-ocimene. In Bedrobinol ∆9-THC, myrcene, CBG, CBC, and camphene were 
major components and in Bediol CBD, ∆9-THC, myrcene, CBC, and CBG.    
 
Table 3 lists the components identified and quantified in the vapor samples. 
Most of the components identified in the initial extracts can also be seen in the vapor 
samples. The major components of Bedrocan vapor (>1.0 mg/g) were ∆9-THC, 
terpinolene, myrcene, CBG, cis-ocimene, and CBD. Bedrobinol contained mostly ∆9-
THC, myrcene, and CBD. Note that the levels of CBD were higher in Bedrocan and 
Bedrobinol vapor samples than they were in the original extracts. We suspect this 
observation is a result of the degradation of another cannabinoid, perhaps ∆9-THC, into 
CBD. Since the %RSD was also very high (>50%) and the effect was not observed in 
cannabis smoke (Table 4) we suspect that such degradation is not reproducible. In 
Bediol vapor the major components (>1.0 mg/g) were CBD, ∆9-THC, myrcene, CBC, 
and terpinolene. Only a small amount of CBN (<0.1 mg/g) was formed in vapor 
samples. No new compounds that were not observed in the cannabis extracts were 
detected in cannabis vapor.  
 
In contrast to vapor samples smoked cannabis contained many compounds not 
observed in extracts or vapor (Table 4). In total 23 unknown cannabinoids, various 
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hydrocarbons, phenolic compounds, nitrogen containing compounds, Δ8-THC, 1-oxo-
cannabinol and significant amounts of CBN (>2.0 mg/g) were observed in cannabis 
smoke. These results suggest a much higher degree of pyrolytic degradation in cannabis 
smoke when compared to cannabis vapor and is consistent with previous literature 
(Gieringer et al., 2004). The major compounds in Bedrocan smoke (>1.0 mg/g) were ∆9-
THC, CBN, terpinolene, CBG, myrcene and cis-ocimene. In Bedrobinol ∆9-THC, CBN 
and myrcene were the major compounds. In Bediol CBD, ∆9-THC, CBN, myrcene, 
CBC and terpinolene were the major compounds. 
 
CB1 binding activity 
 
Cannabis smoke and vapor samples were diluted to a concentration of 10 nM 
which is very near the EC50 of ∆9-THC. This was done to maximize the ability of the 
assay to show an increase or decrease in binding. The EC50 of ∆9-THC was determined 
to be 9.9 nM with a Ki of 3.8 nM from a dose response curve performed under the same 
assay conditions using the same batches of ligands and receptors (data not shown). The 
Ki and EC50 for ∆9-THC is comparable with literature reports (Pertwee, 2008). Figure 2 
shows the % displacement of CP-55,940, [Side chain-2,3,4(N)-3H]  caused by binding 
to the CB1 receptor. No significant difference was found between smoke and vapor 
samples when compared with pure ∆9-THC (Figure 2). This suggests that no additional 
CB1 binding is taking place in cannabis smoke or vapor samples when compared with 




Our CB1 binding results verify previous reports in humans which showed that 
the subjective psychoactive effects of cannabis are primarily due to ∆9-THC content 
(Wachtel et al., 2002; Ilan et al., 2005). Our results demonstrate that any non-∆9-THC 
components in cannabis smoke and vapor are too diluted to have any significant effects 
in vitro on CB1 binding. However there still exists evidence that other components in 
cannabis extracts play a role in the plant’s overall therapeutic effects (Pickens, 1981; 
Fairbairn and Pickens, 1981; Zuardi et al., 1982; Wilkinson et al., 2003; Whalley et al., 
2004; Ryan et al., 2006). There has even been considerable controversy over this issue 
(ElSohly et al., 2003; Russo and McPartland, 2003). We propose that any additional 
beneficial effects observed by patients using cannabis are due to effects other than CB1 
agonism. Such benefits could come from other components in cannabis that interact 
with the CB2 receptors or new potential cannabinoid receptors such as the transient 









Quantitative comparison of cannabis smoke and vapor shows that vaporizing 
cannabis with the Volcano is a more reliable and safer administration form for the 
delivery of ∆9-THC due to the lack of pyrolytic degradation and more efficient ∆9-THC 
volatilization. Analysis of cannabis smoke and vapor showed for the first time in a 
quantitative manner that terpenoids are major components of the smoke and vapor of 3 
medicinal cannabis varieties. Myrcene has analgesic and anti-inflammatory properties 
which may contribute to the medical benefits of cannabis. Other compounds identified 
42 
 
in our samples terpineol, terpinene-4-ol, γ-terpinene, limonene and α-pinene are 
acetylcholine esterase inhibitors that may act by reducing acetylcholine deficits in the 
hippocampus induced by ∆9-THC (McPartland and Russo, 2001). Further research 
should be done to determine whether or not terpenoids and other non-∆9-THC 
components of cannabis are contributing to the overall medical benefits of herbal 
cannabis.   
 






Table 2. GC Identification and Quantification of Components in Cannabis Extracts 
RT 















4.20 α-pinene 0.4 5 0.9 8 0.6 6 
4.34 camphene 0.4 4 1.1 8 0.7 7 
5.23 sabinene 0.5 8 ND  0.2 10 
5.35 β-pinene 0.9 1 0.3 4 0.4 9 
5.60 myrcene 5.0 10 12.0 8 11.3 3 
6.08 α-phellandrene 0.5 4 ND  ND  
6.14 ∆3-carene 0.3 6 ND  0.2 0.0 
6.37 α-terpinene 0.2 7 ND  ND  
6.75 β-phellandrene 0.9 4 ND  0.2 2 
6.77 limonene 0.7 1 ND  0.2 4 
7.25 cis-ocimene 3.0 13 0.7 4 0.7 3 
7.64 γ-terpineol 0.2 0.4 ND  ND  
8.56 terpinolene 8.9 4 ND  1.9 17 
9.15 linalool 0.3 15 ND  0.3 0.0 
10.70 camphor ND  ND  0.2 18 
12.49 terpinene-4-ol 0.2 10 ND  0.2 0.0 
12.74 terpineol 0.7 8 ND  0.6 1 
22.30 β-caryophyllene 1.7 13 0.6 8 0.8 2 
22.82 trans-α-bergomotene 0.2 6 ND  ND  
23.03 α-guaiene 0.6 16 ND  0.5 3 
23.82 α-humulene 0.6 13 0.4 33 0.3 23 
23.95 cis-β-farnesene 0.5 23 ND  0.5 5 
25.24 β-selinene 0.2 32 0.2  0.3 0.0 
25.55 α-selinene 0.2 30 0.3 32 0.2 45 
25.83 ST m/z: 204 (M+) 189, 107, 
91, 77 0.5 14 ND  0.3 25 
26.14 γ-cadinene 0.2 13 0.3 26 0.4 6 
27.11 
ST m/z: 204 (M+) 189, 161, 
133 0.2 0.0 ND  ND  
27.24 
ST m/z: 204 (M+) 161, 133, 
105 0.5 15 0.2 20 0.2 16 
27.42 
ST m/z: 204 (M+) 161, 122, 
102 0.7 16 0.2 10 0.2 5 
28.10 γ-elemene 1.1 9 0.3 62 0.3 58 
48.85 
CB m/z: 258 (M+) 243, 215, 
275 ND  ND  0.3 0.0 
51.19 
CB m/z: 286 (M+) 271, 243, 
203 ND  ND  0.3 10 
54.16 THCV 1.5 7 0.8 6 0.5 13 
57.31 CBD 0.8 2 0.4 4 85.6 2 




CB m/z: 313 (M+) 297, 272, 
244 1.8 12 0.7 9 0.5 5 
59.02 
CB m/z: 314 (M+) 299, 272, 
244 ND  ND  1.4 2 
60.36 ∆9-THC 220.8 4 110.1 5 67.6 2 
61.38 CB m/z: 314 (M+) 297, 232 0.3 25 ND  ND  
61.86 CBG 16.0 11 2.7 22 3.1 3 
63.91 
CB m/z: 314 (M+) 294, 272, 
232 ND  ND  0.5 14 
ND= not detected. ST= unknown sesquiterpenoid. CB= unknown cannabinoid. a) 
Retention time in GC-FID. 
 
Table 3.  GC Identification and Quantification of Components in Cannabis Vapor 
RT 













4.26 α-pinene 0.2 34 0.7 12 0.3 3 
4.33 camphene 0.2 7 0.9 10 0.4 9 
5.26 Sabinene 0.3 3 0.2 3 0.1 4 
5.35 β-pinene 0.6 6 0.3 5 0.2 10 
5.60 Myrcene 2.8 10 7.1 4 5.6 6 
6.08 α-phellandrene 0.3 13 ND  ND  
6.13 ∆3-carene 0.2 7 ND  ND  
6.37 α-terpinene 0.2 8 ND  ND  
6.74 β-phellandrene 0.7 35 0.1 6 ND  
6.77 limonene 0.4 8 ND  0.2 11 
7.25 cis-ocimene 1.7 13 0.6 5 0.4 5 
7.64 γ-terpinene 0.2 7 ND  ND  
8.55 terpinolene 6.5 10 0.6 83 1.9 3 
12.74 terpineol 0.3 24 0.2 2 0.3 31 
22.30 β-caryophyllene 0.9 16 0.6 13 0.6 12 
23.02 α-guaiene 0.2 20 0.2 12 0.3 19 
23.83 α-humulene 0.3 16 0.2 10 0.2 11 
23.95 cis-β-farnesene 0.2 19 0.1 18 0.2 20 
25.55 α-selinene 0.1 11 ND  0.1 0.0 
25.83 
ST m/z: 204 (M+) 189, 
107, 91, 77 0.4 19 0.2 24 0.4 17 
26.13 γ-cadinene 0.1 11 0.1 0.0 0.1 15 
27.24 
ST m/z: 204 (M+) 161, 
133, 105 0.2 19 0.2 18 0.2 33 
27.42 ST m/z: 204 (M+) 161, 
122, 102, 91 0.4 17 0.3 14 0.3 15 
28.10 γ-elemene 0.4 23 0.2 43 0.2 26 
51.19 
CB m/z: 286 (M+) 271, 
243, 203 ND  ND  0.2 0.0 
54.16 THCV 0.4 8 0.3 8 0.1 3 
57.27 CBD 1.5 109 1.6 70 28.0 20 





CB m/z: 314 (M+) 299, 
272, 244 ND  ND  0.4 21 
60.18 ∆9-THC  46.5 6 35.4 10 23.5 22 
61.81 CBGb)  2.3 11 0.7 20 0.9 20 
61.81 CBN b) 0.1 5 0.1 8 <0.1 27 
ND= not detected. ST= unknown sesquiterpenoid. CB= unknown cannabinoid. a) 
Retention time in GC-FID. b) Values determined by HPLC due to overlap in GC-FID.  
 
Table 4. GC Identification and Quantification of Components in Cannabis smoke  
RT 













3.10 ethyl benzeneb) 0.2 30 0.1 19 0.2 16 
3.14 ortho-xylene b) 0.2 12 0.1 27 0.2 22 
3.47 1, 3, 5, 7-cyclooctatetraene b) 0.1 12 0.1 36 0.2 8 
3.75 Ethanone, 1-(2-furanyl) b) ND  0.1 17 0.1 10 
3.84 1,3-benzenediamine b) ND  0.1 9 0.1 13 
3.78 
unknown m/z: 110 (M+) 95, 
58 0.1 22 ND  ND  
4.08 α-thujene 0.1 8 ND  ND  
4.23 α-pinene 0.4 7 0.7 5 0.3 8 
4.92 1,3,5-trimethylbenzene b) ND  ND  0.1 7 
5.13 sabinene 0.1  ND  ND  
5.27 β-pinene 0.8 9 0.6 14 0.5 13 
5.53 β-myrcene 2.1 8 1.9 4 1.9 8 
5.99 α-phellandrene 0.3 10 ND  0.5 14 
6.14 ∆3-carene 0.2 7 ND  0.1 4 
6.30 α-terpinene 0.2 21 ND  ND  
6.53 cymene 0.1 18 0.1 40 0.9 8 
6.68 β-phellandrene 0.5 12 0.1 4 0.3 7 
6.70 limonene 0.4 21 ND  ND  
7.20 cis-ocimene 1.4 7 0.2 3 0.2 3 
7.41 phenol, 3-methyl b) ND  0.1 15 0.1 17 
7.58 γ-terpineol 0.1 1 ND  ND  
8.17 phenol, 4-methyl b) 0.2 24 0.3 37 0.2 0.4 
8.51 terpinolene 5.4 11 0.2 24 1.3 9 
8.69 para-cymene 0.1 25 0.1  0.4 10 
9.06 linalool 0.1 16 ND  ND  
9.28 4-pyridinol b) 0.4 21 0.4 36 0.4 19 
9.51 1,3,8-p-menthatriene b) ND  ND  0.9 18 
10.32 
cycloheptane, 1,3,5-
tris(methylene) b) ND  ND  0.1 11 
10.44 
benzene, 1-isocyano-2-
methyl b) 0.1 28 0.1 13 0.2 23 




unknown m/z: 134 (M+) 89, 
71, 56  0.2 4 ND  0.4 6 
12.76 terpineol 0.2 11 ND  ND  
13.88 benzaldehyde, 2-methyl b) ND  0.2 21 0.2 21 
16.88 indole b) 0.1 26 0.2 17 0.2 7 
20.88 1H-indole, 3-methyl b) ND  0.1  0.1 16 
22.30 β-caryophyllene 0.8 14 0.5 14 0.5 5 
22.81 trans-α-bergomotene 0.2 16 ND  ND  
23.03 α-guaiene 0.3 4 ND  0.4 5 
23.82 α-humulene 0.3 8 0.2 17 0.2 1 
23.95 cis-β-farnesene 0.2 11 ND  0.3 5 
25.24 β-selinene 0.1 36 0.1 11 0.1 9 
25.55 α-selinene 0.1 39 0.1 21 0.1 4 
25.84 
ST m/z: 204 (M+) 189, 107, 
91, 77 0.4 15 ND  0.4 5 
26.14 γ-cadinene 0.1  0.1 20 0.2 13 
26.52 β-gurjunene b) 0.1  ND  ND  
27.10 
ST m/z: 204 (M+) 189, 161, 
133, 105 0.1  0.1 17 ND  
27.24 
ST m/z: 204 (M+) 161, 133, 
105, 91 0.3 19 0.2 17 0.2 2 
27.42 
ST m/z: 204 (M+) 161, 122, 
102, 91 0.5 18 0.3 16 0.3 3 
28.10 γ-elemene 0.3 21 0.1 15 0.1 6 
28.47 
ST m/z: 204 (M+) 161, 107, 
91, 69 0.1  ND  0.1 9 
32.02 Δ-selinene b) ND  ND  ND  
36.21 olivitol b) 0.1 34 0.1  0.6 6 
37.57 1-(3-methylbutyl)-2,3,5,6-
tetramethylbenzene b) 
0.1  ND  0.1 
 
39.04 7-octadecyne, 2-methyl b) 0.2 7 0.2 11 0.3 3 
40.54 3, 7, 11, 15-tetramethyl-2-
hexadecen-1-ol b) 
0.1 3 0.1 19 0.1 4 
43.42 CB m/z: 232 (M+) 231, 174 0.2 36 0.3 33 0.3 17 
43.94 
CB m/z: 246 (M+) 232, 231, 
190, 175   0.1 23 ND  0.4 6 
47.95 
CB m/z: 258 (M+) 244, 243, 
215, 175 0.1 2 0.2 24 0.1  
48.90 
CB m/z: 248 (M+) 206, 193. 
136 ND  ND  0.2 13 
49.07 
CB m/z: 258 (M+) 243, 215, 
175 ND  ND  0.2 10 
51.23 
CB m/z: 286 (M+) 271, 243, 
203 ND  ND  0.1 5 
53.12 
CB m/z: 314 (M+) 299, 271, 
258, 232 0.3 29 0.3 16 0.8 3 
54.24 THCV 0.3 34 0.2 6 0.1 7 
54.79 
CB m/z: 314 (M+) 299, 258, 
243, 232 0.2 11 0.1 22 0.3 9 
54.99 
CB m/z: 312 (M+) 270, 256, 





CB m/z: 310 (M+) 295, 238, 
223 0.1 8 0.1  0.2  
56.25 
CB m/z: 316 (M+) 274, 260, 
232 0.1  0.1 35 0.2 44 
56.73 
CB m/z: 314 (M+) 246, 231, 
175 ND  ND  0.4 11 
57.35 CBD 0.5 80 0.1  21.1 7 
57.82 CBC 0.4 34 0.3 36 1.3 11 
58.48 
CB m/z: 313 (M+) 297, 272, 
244, 231 0.2  0.2 59 0.1 3 
58.68 
CB m/z: 314 (M+) 299, 272, 
244, 232 0.1  ND  ND  
59.02 
CB m/z: 314 (M+) 299, 272, 
243, 232 0.2  ND  ND  
58.99 Δ8-THC 1.0 17 0.2 12 0.5 4 
59.39 
CB m/z: 352 (M+) 314, 282, 
259, 232 ND  ND  0.5 4 
59.67 CB m/z: 299 (M+) 300  0.4 18 0.3 41 0.1  
60.23 ∆9-THC 36.2 39 26.7 9 17.6 12 
60.80 
CB m/z: 314 (M+) 299, 272, 
256, 243 ND  ND  0.3  
61.71 
CB m/z: 312 (M+) 298, 270, 
257, 232 0.4 97 0.2 41 0.2 9 
61.94 CBGc) 2.5 16 0.9 25 1.0 3 
61.94 CBNc) 6.9 2 3.5 25 2.9 4 
62.33 
CB m/z: 312 (M+) 296, 272, 
270, 257 0.1 17 ND  ND  
62.70 
CB m/z: 337 (M+) 312, 298, 
282 0.2 18 ND  ND  
63.22 1'-oxo-cannabinol b) 0.1 12 ND  ND  
63.56 
CB m/z: 334 (M+) 319, 300, 
263 0.1 13 ND  ND  
63.74 
CB m/z: 352 (M+) 338, 310, 
270 0.2 38 ND  ND  
ND= not detected. ST= unknown sesquiterpenoid. CB= unknown cannabinoid. a) 
Retention time in GC-FID. b) Compounds putatively identified on NIST (2005) library 
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 Cannabis sativa L. is an important medicinal plant. In order to develop 
cannabis plant material as a medicinal product quality control and clear 
chemotaxonomic discrimination between varieties is a necessity. Therefore in this study 
11 cannabis varieties were grown under the same environmental conditions. Chemical 
analysis of cannabis plant material used a gas chromatography flame ionization 
detection method that was validated for quantitative analysis of cannabis 
monoterpenoids, sesquiterpenoids, and cannabinoids. Quantitative data was analyzed 
using principal component analysis to determine which compounds are most important 
in discriminating cannabis varieties. In total 36 compounds were identified and 
quantified in the 11 varieties. Using principal component analysis each cannabis variety 
could be chemically discriminated. This methodology is useful for both 
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Cannabis sativa L., (cannabis) is an annual dioecious plant belonging to the 
family Cannabaceae. Cannabis has a long history of human use as a medicinal plant, 
intoxicant, and ritual drug (Russo, 2007). Today most nations worldwide regard 
cannabis as an illegal drug of abuse. Despite the abuse potential of cannabis research 
into its chemistry and pharmacology has demonstrated that it also has medical 
properties. Chemical analysis of cannabis in the 1940’s and 60’s led to the discovery of 
a unique group of terpenophenolic secondary metabolites, known as cannabinoids, of 
which trans-(-)-∆9-tetrahydrocannabinol (∆9-THC) was shown to be the primary 
psychoactive ingredient (Pertwee, 2006). At least 90 plant cannabinoids, also known as 
phytocannabinoids, have been isolated from cannabis (Ahmed et al, 2008; ElSohly and 
Slade, 2005; Radwan et al, 2009). In the early 1990’s the G-protein coupled 
cannabinoid receptors (CB) were discovered. Two types of cannabinoid receptors CB1 
and CB2 revealed a receptor based mechanism for the action of ∆9-THC (Pertwee, 
2009). 
 
 Clinical trials into cannabis, pure cannabinoids, and synthetic analogues have 
demonstrated some effectiveness as analgesics for chronic neuropathic pain, appetite 
stimulants’ for cancer or AIDS patients, and multiple sclerosis. The increased medical 
interest in these substances has prompted the development of various cannabis based 
medicines such as the oral ∆9-THC preparation Marinol® (Solvay Pharmaceuticals, 
Belgium), a synthetic analogue of ∆9-THC Nabilone® (Valeant Pharmaceuticals 
International, USA), and Sativex® (GW Pharmaceuticals, UK) an oral mucousal spray 
containing 1:1 ratio of ∆9-THC and CBD (Ben Amar, 2006; Hazekamp and 
Grotenhermen, 2010). Since 2003 The Netherlands has allowed the distribution of 
standardized herbal cannabis in pharmacies to patients with a prescription (Hazekamp, 
2006). In the USA 14 states have legalized under state law the use of medical cannabis. 
In order to facilitate research into clinical safety and effectiveness the American 
Medical Association (AMA) has recently called for the rescheduling of cannabis’s legal 
status from Schedule I to Schedule II (Hoffmann and Weber, 2010). These 
developments highlight the urgency to define the criteria necessary for the 
chemotaxonomic classification of medicinal cannabis for drug standardization and 
clinical research purposes.  
 
 There has been considerable debate over whether or not whole herbal cannabis 
has any additional therapeutic benefits when compared to pure cannabinoids (ElSohly et 
al., 2003; Llan et al., 2005; McPartland and Russo, 2001; Russo and McPartland, 2003; 
Wachtel et al., 2002). However, there is some evidence that certain cannabis 
preparations exhibit different effects when compared to pure cannabinoids (Fairbarin 
and Pickens, 1981; Johnson et al., 1984; Pickens, 1981; Ryan et al., 2006; Segelman et 
al., 1974; Whalley et al., 2004; Wilkinson, 2003). Both the terpenes and minor 
cannabinoids present in cannabis are known to have various biological activities 
(McPartland and Russo, 2001). A lack of detailed chemical characterization beyond ∆9-
THC, CBD or cannabinol (CBN) quantification is shown in the above mentioned 
preclinical as well as clinical research making it difficult to compare results across 




draw any strong conclusions about what components other than ∆9-THC and 
occasionally, depending on the study design CBD, present in cannabis preparations may 
have an influence on the drug’s effects.  
 
Cannabinoids are produced biosynthetically in cannabis as their carboxylic 
acid derivatives and are known as cannabinoid acids. Cannabinoid acids degrade into 
their neutral counterparts through the action of heat, sunlight, and storage (Taura et al., 
2007). Cannabis is most commonly administered by smoking the dried flower buds due 
to the avoidance of first pass metabolism of orally administered ∆9-THC as well as ease 
of self titration by the user or patient (Williamson and Evans, 2000). In a recent study 
we demonstrated that cannabis ethanol extracts, smoke, and vapor produced by a 
vaporizing device are composed of a complex mixture of terpenoids and cannabinoids 
(Fischedick et al., 2010). Therefore quality control methods for the major volatile 
compounds in cannabis should be utilized prior to and during clinical studies of 
cannabis administered with a vaporizing device or by smoking.  
 
Two morphological types of cannabis are commonly recognized, C. sativa 
being taller and more highly branched typically representing fiber type varieties and 
Cannabis indica being shorter with broader leaves typically representing strains used 
for recreational or medicinal purposes. Whether or not these two morphotypes are 
different species is still a matter of debate (Russo, 2007). A third subtype, Cannabis 
ruderalis has also been recognized, and is described as having low levels of 
cannabinoids with a bushy appearance (Hillig and Mahlberg, 2004). Today many 
cannabis varieties used recreationally and for medical purposes are hybrids of the 
various cannabis morphotypes mostly C. sativa and C. indica. Chemotaxonomic 
evaluation of cannabis has led to the recognition of 3 chemotypes, a drug type with 
higher levels of ∆9-THC, a fiber type with higher CBD, and an intermediate type with 
similar levels of each (Fetterman et al., 1971; Small and Beckstead, 1973a; Small and 
Beckstead, 1973b). More recent studies using gas chromatography (GC) analyzing 
cannabinoids (Hillig and Mahlberg, 2004) or terpenoids (Hillig, 2004) have been 
performed for chemotaxonomic purposes. 1H-NMR has been used to fingerprint 
cannabis aqueous extracts and tinctures (Politi et al., 2008) as well as to chemically 
differentiate cannabis cultivars (Choi et al., 2004). However, none of these methods 
offer validated quantitative methods for the analysis of cannabis terpenoids and 
cannabinoids simultaneously. Furthermore the sample preparation used by Hillig (2004) 
for terpenoid analysis utilized extensive sample drying (2 months at room temperature) 
and heating at 30 °C prior to analysis. This would have resulted in a higher rate of 
volatilization for the monoterpenoids thus biasing the chemotaxonomic evaluation 
towards the less volatile sesquiterpenoids.   
 
Metabolic fingerprinting, also known as metabolic profiling, is a targeted 
analytical approach which aims to quantify a group or groups of compounds found in an 
organism or group of organisms. Metabolic fingerprinting with GC, HPLC, coupled 
with mass spectrometry, or 1H-NMR is useful for studying plant biochemistry, 
chemotaxonomy, ecology, pharmacology, and quality control of medicinal plants (van 
der Kooy et al., 2009). To metabolically fingerprint cannabis we validated a GC-flame 
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ionization detection (GC-FID) method for monoterpenoids, sesquiterpenes, and 
cannabinoids. The analytical method was used to study the chemical composition and 
variability of terpenoids and cannabinoids in 11 cannabis varieties grown under 
standardized environmental conditions. Principal component analysis (PCA) was used 
to identify the compounds most important in distinguishing cannabis varieties. We also 
studied the variation on cannabis chemical profiles as a result of growing plants in 
different batches and with deviations in growth time. This study establishes useful 
criteria for quality control and standardization of cannabis varieties for clinical studies 
as well as chemotaxonomy.  
 




 Reference terpenoids of caryophyllene-oxide, camphor, α-bisabolol, β-pinene, 
myrcene, α-pinene, γ-terpineol, (R)-limonene (limonene), (S)-limonene, 1-8-cineol, 
carvacrol, and β-caryophyllene were purchased from Sigma-Aldrich (Steinheim, 
Germany). Terpineol mixture of isomers, α-humulene, and linalool were purchased 
from Fluka (Steinheim, Germany). Geraniol was purchased from Chromadex (Irvine, 
California, U.S.A). Camphene, α-thujene, sabinene, terpinene-4-ol, 1-4-cineol, ∆3-
carene, p-cymene, terpinolene, citronellal, geranyl acetate, pulegone, citral, α-terpinene, 
α-fenchyl alcohol, calamanene, γ-cadinene, bornyl acetate, a mixture of cis/trans-
ocimene, α-cedrene, α-phellandrene, nerol, β-phellandrene, nerolidol, and piperitone-
oxide were from a chemical bank of the authors. The cannabinoid references for ∆9-
THC, ∆8-THC, CBD, cannabigerol (CBG), cannabichromene (CBC), trans-(-)-∆9-
tetrahydrocannabivarin (THCV), and cannabinol (CBN) were purified and quantified by 
PRISNA BV as previously described (Leiden, The Netherlands) (Hazekamp et al., 
2004a; Hazekamp et al., 2004b). All cannabinoids references were > 98% pure, except 
THCV. Absolute ethanol (EtOH) used for extraction and sample preparation was of 
analytical reagent (AR) grade (Biosolve BV, Valkenswaard, The Netherlands). 1-




 Cannabis plant material was grown indoors. The plant material was produced 
by taking cuttings from standardized plants (mother plants) kept under vegetative 
conditions. Cannabis plants were grown in two growth cycles. First a vegetative period 
in which plants are grown under 18 h of uninterrupted light per day producing only 
roots, stems, and leaves. After an optimized vegetative period plants are switched to 12 
h of uninterrupted light per day which induces flowering. The period for which each 
variety exists in each phase can differ and has been optimized by Bedrocan BV for 
efficient growth.  
 
Environmental conditions for all varieties were the same. Plants were 
harvested after a standardized amount of days when the pistils faded from white to 
brown and the branches started to hang. The plants were then dried under the same 




weight. The plants were then processed by removing leaves from the buds and clipping 
buds from the main stems. Remaining plant material (buds) was packaged into 50 ml 




 Cannabis plant material was weighed to the nearest mg with a typical weight 
range of 0.9-1.1 g. The plant material was crushed with a metal spoon within a falcon 
tube and the spoon was rinsed with a few ml of EtOH into the falcon tube. The volume 
was then brought up to 45 ml with ethanol. Falcon tubes were placed on a Yellow Line 
Orbital Shaker OS 2 Basic (IKA GmbH, Staufen, Germany) at 400 revolutions per 
minute (rpm) for 15 min. Samples were centrifuged briefly for 30 s at 2000 rpm. 
Supernatant was collected in a 100 ml glass volumetric flask. Samples were extracted 
two more times with 25 ml ethanol. As an internal standard 1 ml of an EtOH soln. 
containing 1-octanol (1%) was added to the volumetric flasks. Samples were finally 
brought to a volume of 100 ml with ethanol. Samples were filtered into 20 ml glass vials 
with a PTFE syringe filter (0.45 µM, 25 mm diameter). Samples were stored air tight in 




 An Agilent GC 6890 series equipped with a 7683 autosampler, a DB5 (30 m 
length, 0.25 mm internal diameter, film thickness 0.25 µm, J&W Scientific Inc, Folsom, 
CA, USA) column and a flame ionization detector (FID) was used for quantitative 
analysis. The injector temperature was set to 230 °C, an injection volume of 4 µl, a split 
ratio of 1:20 and a carrier gas (N2) flow rate of 1.2 ml/min. The oven temperature 
program began at 60 °C with a ramp rate of 3 °C/min. The final temperature was set to 
240 °C which was held for 5 min making a total run time of 65 min/sample. The FID 
detector temperature was set to 250 °C. The GC-FID was controlled by GC 





 GC-MS analysis was performed on an Agilent 7890A series gas 
chromatograph equipped with a 7693 autosampler, an HP5-ms column (30 m length, 
0.25 mm internal diameter, film thickness 0.25 µm, Agilent Technologies Inc, Santa 
Clara, CA, USA), and a single quadropole mass spectrometer 5975C. The MS source 
was set to 230 °C, the single quad temperature was 150 °C, and the transfer line 
temperature was set to 280 °C. The GC-column was linked to the MS via a quickswap 
(Agilent Technologies Inc, Santa Clara, CA, USA) and restrictor (0.11 mm internal 
diameter, Agilent Technologies Santa Clara USA). The injector temperature was 230 °C 
with an injection volume of 2 µl, a split ratio of 1:20, and a carrier gas (He) flow rate of 
1.2 ml/min. The oven temperature program was the same as the GC-FID. The mass 
range analyzed by the mass spectrometer was 50-500 amu. The GC-MS was controlled 
by Enhanced Chemstation software version E.02.00.493 (Agilent Technologies Inc, 
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Santa Clara, CA, USA). The NIST library version 2.0f (Standard Reference Data 
Program of the National Institute of Standards and Technology, Distributed by Agilent 




 Mono and sesquiterpenoid references were weighed to 50 mg in a tarred 
volumetric flask using a Satorius analytical balance A200S 0.01 mg (Satorius 
Mechatronics, Utrecht, The Netherlands). Volume was brought to 25 ml with EtOH to 
make 2 mg/ml stock solutions. Stock solutions were used to make dilutions for standard 
curves. Stocks were stored at -20 °C in sealed glass vials in the dark until needed. 
Cannabinoid references were supplied already quantified in EtOH. References were 
diluted in EtOH to make standard curves. Cannabinoid references were stored at -20 °C 






Intra-day reproducibility was determined by injecting an aliquot of a cannabis 
extract 5 times from the same vial in a single day and a reference sample of γ-terpinene 
(1 mg/ml) 5 times from the same vial in a single day (n = 5). Inter-day reproducibility 
was determined by taking a fresh aliquot of the same cannabis extract and γ-terpinene 
reference and injecting 5 times for an additional two days (n = 15) using fresh aliquots 
on each day. All injections performed on the GC-FID. 
 
Extraction efficiency  
 
Three 1 g samples of a batch of Bedrocan that had been used in previous 
studies (Fischedick et al., 2010) and stored for 7 months at 4 °C in the dark were 
extracted with the procedure outlined above. After 3 extractions a 4th extraction was 
performed on each Bedrocan sample with an additional 25 ml of ethanol and analyzed 




Accuracy was determined by checking the recovery of the extraction method 
with spiked monoterpenoids and sesquiterpenoids. Five 1 g samples of a batch of 
Bedrobinol used in previous studies (Fischedick et al., 2010) and stored for 7 months at 
4 °C in the dark were extracted as outlined above.  Five 1 g samples of the same batch 
of Bedrobinol were spiked with 50 µl of the pure references of β-pinene, linalool and β-
caryophyllene while in falcon tubes then extracted as described above. Five volumetric 
flasks were spiked with 50 µl of the pure references of β-pinene, linalool, and β-
caryophyllene and brought to 100 ml with EtOH. All samples analyzed by GC-FID. 
Percent recovery was calculated by subtracting the peak area of each terpenoid from the 
spiked samples minus the un-spiked controls. This number was then divided by the peak 





Linear range, LOD, LOQ, and RF 
 
The linear range was determined empirically by injecting standard compounds 
in a range of 0.01 mg/ml to 2 mg/ml. The LOD and LOQ were determined empirically 
and using signal to noise calculations with Chemstation software. The detector response 
for monoterpenoids, sesquiterpenoids, and cannabinoids was determined by running 
standard curves (0.02 mg/ml – 1.0 mg/ml) of γ-terpinene, limonene, α-pinene, β-pinene, 
(S)-limonene, camphor, linalool, 1,8-cineol, β-caryophyllene, humulene, caryophyllene 




The variation in peak area of the internal standard 1-octanol for all cannabis 




 Principal component analysis (PCA) was performed on SIMCA-P+ version 
12.0.0.0 (Umetrics, Umeå Sweden). Unit variance scaling was used. Hierarchical 
clustering analysis was also done on SIMCA-P+ software and used PC’s 1-6 with the 
Ward method sorted by size.    
 
Results and discussion  
 
Plant material  
 
 Bedrocan BV (Groningen, The Netherlands) is a company licensed and 
contracted by the Dutch government to produce standardized cannabis plant material 
under Good Agricultural Practice (GAP) conditions to be supplied to patients on 
prescription, through pharmacies (OMC, 2010). All plant material in these experiments 
was grown by Bedrocan BV. The varieties Bedrocan® (Bedrocan), Bedropuur® 
(Bedropuur), and Bediol® (Bediol), have been bred by Bedrocan BV for use in 
medicine or research. All other varieties grown in this study are currently used for 
research purposes only. In total 11 cannabis varieties were grown (Table 1). Standard 
growth conditions are defined as the optimum vegetative and flowering growth times 
for each variety. The morphological type classification for each variety is based on 
morphological traits as well as knowledge Bedrocan BV has of the varieties origin and 
breeding history. Hybrids are described as having either equal morphological traits from 
C. indica or C. sativa (ie. hybrid indica/sativa) or having traits of both but mostly 
having traits representative of one of the morphotypes (ie. hybrid mostly sativa). The 
letter codes have no meaning other than to distinguish between varieties. All plants 
were grown from clones of a ‘motherplant’. A motherplant is defined as a female 




Table 1: Cannabis plant information and growth conditions. Vegetative and flowering 
columns show the number of days each sample was grown in each stage under standard 
conditions.  
Variety Vegetative Flowering Morphological type Growth conditions 
AG (1,2,3) 37 54 hybrid indica/sativa 1 and 2- standard 
3- vega +1 wkb, flc +1 
wk 
AE (1,2,3) 37 54 hybrid mostly sativa 1 and 2- standard 
3- veg +1 wk, fl +1 wk 
Ai94 (1,2,3) 37 54 hybrid mostly sativa 1 and 2- standard 
3- veg +1 wk, fl +1 wk 
AO (1,3,5,6,7) 37 47 indica 1,3,5,6- standard(4 
seeds) 
7- fl +1 wk 
AN 37 54 indica standard 
AD 37 47 indica standard 
AM 37 40 indica standard 
AF 37 54 indica standard 
Bedropuur 
(A,B,C,D) 
37 40 indica A- veg -1 wk fl +1 wk 
B- standard 
C- veg +1 wk 
D- veg +1 wk fl +1 wk 
Bedrocan (C) 37 54 hybrid indica/sativa bedrocan- standard 
C- lower branches 
clipped 
Bediol 29 54 indica/sativa/ruderalis standard 
aVeg = vegetative, bwk = week, cfl = flowering. 
Two female cannabis plants were grown for each batch and each growth 
treatment. Five random samples of dried flower material were selected for the analysis 
of each batch and each growth treatment. The purpose of growing plants in different 
batches and with deviations from standard growth conditions was to test the robustness 
of our chemical classification as well as determine the reproducibility of a cannabis 
varieties chemical profile. The AO variety was grown in 5 batches at the same time. 
Each batch originated from a different seed from the same cannabis variety. Seeds were 
grown and female plants were selected for cloning. Each number for the AO variety 
thus denotes a different original seed and its subsequent female clones. Therefore each 
AO batch was not genetically identical. For all other varieties the plants grown were 
genetically identical. The AO7 batch was grown for an extra week in the flowering 
state. The varieties AG, AE, Ai94 were each grown in 3 separate batches (1, 2, and 3). 
Batches 1 and 2 were grown about a month apart while batch 3 was grown at the same 
time as 2 except with an extra week of vegetative growth and an extra week of 
flowering (Table 1). Bedrocan was grown in 2 batches at the same time. One batch had 
its lower branches clipped (c) while the other batch was grown under standard 
conditions (Table 1). Bedropuur was grown in 4 batches at the same time with 1 batch 
grown under standard conditions and the other 3 batches grown with deviations from 







 Results of GC method validation are summarized in Table 2. For precision the 
percent relative standard deviation (RSD) of the peak area of 1-octanol from the 120 
cannabis samples analyzed was calculated. The low RSD of 1-octanol (2.8%) indicates 
that the method was precise in terms of needle injections and FID response over the 
duration of the analytical period. This period consisted of 130 h of GC time excluding 
calibration curves and other validation analyses. Reproducibility was determined by 
comparing peak areas of each compound in a Bedropuur extract for both intraday and 
interday analyses. All compounds had a RSD of <5%. The reproducibility of a pure 
compound, γ-terpinene had a RSD of <2%. These low RSD values indicate that the 
method is reproducible for the analysis of cannabis terpenoids and cannabinoids. 
 
The extraction method chosen for this study had previously been demonstrated 
to be exhaustive and exhibit a high recovery for the quantitative analysis of 
cannabinoids by HPLC (Hazekamp, 2007). Therefore we sought to determine whether 
or not the extraction procedure utilized for cannabinoids was also exhaustive for the 
terpenoids present in cannabis. Bedrocan was selected because it has been shown to 
contain high levels of ∆9-THC and terpenoids (Fischedick et al., 2010). By the fourth 
ethanol extract only 2% ∆9-THC compared to the total peak area of ∆9-THC in the first 
3 extracts remained. This was consistent with previous results concerning the recovery 
of cannabinoids with this extraction method (Hazekamp, 2007). No other residual 
compounds were detected in the fourth extract indicating that the method is also 
exhaustive for the extraction of terpenoids in cannabis. Accuracy of the extraction 
method was demonstrated by determining the recovery of spiked terpenoids. We 
selected Bedrobinol plant material for this experiment because in previous studies 
(Fischedick et al., 2010) this plant material was shown to have low levels of β-pinene 
and β-caryophyllene with no detectable levels of linalool. All terpenoids were 
completely recovered indicating that the method is accurate for the analysis of cannabis 
terpenoids (Table 2). 
 
 Linear standard curves (r2> 0.99) for all compounds tested could be generated 
in the range of 0.01 mg/ml to 1 mg/ml. For ∆9-THC linear standard curves up to 2 
mg/ml could be generated. The limit of quantification (LOQ) for monoterpenoids with a 
molecular weight (Mr) of 136 was 0.4 mg/g, monoterpenes with oxygen was 0.5 mg/g, 
sesquiterpenoids with a Mr of 204 was 0.4 mg/g, sesquiterpenoids with oxygen was 0.5 
mg/g, and for cannabinoids was 0.6 mg/g. The signal to noise ratio was greater then 
1:10 for all compounds present at a concentration above their LOQ. A signal to noise 
ratio of 1:5 was selected as the limit of detection (LOD) and is therefore half that of the 
LOQ for each compound group. The response factor (RF) for each compound is shown 
in table 2. The low variability in RF among compounds with similar mass and chemical 
structure using the FID is consistent with other research done on the quantification of 
essential oils with GC-FID (Bicchi et al., 2008). Therefore terpenoids or cannabinoids 
for which no reference is available could be accurately quantified with components of 
similar or identical molecular mass/formula. 
 




 Compounds were identified by comparing their mass spectra, and retention 
times with authentic references as well as literature reports (Adams, 1989; Hillig, 2004; 
Komori et al., 1968; Ross and ElSohly, 1996; Rothschild et al., 2005). The NIST library 
was also used to assist in compound identification. A summary of quantitative data for 
all compounds in all 11 cannabis varieties is shown in Table 3. The compounds γ-
terpinene, limonene, α-pinene, β-pinene, linalool, β-caryophyllene, humulene, ∆9-THC, 
trans-(─)-∆8-tetrahydrocannabinold (∆8-THC), CBD, and cannabigerol (CBG) were 
quantified using their standard curve RF values. All other compounds were quantified 
using the average RF for compounds with the closest molecular mass/formula. In total 
36 compounds were quantified. 
 
The sesquiterpenoids δ-guaiene and bulnesol are reported as putatively 
identified because they have not been reported in cannabis previously and a reference 
compound was not available for structural confirmation. Five compounds could not be 
identified so we report their characteristic mass ions. Unknown monoterpenoid TP(1) 
m/z: 152 [M+], 91, 84, 69 (base). The unknown sesquiterpenoids (SQ) SQ(1) m/z: 204 
[M+], 161 (base), 133, 105; SQ(2) m/z: 236 [M+], 204, 161, 119, 93 (base); SQ(3) m/z: 
204 [M+], 161 (base), 122, 93. The unknown cannabinoid CB(1) m/z: 356 [M+], 313, 
297 (base), 243, 231. The monoterpenoid TP(1), we suspect is oxygen substituted due to 
its Mr of 152. The unknown sesquiterpenoids SQ(1) and SQ(3) appear to have been 
reported as unknowns in previous studies (Hillig, 2004; Ross and ElSohly, 1996). SQ(2) 
is a sesquiterpenoid with unknown substitution. No detectable levels of the ∆9-THC 
breakdown product CBN were detected in any samples. This indicates that the drying 
and storage process used in this study resulted in no significant amount of ∆9-THC 
degradation except perhaps that of trans-(-)-∆9-tetrahydrocannabinolic acid A (THCA) 
into ∆9-THC.  
 




Table 2: Validation results.  





RSD TPa Mr = 136 RF 
β-pinene 0.4 0.5 γ-terpinene 4604 
myrcene 0.5 0.4 (R)-limonene 4598 
limonene 0.7 0.5 α-pinene 4625 
1-octanol 1.3 0.6 β-pinene 4753 
linalool 1.2 0.6 (S)-limonene 4649 
β-caryophyllene 1.3 0.5 average 4646 
humulene 1.3 0.5 RSD 1.4 
δ-guaiene 4.2 1.6 TP with oxygen  
SQ(1) 1.9 0.6 camphor 3894 
SQ(2) 4.9 1.1 linalool 3936 
elemene 1.7 0.6 1,8-cineol 3827 
guaiol 1.5 0.7 average 3886 
γ-eudesmol 1.4 1.3 RSD 1.4 
THCV 1.1 1.6 SQb Mr = 204  
CBC 2.6 1.3 β-caryophyllene 4754 
CBGM 1.9 0.4 humulene 4661 
Δ9-THC 1.6 0.9 average 4708 
CBG 2.0 0.8 RSD 1.4 
Pure compound   SQ with oxygen   
γ-terpinene 0.5 1.9 caryophyllene-oxide 4285 
Precision RSD (n=120)  Cannabinoids   
1-octanol 2.8  ∆9-THC 3490 
Extraction 
efficiency % Remaining (n=3)  ∆8-THC 3674 
Δ9-THC 2  CBD 3502 
Accuracy % Recovery (n=5) RSD CBN 3521 
β-pinene 102 3.2 CBG 3614 
linalool 102 2.2 average 3560 
β-caryophyllene 100 3.5 RSD 2.2 
aTP = terpenoid. bSesquiterpenoid.
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Table 3: Quantitative data for cannabis strains (mg/g plant material). Compounds with no ± had standard deviations of < 100 µg. 
Compound RRta AO Bedropuur Bedrocan Bediol AG AE Ai94 AN AF AM AD 
number of 
samples  25 20 10 5 15 15 15 5 5 5 5 
α-pinene 0.26 6.7±2.4 0.5 0.8±0.1 1.7±0.1 2.8±0.4 Trc 0.8±0.5 Tr 0.5 3.2±0.1 NDb 
β-pinene 0.31 1.9±0.6 0.7±0.1 1.2±0.2 0.8±0.1 1.4±0.2 Tr 0.5±0.1 Tr 0.7 1.2 Tr 
myrcene 0.33 14.8±7.3 1.6±0.7 6.1±1 19±1.9 13±1.6 0.4±0.1 7.1±0.8 0.8±0.2 3.4±0.1 6.7±0.6 13.8±0.9 
α-phellandrene 0.35 ND ND 0.6±0.1 Tr ND Tr Tr ND Tr ND ND 
Δ3-carene 0.36 ND ND 0.5±0.2 Tr ND Tr Tr ND Tr ND ND 
α-terpinene 0.36 ND ND 0.4 Tr ND Tr Tr ND Tr ND ND 
β-phellandrene 0.38 ND ND 2.1±0.3 0.7±0.1 ND Tr 0.5 ND 1.0 ND Tr 
limonene 0.38 2.5±0.7 4.9±0.8 ND ND 2.4±0.4 ND ND 2.3±0.3 ND 0.7±0.1 ND 
cis-ocimene 0.40 1.4±0.4 ND 3.9±0.6 1±0.1 0.6±0.1 0.7±0.1 1±0.1 ND 1.0±0.1 ND ND 
terpinolene 0.47 ND ND 11.3±1.7 3.7±0.4 ND 1.9±0.9 2.9±0.3 ND 5.4±0.2 ND ND 
linalool 0.48 0.9±0.1 1.2±0.2 Tr ND Tr ND Tr Tr Tr Tr Tr 
terpineol 0.63 Tr Tr 0.7±0.1 0.6 ND Tr Tr Tr Tr Tr ND 
TP(1) 0.86 ND ND 0.7±0.2 Tr ND Tr ND ND Tr ND ND 
β-
caryophyllene 1.00 3.5±2.4 2.6±0.2 1.6±0.2 0.8±0.1 1.4±0.4 0.5±0.3 0.8±0.4 1.4±0.2 0.5 0.5 2.0±0.1 
α-guaiene 1.03 ND Tr Tr Tr 0.5 ND Tr ND Tr Tr Tr 
humulene 1.05 1.2±0.9 0.8±0.1 0.9±0.1 0.6±0.1 0.7±0.1 Tr 0.7±0.1 Tr Tr ND 0.6 
δ-guaieneP 1.13 ND 0.7±0.1 0.8±0.1 0.8 0.7±0.2 ND ND ND ND ND 0.6 
SQ(1) 1.18 0.5±0.1 0.6±0.1 0.6±0.1 Tr Tr ND ND 1.3±0.1 Tr ND ND 
SQ(2) 1.19 0.6±0.2 ND ND ND ND ND ND ND ND ND ND 
SQ(3) 1.19 ND 1.0±0.2 0.6±0.1 Tr 0.5±0.1 Tr ND 1.8±0.1 ND ND ND 




guaiol 1.27 0.6±0.2 0.6 ND ND ND 0.4 ND ND Tr ND ND 
γ-eudesmol 1.30 0.7±0.2 0.6 ND ND ND 0.4 ND ND Tr ND ND 
β-eudesmol 1.34 0.4 Tr ND ND ND Tr ND ND Tr ND ND 
agarospirol 1.35 0.5±0.1 Tr ND ND ND Tr ND ND Tr ND ND 
bulnesolP 1.37 0.5 ND ND ND ND ND ND ND ND ND ND 
α-bisabolol 1.39 0.5±0.1 Tr ND ND ND ND ND 0.5±0.1 ND ND Tr 
CBDV 2.04 ND ND ND Tr ND ND 1.5 ND ND ND ND 
THCV 2.15 1.3±0.4 1.3±0.3 1.3±0.2 Tr 0.7±0.1 Tr ND 0.6 0.7±0.1 1±0.1 0.6 
CBD 2.27 Tr Tr Tr 79.8±1.8 ND ND 73.6±2.1 ND1 ND Tr ND 
CBC 2.27 2.1±0.4 2.1±0.3 2.3±0.1 5.4±0.1 1.4±0.1 1.6±0.8 4.6±0.3 0.9±0.1 0.9 1.4±0.1 2.2±0.2 
CB(1) 2.32 0.8±0.5 1.1±0.2 1.6±0.3 1.2 0.7 ND ND Tr Tr Tr Tr 
CBGM 2.32 ND 1.1±0.1 ND ND ND ND ND 1.8±0.3 2.6±0.1 Tr Tr 
























CBG 2.42 10±1.6 4.1±1.3 11.2±2 1.7±0.2 2.8±0.6 1±0.4 ND 1.9±0.2 3.0±0.3 2.1±0.1 1.2±0.1 
aRRt relative retention time to β-caryophyllene. bND = not detected (< LOD). cTr = trace levels detected (< LOQ). pPutative identification.
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Higher levels of cannabinoids were positively correlated to higher levels of 
terpenoids (Figure 1). Both the cannabinoids and terpenoids of cannabis are localized 
primarily in glandular trichomes (Malingre et al., 1975; Taura et al., 2007). This may 
explain why in some varieties their levels are correlated, however it does not prove that 
their biosynthesis is necessarily correlated. This is demonstrated by the Bedropuur 
variety whose ∆9-THC levels are high but its terpenoid levels are similar to the varieties 
AD and AG. This suggests that it is possible to breed cannabis that contains high levels 
of ∆9-THC but not necessarily higher levels of terpenoids.  
 
Figure 2 PCA of all cannabis varieties. PC1 versus PC2, scatter plot (top) and loading 
plot (bottom). (1) AO, (2) Bedropuur, (3) Bedrocan, (4) Bediol, (5) AG, (6) AE, (7) 





Figure 3 PCA of all cannabis varieties. PC1 versus PC3, scatter plot (top) and loading 
plot (bottom). (1) AO, (2) Bedropuur, (3) Bedrocan, (4) Bediol, (5) AG, (6) AE, (7) 
Ai94, (8) AN, (9) AF, (10) AM, and (11) AD. 
 
 
Metabolic fingerprinting of cannabis 
 
It’s clear from the data that each cannabis variety is both qualitatively and 
quantitatively different (Table 3). The levels of ∆9-THC ranged from 20.8% (Bedrocan) 
to 0.3% (Ai94). Bedrocan, Bedropuur, and AO all contained high levels of ∆9-THC 
(>15%). AG, AM, AD, AN, and AF all contained a medium level of ∆9-THC (<15%, 
>5%). Bediol also contained a medium level of ∆9-THC (6%) however its relatively 
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high level of CBD (8%) makes it unique compared to the other varieties. AE and Ai94 
contained low amounts of ∆9-THC (<5%). Ai94 contained a relatively high level of 
CBD (7.4%) compared to the other varieties. Ai94 also contained the C3 side chain 
variant of CBD, (-)-cannabidivarin (CBDV). Bediol only contained trace levels of 
CBDV. The levels of propyl side chain analogues of cannabinoids have been reported to 
be of chemotaxonomic significance. It has been hypothesized that the enzymes involved 
in enhancing the levels of these compounds originate from C. indica and are not 
commonly present in C. sativa subtype (Hillig and Mahlberg, 2004). CBD was only 
detected in trace amounts (<0.6 mg/g) or not at all among the high, medium, and low 
∆9-THC varieties making them representatives of the drug/∆9-THC chemotype. Bediol 
is representative of the intermediate chemotype and Ai94 is representative of the 
fiber/CBD chemotype. The levels of ∆9-THC and CBD alone do not chemically 
distinguish the high or medium ∆9-THC containing varieties well from one another.  
 
Therefore to further chemically classify cannabis principle component analysis 
(PCA) was used. PCA is a multivariate projection method which extracts and displays 
systemic variation from a set of matrix data consisting of observations and variables 
(Eriksson et al.,, 2006). The 36 compounds were the variables and their mg/g levels the 
observations. Initially all the cannabis samples were analyzed by PCA (Figure 2). 
Principal component 1 (PC1) and PC2 explains 44% of the variance. The highest ∆9-
THC containing varieties Bedropuur, Bedrocan, and AO are separated along the 
positive PC1. The Bedrocan variety was also well separated along negative PC2. The 
compounds responsible for making Bedrocan different according to the loading plot are 
terpinolene, β-phellandrene, α-phellandrene, terpineol, cis-ocimene, and ∆3-carene. 
Bedrocan contained higher levels of these compounds compared with other varieties. 
Terpinolene was a very dominant monoterpenoid (11.3 mg/g) in the Bedrocan variety 
(Table 3). Bediol partially separated along the negative PC2 also contained terpinolene, 
β-phellandrene, α-phellandrene, terpineol, and ∆3-carene but in lower levels than 
Bedrocan. This observation is interesting because the Bediol variety was bred by 
hybridizing the Bedrocan variety with higher CBD containing varieties.  
 
The loading plot along the positive PC1 and positive PC2 shows that 
Bedropuur and AO contained more of the sesquiterpene alcohols guaiol, γ-eudesmol, β-
eudesmol (Figure 2). The study by Hillig (2004) reported that guaiol, γ-eudesmol, and 
β-eudesmol were characteristic terpenoid compounds of the C. indica varieties 
originating from Afghanistan. These sesquiterpenoid alcohols appear to be important in 
distinguishing C. indica varieties from one another because the AG, AN, AM, and AD 
varieties which are also C. indica morphotypes did not contain detectable levels of these 
compounds. AF another C. indica only contained trace amounts of these compounds 
(Table 3). In order to distinguish Bedropuur and AO further PC1 and PC3 were 
compared (Figure 3). PC3 was able to explain an additional 15% of the variance. The 
Bedropuur variety contained higher levels of limonene as well as the sesquiterpenoid 
elemene while the AO variety contained higher levels of myrcene and α-pinene. Also 
along PC3 information was obtained about the AN variety which contains a medium 
level of ∆9-THC (95.2 mg/g) but higher levels of the sesquiterpenoids SQ(1), SQ(3), 





The medium ∆9-THC varieties AG, AF, AM, and AD were not well separated 
along PC1, 2, or 3. Therefore these varieties were reanalyzed by PCA with all other 
varieties excluded (Figure 4). AG and AD had higher and very similar levels of ∆9-
THC, myrcene, and β-caryophyllene compared with AM and AF. AG and AD were 
distinguished along PC2. AG contained more α-pinene, β-pinene, limonene, α-guaiene, 
elemene, and SQ(3). AD however contained low levels of monoterpenoids and 
sesquiterpenoids in general and only slightly higher levels (<1.0 mg/g) of myrcene, β-
caryophyllene, and CBC compared to AG. AF contained the highest levels of 
cannabigerol monomethyl ether (CBGM) while AM contained higher levels of myrcene 
and α-pinene.  
 
Hierarchical cluster analysis (HCA) was used to confirm the PCA analysis 
(Figure 5). The AO batches are all clustered together and each genotype (different seed) 
is also grouped together. The Bedropuur batches are clustered together and AN was the 
next similar variety. Both Bedropuur and AN were separated along the negative PC3 
(Figure 3) because of the presence of the cannabinoid CBGM as well as numerous 
similarities in monoterpenoids and sesquiterpenoids (Table 3). Bedrocan was in its own 
group which is consistent with PCA analysis. The clipped Bedrocan batch exhibits some 
differences according to HCA when compared to unclipped. Bediol and Ai94 are related 
due to higher levels of CBD but each clustering on their own. Ai94(2) however was 
clustered closer too AE and AF most likely because of small differences caused by 
growing this variety in different batches. The medium ∆9-THC varieties are all clustered 
close to one another except AF. AF was closer to AE and Ai94(2) most likely because it 
has the lowest amount of ∆9-THC compared to the other medium varieties. Each 
medium ∆9-THC variety is clustered with itself except AG because it was grown in 
different batches which caused small differences in chemical profile. The morphotype 
of each medium ∆9-THC variety does not seem important in relating these varieties.  
 
These observations represent a significant improvement compared with other 
methodologies, discussed in the introduction, using chemotaxonomy to discriminate 
cannabis varieties. By using quantitative data on cannabinoid and terpenoid levels it was 
possible to chemically distinguish each variety from one another with the aid of PCA. 
Both Hillig (2004) and Hillig and Mahlberg (2004) had difficulty discriminating drug 
type cannabis accessions from one another. Furthermore the conclusion in the study of 
Hillig (2004) that sesquiterpenoids were more important than monoterpenoids in 
chemically differentiating cannabis varieties is not accurate. In this study 
monoterpenoids were able to distinguish varieties which had similar sesquiterpenoid 
levels and similar cannabinoid levels such as AO and Bedropuur as well as a number of 
the medium ∆9-THC varieties.  
 
Effect of growing cannabis in different batches and growth cycle deviations 
 
 The effect on chemical profile from growing cannabis varieties in separate 
batches about a month apart as well 1 week extra vegetative and flowering periods was 
studied in the AG, AE, and Ai94 varieties. A comparison of the compounds within the 
AG varieties batches is shown in Figure 6. The differences between each batch were 
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minor with no clear distinction between them. The largest differences are between 
AG(1) and AG(2) with the level of myrcene being 1.8 mg/g higher on average in AG(1) 
compared with AG(2), β-caryophyllene being 0.5 mg/g higher on average in AG(2) 
compared to AG(1), CBG being 0.8 mg/g higher in AG(2) compared to AG(1), and ∆9-
THC being 17.3 mg/g higher in AG(2) compared to AG(1). Most compounds in the AE 
batches did not differ much in concentration (<1.0 mg/g), except terpinolene and ∆9-
THC (Figure 7). The Ai94 batches also only had minor differences (Figure 8). These 
results importantly demonstrate that genetically identical cannabis plants grown in 
batches at separate times under standardized environmental conditions are reproducible 
in terms of terpenoid and cannabinoid concentrations.  
 
Figure 4 PCA of the varieties AG, AD, AM, and AF. PC1 versus PC2 scatter plot (top) 





Figure 5 Hierarchical clustering analysis of all cannabis samples.  
 
 
A detailed look into the chemical variation among the Bedropuur batches is 
shown in Figure 9. Batches A, C, and D differed in the concentrations of certain 
compounds compared with the standard batch B. The levels of limonene were lower in 
A, C, and D. Myrcene was lower in A and D compared with B and C. The levels of ∆9-
THC were about 30 mg/g higher in Bedropuur C compared to the other 3 batches. 
Bedropuur D had the lowest amount of ∆9-THC. Bedropuur A had lower concentrations 
of the β-caryophyllene, elemene, and CBG when compared to batches B and C. These 
results demonstrate that alterations in growth cycle time can cause changes in the 
chemical profile of cannabis plants grown under environmental conditions that were 
otherwise the same. Alterations in growth cycle time appear to cause more differences 
in a cannabis varieties chemical profile then growing the plant material in different 
batches. However more experiments with more varieties, grown with more deviations in 
growth cycle time, and more replicates would be needed to confirm these observations.  
 
Clipping the lower branches on the Bedrocan variety caused some compounds 
to be present at lower concentrations (Figure 10). These compounds include myrcene, 
cis-ocimene, β-caryophyllene, elemene, CBG, and ∆9-THC. This suggests that by 
clipping the lower branches, which would allow more water and nutrients to flow to the 
upper parts of the plant closest to the light, does causes some changes in the chemical 
profile. Further experiments would be needed to determine if this represents a consistent 
pattern and explain why it occurs.  
 
The different AO batches exhibited the greatest quantitative differences in 
chemical profile compared with all other varieties (Figure 11). AO batches exhibited a 
wide range of concentrations for α-pinene, myrcene, β-caryophyllene, and ∆9-THC. The 
different AO batches could even be clearly distinguished by PCA (Figure 12). This 
observation shows that by metabolically profiling cannabis strains based on cannabinoid 
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and terpenoid levels it is also possible to distinguish separate genotypes of the same 
variety.  
 
Overall these experiments demonstrate that the best way to grow reproducible 
batches of cannabis is by using genetically identical plant material grown from clones, 
under standardized environmental conditions, with the same growth cycle. Deviations in 
growth cycle and clipping of lower branches can cause quantitative differences, 
although minor in absolute terms, in chemical profile. These deviations can obscure 
their chemical classification as was observed in the HCA. Cannabis plants from seeds 
representing different genotypes but the same variety can differ considerably in 
quantitative chemical profile. Future research should aim to determine if cannabis could 
be grown in such a reproducible manner for many years. As a preliminary indication of 
chemical profile reproducibility a previous study in our laboratory using similar 
methodology analyzed the Bedrocan variety. This plant material was grown about 1 
year previously to the batches analyzed in this study. This batch had similar levels of 




 In this study a simple quantitative GC-FID method was validated for the 
quantitative analysis of cannabis monoterpenoids, sesquiterpenoids, and cannabinoids. 
Quantitative GC data was used to chemically discriminate cannabis varieties with the 
aid of principal component analysis. Our results show for the first time using validated 
methodology the absolute (mg/g) levels of cannabinoids and terpenoids in cannabis 
simultaneously. This data can be useful for guiding pharmacological or clinical studies 
that want to examine the potential interactions of the volatile constituents of cannabis. 
The chemical profile of cannabis varieties could potentially be more closely correlated 
to therapeutic effectiveness. The reported methodology could be implemented in the 
quality control of medicinal cannabis. Our methodology also appears to be able to 
overcome the difficulties in chemotaxonomic analysis of cannabis observed by other 
researchers in distinguishing drug type cannabis varieties from one another. These 
techniques should be applied on a wider range of cannabis samples representing both 
geographically and morphologically distinct varieties. By combining genomic 
approaches with metabolic fingerprinting it may be possible to elucidate exactly which 
biochemical pathways differ in various cannabis varieties and how these differences 





Figure 6 Comparison of AG batches. Compounds that are missing in certain batches 




Figure 7 Comparison of AE batches. Compounds that are missing in certain batches 
were present at levels < LOQ. 
 
 
Figure 8 Comparison of Ai94 batches. Compounds that are missing in certain batches 





Figure 9 Comparison of Bedropuur batches. Compounds that are missing in certain 




Figure 10 Comparison of Bedrocan batches. Compounds that are missing in certain 





Figure 11 Comparison of AO seed batches. Compounds that are missing in certain 
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 Tanacetum parthenium (Asteraceae) produces biologically active sesquiterpene 
lactones (SL). Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor known 
to activate a series of genes termed the antioxidant response element (ARE). Activation 
of Nrf2/ARE may be useful for the treatment of neurodegenerative disease. In this study 
we isolated 11 SL from T. parthenium with centrifugal partition chromatography and 
semi-preparative HPLC. Compounds were screened in-vitro for their ability to activate 
the ARE on primary mouse cortical cultures as well as for their toxicity towards the 
cultures. All SL containing the α-methylene-γ-lactone moiety were able to activate the 
ARE and cause cellular toxicity. The structure activity relationship among the SL 
isolated indicates that the guaianolides were more active and when lacking the 
endoperoxide functionality less toxic then the germacranolides.  
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Tanacetum parthenium L. (syn. Chrysanthemum parthenium), commonly 
known as feverfew, is a member of the Asteraceae family containing various 
sesquiterpene lactones (SL) from the germacranolide, eudesmanolide, and guaianolide 
groups. In European traditional medicine, T. parthenium has been used for the treatment 
of migraine and rheumatism. The germacranolide, 4α,5β-epoxy-germacra-1-(10),11-
(13)-dien-12,6α-olide (parthenolide (1)) is often regarded as the primary active 
ingredient in T. parthenium (Abed et al., 1995). Parthenolide exhibits numerous 
biological activities such as cytotoxicity, anti-viral, anti-leishmanial, and anti-
inflammatory action (Hwang et al., 2006; Tiuman et al., 2005; Salminen et al., 2008). In 
past decades 1 and other SL have been the subject of cancer clinical trials (Ghantous et 
al., 2010). 
 Nrf2 is a transcription factor known to induce genes encoding cytoprotective 
and antioxidant enzymes by binding to the cis-acting enhancer element called ARE, in 
the promoter of these genes. Activation of Nrf2/ARE pathway with small molecules is a 
potential strategy to treat neurodegenerative diseases (Calkins et al., 2009; de Vries et 
al., 2008). Nrf2 localization and degradation is regulated by its cytoplasmic repressor 
protein the Kelch-like ECH-associated protein 1 (Keap1). Various compounds or 
reactive oxygen species (ROS) can interfere with the ability of Keap1 to bind Nrf2 and 
thereby up-regulate activation of ARE (de Vries et al., 2008). A series of conserved 
cysteine residues on Keap1 are important for compounds like tert-buytlhydroxyquinone 
(tBHQ) or ROS to liberate Nrf2 from Keap1 (Zhang and Hannink, 2003; Itoh et al., 
2004).       
         The biological activity of many SL such as 1 is often attributed to the presence 
of the α-methylene-γ-lactone moiety. The nucleophilic methylene can react with 
biological thiols, such as cysteine residues on proteins, by a Michael addition type 
reaction (Mathema et al., 2012). Mild activation of Nrf2/ARE by 1 has been 
demonstrated using human hepatoma (HepG2) cells and SL from Calea urticifolia 
along with 1 in rat pheochromocytoma (PC12) cells (Jeong et al., 2005; Umemura et al., 
2008). Neither study however investigated 11,13-dihydro versions of the compounds to 
confirm importance of α-methylene-γ-lactone moiety nor the toxicity of 1. Another 
study demonstrated a neuroprotective effect of the SL isoatriplicolide tiglate against 
glutamate induced toxicity on primary rat cortical cells, however molecular mechanisms 
and toxicity were not investigated (Kim et al., 2010). Neurotoxic effects of SL such as 
repin from Centaurea species, which causes a disease in horses called equine 
nigropallidal enchalomalacia, have also been reported (Tukov et al., 2004).   
 Therefore in order to gain further insight into the structure activity 
relationships of SL for Nrf2/ARE activation, a variety of SL were isolated from T. 
parthenium. Due to difficulties reported in the isolation of certain SL from T. 
parthenium (Bohlmann and Zdero, 1982), a centrifugal partition chromatography (CPC) 
method was developed to improve their isolation. Isolated compounds were screened in 
vitro for ARE activation using primary mouse cortical cultures derived from ARE-




2002). Since SL are potentially neurotoxic, the compounds toxicity towards the cultures 
was also evaluated using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl) 2H tetrazoluim inner salt (MTS) assay.  
Materials and Methods  
Chemicals 
 Ethylacetate (EtOAc), n-heptane (Hept), methanol (MeOH), ethanol (EtOH), 
n-hexane (Hex), diethylether (Et2O), acetone, dichloromethane (DCM) of analytical 
reagent grade, and MeOH HPLC grade were purchased from Biosolve BV 
(Valkenswaard, The Netherlands). Et2O was distilled at 35 °C prior to use. Vanillin, 
parthenolide (90% purity), and chloroform (CHCl3) were from Sigma-Aldrich Inc. (St. 
Louis, Missouri, USA). Sulfuric acid 95-97% from Fluka GmbH (Buchs, Switzerland), 
magnesium sulfate (MgSO4) from Brocacef BV (Maarssen, The Netherlands), silica gel 
60 (0.063 - 0.2 mm) for column chromatography, and silica gel 60 F254 10 x 20 cm TLC 
plates (Merck, Darmstadt, Germany) were used. CDCl3 was purchased from Eurisotop 
SA (Gif-Sur-Yvette, France).  
Plant material 
 One kg of the dried aerial parts of T. parthenium was purchased from De 
Groene Luifel BV (Sluis, The Netherlands) referred to as NL and 2 kg of the dried 
flower heads of T. parthenium was grown at the University of Belgrade Institute for 
Biological Research referred to as IBRSS. Plant material was identified by Wout 
Holverda and voucher specimens were deposited in the economic botany collection of 
the National Herbarium Nederland in Leiden under the following barcodes 0991399 J. 
Fischedick No. 132010 and 0991384 J. Fischedick No. 172010.  
Crude extraction preparation 
 Two hundred and fifty g of NL plant material was extracted 3 times with 4, 3, 
and 3 L of EtOH with stirring for 24 h each with an initial 30 min of ultra-sonication. 
EtOH extracts were combined and solvent removed under reduced pressure at 40 °C. 
The extract was then dissolved in 500 mL EtOAc and rinsed 3 times with 500 mL H2O. 
The EtOAc fraction was dried over MgSO4, filtered, and EtOAc removed under reduced 
pressure at 40 °C yielding 8.0 g of a dark green extract (Extract 1). Extract 2 was 
prepared in the same way as extract 1 except 250 g of IBRSS plant material, flower 
heads only, was used and yielded 17.3 g of a dark golden extract.  
 CPC apparatus and solvent system selection 
CPC experiments were carried out on a Fast Centrifugal Partition 
Chromatograph with a 1 L internal volume rotor (Kromaton Technologies, Angers, 
France). The CPC was connected to a Rheodyne injector equipped with a 30 mL 
injection loop (Rheodyne Inc, Cotati, CA, USA), an AP100 Armen instruments pump 
(Saint-Avé, France), and a LKB Bromma Fraction Collector 2211 SuperRac (Bromma, 
Sweden). A Tamson Instruments BV (Bleiswijk, The Netherlands) Low Temperature 
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Circulator TLC15 set at 21 °C was used to maintain a constant temperature inside the 
rotor chamber. The CPC solvent system was selected by screening 3 and 4 solvent bi-
phasic mixtures described in (Foucault, 1995) for the ability to solubilize a crude T. 
parthenium extract and evenly partition compounds between the upper (↑) and lower (↓) 
layers. Partitioning of compounds was assessed visually by TLC (CHCl3: EtOAc; 7: 3; 
vanillin/sulfuric acid reagent) analysis of ↑ and ↓ layers. Finally a solvent system 
composed of Hept: EtOAc: MeOH: H2O, 1:1:1:1 (HEMW) solvent system was selected 
for fractionation of extract 1 and 2. 
CPC experiments 
Extract 1 could be dissolved in 90 mL of 1:1 mixture of ↑:↓ layer of the 
HEMW system while extract 2 could be dissolved in 110 mL. In total six CPC 
experiments were performed to process extracts 1 (CPC1-3) and 2 (CPC4-6). Each CPC 
experiment consisted of the following procedure. Four L HEMW was prepared by 
mixing for 1 h, settling for 1 h, and separating into ↑ and ↓ layer. Initially 1.1 L of the ↓ 
layer was pumped into the CPC system to act as the stationary phase. The CPC was 
equilibrated by pumping the ↑ layer in ascending mode, at a flow rate of 10 mL/min, 
and rotor speed of 1000 rpm. The system was in equilibrium when the ↑ layer began to 
elute and the volume of ↓ layer displaced was recorded (void volume). Thirty mL of 
sample was injected for all experiments except for experiment 6 which was 50 mL. The 
50 mL injection was performed by first injecting 30 mL of the sample, allowing 10 
mL/min flow rate to run for 3 min, flow stopped while remaining 20 mL of sample was 
injected, and the run was continued as normal.  
Initially during each CPC experiment 400 mL of the eluent was collected in a 
glass bottle (FrI) then 85 x 10 mL fractions (Fr) were collected in glass test tubes. After 
the 85th fraction was collected the ↓ layer was pumped into the system. The remaining ↑ 
layer was collected in a glass bottle and the fraction labeled Fr↑. Finally 800 mL of the 
↓ layer was eluted and this fraction labeled Fr↓. Some ↓ layer bleeding was observed in 
each experiment however it was confined to FrI. Fractions were analyzed by TLC in the 
same way as above and combined based on similarity of chemical profile.  
HPLC 
 An Agilent 1200 series HPLC was used for analyzing purity of combined 
fractions and isolated compounds. The system consisted of a G1322A degasser, 
G1311A quaternary pump, G1367B Hip automated liquid sampler, and G1315D diode-
array (DAD) detector (Agilent technologies Inc, Santa Clara, CA, USA). The software 
used was Chemstation Rev. B03.02. A 150 x 4.6 mm Luna 5 micron C18 (2) 100A 
column equipped with a guard column containing C18 4 x 3 mm cartridges was used for 
separation (Phenomenex Inc, Torrance, CA, USA). Gradient elution with a flow of 0.5 
mL/min consisted initially of 50% H2O and 50% MeOH which increased to 100% 
MeOH over 40 min and remained at 100% MeOH for 10 min. The DAD detector was 
set at 210 nm with a UV spectrum scan from 190-390 nm. 




Semi-preparative HPLC (pHPLC) was performed with 2 LC-10ADvp liquid 
chromatograph pumps, a SPD-10Avp UV-vis detector, a SCL-10Avp system controller, 
a FRC-10A Fraction Collector, and controlled by software LCsolution Version 1.21 SP1 
all manufactured by Shimadzu (Kyoto, Japan). A Luna C18 (2) 100 A 5 micron 250 x 
10 mm column was used for reverse phase pHPLC (RP) and a Luna Silica (2) 100 A 5 
micron 250 x 10 mm column equipped with a security guard cartridge holder (10 mm 
internal diameter) containing a security guard semiprep cartridge silica (10 x 10 mm) 
was used for normal phase pHPLC (NP) (Phenomenex, Torrance, CA, USA). Flow 
rates were 5 mL/min, UV 210 and 254 nm, and 10 mL fractions were collected. After 
filtration over a 25 mm 0.45 µm PTFE syringe filter samples were injected manually 
into the pHPLC system using a Rheodyne injector equipped with a 5 mL injection loop. 
NP samples were dissolved in 5 mL DCM for injection. After each NP experiment 
column was rinsed with 100 mL of acetone or EtOAc (rinse fraction) and fractions were 
combined based on similarity of TLC profile. RP samples were dissolved in 1-5 mL 
mobile phase or pure MeOH. RP fractions were combined based on UV 
chromatograms, MeOH removed under reduced pressure at 40 °C, remaining H2O 
frozen at -20 °C, and sample lyophilized to dryness.  
Purification 
 CPC experiments 1-3 Fr43-70 (540 mg) was fractionated by NP (Hept: EtOAc, 
9:1). Fr13-26 were combined and solvent removed to yield of 1 (408 mg, 96% pure) as a 
clear gum which can be crystallized to white needles using cyclohexane. Fr27-33 (11 mg) 
was further purified with RP (H2O: MeOH, 1:1, isocratic) yielding 11,13-
dihydroparthenolide (2) (4.9 mg, >99%). CPC 1-3 Fr71-85 (55 mg) was fractionated by 
NP (Hept: EtOAc, gradient) with Fr29 (1.9 mg) and Fr44 (0.8 mg) being purified with RP 
(H2O: MeOH, 1:1, isocratic) yielding anhydroverlotorin (3) (0.2 mg, 82%) and 
santamarine (4) (0.4 mg, >99%) respectively. CPC 1-3 Fr↑ (78 mg) was fractionated by 
NP (Hept: EtOAc, gradient) with Fr7 being purified with RP (H2O: MeOH, 3:7, 
isocratic) yielding 3 (0.8 mg, 87%) and Fr34-35 (0.4 mg) purified with RP (H2O: MeOH, 
1:1, isocratic) yielding reynosin (5) (0.3 mg, 88%). CPC 1-3 Fr↓ (2.2 g) was 
fractionated with an additional CPC experiment (7) using a 200 mL rotor, HEMW 
4:6:4:6 solvent system, with all other CPC conditions same as described above. Seventy 
10 mL fractions were collected. CPC 7 fractions Fr10-20 (508 mg), Fr21-42 (506 mg), Fr43-
50 (78 mg), and Fr51-70 (130 mg) were each further separated by NP (Hept: EtOAc, 7:3) 
with subsequent fractions being purified with repeated RP to yield 3β-
hydroxycostunolide (6) (4.8 mg, 94%), costunolide diepoxide (7) (13 mg, 90%), 3-
hydroxyparthenolide (8) (20.2 mg, 94%), artemorin (9) (4.6 mg, 98%), and artecanin 
(10) (1.1 mg, 95%).   
CPC 4-6 Fr40-70 was dissolved in 30 mL EtOAc, loaded onto 10 g of silica gel, 
eluted with 200 mL EtOAc, and solvent removed to yield 1 (2.3 g, 98%), which was 
crystallized from Et2O: Hex to white/yellow needles. CPC 4-6 Fr71-85 and Fr↑ were 
combined (490 mg) and separated with NP (Hept: EtOAc, gradient) with Fr15-16 (44 mg) 
and Fr22-24 (22 mg) further purified with RP (H2O: MeOH, gradient) to yield 3 (1.5 mg, 
99%) and 6 (3.6 mg, 74%) respectively. CPC 4-6 Fr↓ (4 g) was separated by flash 
chromatography (150 g silica) using Hex with increasing proportion EtOAc followed by 
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EtOAc with increasing proportions of acetone into 17-100 mL fractions. Flash Fr8-9 
(434 mg) was further purified with repeated RP to yield 8 (1.7 mg, 90%), 6 (27.5 mg, 
86%), and tanaparthin-β-peroxide (11) (3.9 mg, 76%). Flash Fr10-17 (2.6 g) was again 
fractionated by flash chromatography (100 g silica) using Hex with increasing 
proportion of acetone. Subsequent fractions were purified with repeated RP to yield 7 
(18 mg, 99%), 10 (13.3 mg, 82%), 9 (32.1 mg, 96%), and 11 (2.3 mg, 87%).      
 Structure elucidation 
1H-NMR and COSY spectra were acquired on a Bruker DMX 500 MHz NMR 
(Karlsruhe, Germany). The solvent was CDCl3 and chemical shift was calibrated to 
residual solvent (7.26 ppm). High resolution mass spectrometry was performed on an 
LC-LTQ-Orbitrap FTMS system (Thermo Scientific, Waltham, Massachusetts, USA). 
The instrument consisted of an Accela HPLC, an Accela photodiode array detector, 
connected to a LTQ/Orbitrap hybrid mass spectrometer equipped with an ESI source. 
Chromatographic separation took place on a Phenomenex Luna C18(2) analytical 
column (150 x 2.0 mm, 3 µm particle size), using H2O and acetonitrile, both containing 
0.1 % v/v formic acid, at a flow rate of 0.19 mL/min and a column temperature at 40 
°C. A linear gradient from 5 to 75% acetonitrile in 45 min was applied, which was 
followed by 15 min of washing and equilibration. FTMS full scans (m/z 100−1200) 
were recorded with a resolution of 60.000, whereas for MSn scans a resolution of 15.000 
was used. The FTMS was externally calibrated in negative mode using sodium formate 
clusters in the range m/z 150-1200 and automatic tuning was performed on m/z 384.93.  
Primary Cortical Neuronal Cultures 
 Cultures were derived from ARE-hPAP reporter mice as previously described 
(Johnson et al., 2002; Kraft et al., 2004). Briefly, cortices from E15 mouse pups were 
pooled in 10 mL ice-cold Ca2+ and Mg2+ free HBSS (Life Technologies, Carlsbad, CA, 
USA). Tissue was minced, centrifuged and digested in 0.05% trypsin without EDTA in 
HBSS for 15 min at 37 °C. Following trypsinization, cells were rinsed 3 times with 
HBSS. Cells were then washed with CEMEM (minimum essential media with Earle’s 
salts; (Life Technologies), 2 mM glutamine, 1% penicillin/streptomycin, and 10% each 
of heat inactivated fetal bovine serum and horse serum (Atlanta Biologicals, Inc., 
Lawrenceville, GA, USA) and triturated to a single-cell suspension and strained through 
a 70 µM cell strainer (BD Biosciences, San Jose, CA, USA). Cells were counted, 
assayed for viability using trypan blue, and plated at a density of 3 x 105 cell/cm2 on 
poly-D-lysine coated plates. Cells were maintained in CEMEM for 45 min, followed by 
a medium change with CEMEM. After two days, medium was changed from CEMEM 
to NBM (Neurobasal media; Life Technologies) supplemented with B27 with 
antioxidants and 2 mM glutamine. These mixed cultures (~ 40% astrocytes and 60% 
neurons), were left for at least 48 hours in NBM prior to initiating experiments. Cells 
were incubated at 37 °C in a tri-gas incubator with 5% O2, 5% CO2, and 90% N2.  
 Compounds were dissolved in 100% DMSO and administered to cells for 48 
hours (final concentration of DMSO was 0.1%) after 6 days in culture. Nrf2 activation 




described previously (Kraft et al., 2004). Briefly, cells were lysed in TMNC lysis buffer 
(50 mM Tris, 5 mM MgCl2, 100 mM NaCl, 1% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)) and freeze-thawed 
at -20 oC. Extracts were incubated with 200 mM diethanolamine (DEA) buffer at 65 oC 
to inactivate endogenous alkaline phosphatase activity. hPAP activity was quantified in 
200 mM DEA with 0.8 mM CSPD [disodium 3-(4-methoxyspiro (1,2-dioxetane-3,2’-
(5’-chloro)tricycle(3.3.1.13,7)decan)-4-yl)phenyl phosphate) (Life technologies), 2x 
Emerald and 5 mM MgCl2]. Luminescence was measured on a Berthold Orion 
microplate luminometer with one-second integration. Baseline signal from hPAP 
negative control culture samples was subtracted from all values. Cell viability was 
assayed using the MTS (3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium salt) assay from Promega (Madison, WI, USA) 
following the manufacturer’s suggested protocol. 
Statistical analysis 
All data are represented as mean ± SEM (n = 5). Statistical analysis was 
performed using one-way ANOVA followed by Newman-Keuls multiple comparison 
(GraphPad prism version 4). 
Appendix 
 Detailed T. parthenium growth conditions, NMR data, and high resolution MS, 
are available in chapter 5 appendix.  
Results and Discussion 
For CPC experiments the void volume ranged from 210-250 mL and the 
pressure ranged from 51-57 bar between runs. Up to 7.9 g of extract 2 could be injected 
without destabilizing the CPC system while maintaining a good separation of 1. 
Compound 1 eluted in similar fractions between NL and IBRSS plant material. These 
results indicate that the CPC method is robust and reproducible for the isolation of 1. 
IBRSS flower heads of T. parthenium yielded higher amounts of 1 (0.9% dry weight) 
then NL material which can be explained by observations that 1 accumulates mostly in 
the flower heads compared to other plant parts (Majdi et al., 2011). With CPC the yields 
of 1 from IBRSS material are higher then those using low pressure or open column 
chromatography with silica (Bohlmann and Zdero, 1982; Milbrodt et al., 1997; Rey et 
al., 1992). In total 11 SL were isolated (Figure 1). All compounds were identified based 
on 1H-NMR comparison with literature, COSY, and high resolution MS (Bohlmann and 
Zdero, 1982; El-Feraly and Chan, 1978; Parodi et al., 1989; Sanz et al., 1989; Romo De 
Vivar and Jiménez 1965; Yoshioka et al., 1970; Asakawa et al., 1981; El-Feraly and 
Chan, 1977; Geissman, 1970; Begley et al., 1989).  
The purest samples of each SL were selected for hPAP assay (Figure 2) and 
MTS assay (Figure 3). Compound 2 lacks the α-methylene-γ-lactone moiety and did not 
increase hPAP levels, while all other SL displayed some level of significant activation 
confirming the importance of this functional group. Compounds 4, 5, 6, and 10 showed 
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a linear dose response, although they were weaker compared to the positive control 
tBHQ. Compounds 1, 7, 8, and 9 at higher doses decreased or eliminated activation. 
This observation can be explained by the MTS results for 1, 7, 8, and 9 which show 
increasing cellular toxicity at increasing doses (Figure 3A).  
Figure 1. Structures of isolated SL. Germacranolides - 1, 2, 3, 6, 7, 8, 9; 
eudesmanolides - 4, 5; guaianolides – 10, 11.   
 
 
Compounds 3 and 11 at 12.5 μM had nearly 100 fold and >200 fold hPAP 
activation respectively with considerable toxicity at higher doses (data not shown). 
Therefore both compounds were assayed at lower doses until a linear dose response was 
observed and toxicity was lowered (Figure 2B and Figure 3B). Both the α-methylene-γ-
lactone and endoperoxide moieties are present in 11. The related compound 10, which 
lacks the endoperoxide group but contains 2 epoxides, had weaker hPAP activity 
suggesting that the endoperoxide also contributes to the activity of 11. The potent 
compound 3 had 2 exocyclic methylene groups at C-11,13 and C-10,14 neighboring a 
carbonyl. The replacement of the carbonyl with a hydroxyl group at position 1 as in 9 
weakens activity. The presence of an extra methylene group could provide an additional 
reactive alkylating center in the molecule leading to more activity. Similar observations 




Figure 2. Fold increase in hPAP luminescence over negative controls. *Statistically 
significant increase, p < 0.05.  
 
 
A common structural feature for the germacranolides 1, 7, and 8 is the 
presence of epoxides at positions 4 and 5 as well as 1 and 10 in the case of 7. 
Compounds 1, 7, and 8 were among the most toxic compounds in the MTS assay and 
had both low and non-linear activity in the hPAP assay. Elimination of the epoxide as in 
6, eliminated toxicity at 5 and 12.5 μM and reduced it at 50 μM when compared with 1, 
7, and 8 confirming the importance of epoxide functionality for toxicity. The 
guaianolide 10 also contains epoxide groups, however it is the least toxic of the most 
active SL’s containing α-methylene-γ-lactone moiety, with a potency of about half that 
of tBHQ. This suggests that the differences between the open, germacranolide ring and 
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the bridged, guaianolide ring plays an important role in the activity of these compounds. 
Lewis-acid catalyzed intramolecular cyclization reactions of germanacranolides into 
guaianolides are known to occur (Castaneda-Acosta and Fischer, 1993; Parodi et al., 
1989). Other biological activities such as anti-cancer activity and anti-inflammatory 
action are known to differ between various SL skeletons (Ghantous et al., 2010; 
Neukirch et al., 2003). Whether or not intramolecular cyclizations of germacranolides to 
guaianolides occur in-vivo is worth further investigation. With regards to the 
eudesmanolides 4 and 5, these compounds could only be isolated in very low amounts 
and therefore we were unable to fully evaluate their toxicity (Figure 3A). Compound 4 
was the second most potent germacranolide for hPAP activation (Figure 2A), although 
even at low doses toxicity was observed (Figure 3A). Compound 5 mildly stimulated 
hPAP activation and no toxicity was observed at the doses tested.   
From these results, we can conclude that the guaianolides tested were generally 
more potent activators of Nrf2/ARE in mouse primary cortical cultures then the 
germacranolides and eudesmanolides tested. Furthermore 10, which lacked the 
endoperoxide functionality was the most potent Nrf2/ARE activator and among the least 
toxic SL. Further structure activity studies with guaianolides may lead to interesting 
compounds for drug development or biological research tools for studying the 
Nrf2/ARE pathway. A deeper understanding of the mechanism of SL for Nrf2/ARE 
activity is also required to determine if SL activity is due to direct binding with cysteine 
residues on Keap1 or an indirect mechanism such as depletion of glutathione. Finally, 
whether or not toxicity of SL in vivo is a problem should be investigation in more detail 
as well as toxicity on other cell types.                  
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Appendix Chapter 5 
 
Tanacetum parthenium (IBRSS) growth conditions 
 
The seeds stock (Item No. CA474) was purchased from Jelitto Trade Company 
GmbH (Schwarmstedt, Germany). Seeds were germinated in the greenhouse on 
FLORADUR Fine soil seed starting mixture (Floragard, Vertriebs GmbH, Oldenburg, 
Germany), under long day conditions, 16 h light and 8 h darkness. Four week old 
seedlings were transferred to FLORADUR B soil (Floragard, Vertriebs GmbH, 
Oldenburg, Germany), in separate pots. After 2 months seedlings were transferred from 
the greenhouse to an open-air garden. After several days adaptation to the open air 
environmental conditions seedlings were planted in the cultivation field. Plants were 
grown from spring to autumn 2010. During flowering time, flowers were subsequently 
harvested and dried at the room temperature. 
 
Table A1. 1H-NMR data (CDCl3, 500 MHz) 
 
Parthenolide 11,13-Dihydroparthenolide 3-Hydroxyparthenolide 
H-1 5.21 br dd (2.6, 12.1) 5.17 br dd (2.3, 12.2) 5.14 br dd (4, 12) 
H-2α 2.12-2.23 m 2.11-2.21 m 2.35-2.52 m 
H-2β 2.35-2.46 m 2.34-2.44 m 2.35-2.52 m 
H-3α 1.20-1.28 m 1.22 td (5.7, 12.9) 3.43 dd (7, 11) 
H-3β 2.12-2.23 m 2.11-2.21 m 
 
H-5 2.78 d (8.9) 2.70 d (9) 2.79 d (9) 
H-6 3.86 t (8.6) 3.81 t (9.1) 3.92 t (9) 
H-7 2.76-2.81 m 1.81-1.93 m 2.74 ddddd (3, 4, 6, 9, 9) 
H-8α 2.12-2.23 m 1.81-1.93 m 2.53-2.52 m 
H-8β 1.69-1.77 m 1.61-1.69 m 1.68 m 
H-9α 2.12-2.23 m 2.05 br t (12.5) 2.13 m 





H-13α 6.34 d (3.7) 
1.28 d (7.2) 
6.34 d (4) 
H-13β 5.62 d (3.3) 5.63 d (3) 
H-14 1.72 br s 1.7 br s 1.73 s 




Table A2. 1H-NMR data (CDCl3, 500 MHz) 
 
3β-Hydroxycostunolide Costunolide diepoxide 
H-1 4.90 br dd (2.9, 12) 2.85 dd (1, 11) 
H-2α 2.41-2.48 m 1.51 tdd (5, 11, 14, 14) 
H-2β 2.28 td (10.3, 12, 12.1) 2.16-2.3 m 
H-3α 4.28 m 1.20-1.29 m 
H-3β 
 
2.48 dd (8, 14) 
H-5 4.79 br d (9.9) 2.91 d (9) 
H-6 4.61 dd (8.7, 9.9) 3.94 t (9) 
H-7 2.53 m 2.73 tq (3, 3, 3, 9, 9) 
H-8α 2.06-2.13 m 1.20-1.29 m 
H-8β 1.65-1.73 m 1.61 m 
H-9α 2.41-2.48 m 2.16-2.30 m 
H-9β 2.06-2.13 m 2.16-2.30 m 
H-13α 6.29 d (3.6) 6.34 d (4) 
H-13β 5.54 d (3.2) 5.62 d (3) 
H-14 1.46 br s 1.40-1.35* 












H-2α 2.34-2.65 m 1.9-2.9 br m 
H-2β 3.15 br m 1.9-2.9 br m 
H-3α 2.34-2.65 m 1.9-2.9 br m 
H-3β 2.34-2.65 m 1.9-2.9 br m 
H-5 5.09 br d (10) 5.22 br d (10) 
H-6 4.33 t (10) 4.39 br 
H-7 2.56 m 2.75 m 
H-8α 2.26 m 1.9-2.9 br m 
H-8β 1.41 m 1.9-2.9 br m 
H-9α 2.33-2.62 m 1.9-2.9 br m 
H-9β 2.33-2.62 m 1.9-2.9 br m 
H-13α 6.22 d (3.5) 6.16 d (3) 
H-13β 5.48 d (3.2) 5.44 d (3) 
H-14 5.48 s 5.20 br s 
H-14 5.66 s 4.86 br s 





Table A4. 1H-NMR data (CDCl3, 500 MHz) 
 
Santamarine Reynosin 
H-1α 3.68 ddd (5, 5, 10) 3.53 dd (5, 11) 
H-2α 2.4 dddd (3, 5, 10, 16) 1.50-1.88 m* 
H-2β 1.97 ddd (3, 10, 17) 1.50-1.88 m* 
H-3 5.34 m 2.04-2.16 m 
H-3 
 
2.34 ddd (2, 5, 14) 
H-5 2.35 br d (11) 2.19 br dd (2, 11) 
H-6 3.95 t (11) 4.03 t (11) 
H-7 2.50 ddddd (3, 3, 3, 10, 14) 2.54 m 
H-8 1.65 qd (3, 13.5, 14, 14) 2.04-2.16 m 
H-8 2.02-2.13 m 1.50-1.88 m* 
H-9 1.31 td (4, 13, 13) 1.32-1.40 m* 
H-9 2.02-2.13 m 2.04-2.16 m 
H-13α 6.08 d (3) 6.09 d (3) 
H-13β 5.41 d (3) 5.41 d (3) 
H-14 0.88 s  0.82 s 
H-15 1.83 br s 4.99 d (1) 
H-15 
 
4.87 d (1) 





Table A5. 1H-NMR data (CDCl3, 500 MHz) 
 
Tanaparthin-β-peroxide Artecanin 
H-2 6.33 d (6) 3.55 d (1) 
H-3 6.29 d (6) 3.30 d (1) 
H-5 2.65 d (10) 2.86 d (11) 
H-6 3.75 t (10) 4.09 t (11) 
H-7 3.36 ddddd (3, 3.5, 7, 10, 10) 3.26-3.33 m 
H-8 1.52* 1.64-2.13 
H-8 2.36 dddd (7, 9, 10, 14) 1.64-2.13 
H-9 1.74 m 1.64-2.13 
H-9 2.03 ddd (2, 8, 16) 1.64-2.13 
H-13α 6.15 d (3.5) 6.20 d (3.5) 
H-13β 5.42 d (3) 5.43 d (3) 
H-14 1.39 s 1.14 s 
H-15 1.71 s 1.56 s 
*Signals obscured by H2O 
 
Table A6. High resolution MS data 




[M+H]+ Formula ∆ ppm 
1 parthenolide 249.1489 249.1485 C15H20O3 1.69 
2 11,13-dihydroparthenolide 251.1644 251.1642 C15H22O3 1.04 
3 anhydroverlotorin 247.1332 247.1329 C15H18O3 1.38 
4 santamarine 249.1488 249.1485 C15H20O3 1.08 
5 reynosin 249.1487 249.1485 C15H20O3 0.84 
6 3β-hydroxycostunolide 249.1487 249.1485 C15H20O3 0.72 
7 costunolide diepoxide 265.1435 265.1434 C15H20O4 0.30 
8 3-hydroxyparthenolide 265.1436 265.1434 C15H20O4 0.68 
9 artemorin 249.1486 249.1485 C15H20O3 0.16 
10 artecanin 279.1228 279.1227 C15H18O5 0.25 
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 Five new sesquiterpene lactones (1 – 5) were isolated from Inula britannica 
collected in the wild from Serbia along with five known compounds (6 – 10). 
Sesquiterpene lactones were isolated using centrifugal partition chromatography 
followed by combination of flash chromatography and semi-preparative HPLC. Isolated 
compounds were screened for cytotoxic activity on human cancer cell line, their derived 
multi-drug resistant cell lines, and normal human keratinocytes. Sesquiterpene lactones 
showed similar cytotoxic activity towards drug sensitive and drug resistant cancer cell 
lines.  





Inula britannica L. (Asteraceae) produces a variety of secondary metabolites 
including sesquiterpene lactones, diterpenes, triterpenes, and flavonoids (Khan et al., 
2010). Inula britannica extracts have been reported to possess anti-inflammatory, 
hepatoprotective, anti-bacterial, and cytotoxic activity (Zhao et al., 2006). Sesquiterpene 
lactones of the germacranolide, eudesmanolide, 1,10-seco-eudesmanolide, and 
pseudoguaianolide groups, isolated mainly from flowers of the Chinese herb I. 
britannica var. chinensis are known to display cytotoxic effects against several human 
cancer cell lines (Zhou et al., 1993; Park and Kim, 1998; Bai et al., 2006; Qi et al., 
2008). Although sesquiterpene lactones are present in I. britannica ecotypes growing in 
Europe as well, (Rybalko et al., 1968; Chugunov et al., 1971; Serkerov and Mir-Babaev, 
1988) no investigation regarding the cytotoxicity of the European samples constituents 
has been reported so far. Therefore, we investigated the cytotoxic activity of a series of 
sesquiterpene lactones isolated from I. britannica plants collected in the wild around 
Belgrade, Serbia. This led to the isolation and identification of 10 sesquiterpene 
lactones, five of which have never been reported before. The isolated compounds were 
subsequently tested for their cytotoxicity against human cancer cell lines, their multi-
drug resistant (MDR) counterparts, and normal human keratinocytes (HaCaT).  
Materials and Methods 
General Experimental Procedures  
FT-IR was measured on a Perkin-Elmer FT-IR Spectrometer Paragon 1000. 
Optical rotations were obtained using a Propol Automatic Polarimeter. UV 
measurements were performed using a Shimadzu UV mini-1240. NMR spectra were 
recored in CDCl3 or MeOD on a Bruker DMX 500 MHz NMR calibrated to residual 
CDCl3 (7.26 ppm 1H; 77.16 ppm 13C) or MeOD (3.31 ppm). High resolution mass data 
(HRESIMS) were collected on a Thermo LC-LTQ-Orbitrap FTMS system. LC-APCI 
mass data (APCIMS) were collected in both positive and negative mode on an Agilent 
1100 series HPLC connected to G1956 LC/MSD SL single quadropole mass 
spectrometer. Centrifugal partition chromatography (CPC) was carried out with a 
Kromaton Fast Centrifugal Partition Chromatograph with 1 L internal rotor volume and 
30 mL Rheodyne injector loop. Semi-preparative HPLC (pHPLC) was performed with a 
Shimadzu HPLC system and a 5 mL Rheodyne manual injection loop. Normal phase 
(NP) separation used a Phenomenex Luna Silica (2) 100 A 5 micron 250 x 10 mm 
column with 10 x 10 mm silica guard cartridge while reverse phase (RP) separation 
used a Phenomenex Luna C18 (2) 100 A 5 micron 250 x 10 mm column. All pHPLC 
experiments used 5 mL/min flow rate and 10 mL fractions were collected unless 
otherwise noted. TLC was performed with silica gel 60 (Merck) plates using CHCl3: 
EtOAc 1:1 and visualized with vanillin/sulfuric acid reagent. Flash chromatography 
used silica gel 60 (0.063- 0.2 mm, Merck). All solvents were of analytical and HPLC 
grade.  




Inula britannica plant material was collected in Serbia from several natural 
localities: from the edge of Lipovica forest and from meadows nearby Mladenovac and 
Kragujevac. Species identification was confirmed by Wout Holverda at the Leiden 
Nationaal Herbarium Nederland and a voucher specimen was deposited in the economic 
botany collection under the following barcode: AsteraceaeInulabritannicaL.L 0991383J. 
FischedickNo. 172010. 
Extraction and Isolation  
Inula britannica (200 g) dried flowers were extracted with 4 L EtOH for 24 
hours. Solvent removed in vacuo to yield 14 g yellow solid/syrup. Crude extract was re-
dissolved in 400 mL ethyl acetate (EtOAc) and 400 mL H2O. The H2O layer was 
drained off and EtOAc rinsed 2 additional times with 250 mL H2O. The EtOAc layer 
was dried over MgSO4, filtered, and solvent removed in vacuo to yield 6 g yellow 
solid/syrup. The EtOAc extract was further fractionated with CPC. A 2 phase solvent 
system composed of 4: 6: 4: 6 heptane: EtOAc: MeOH: H2O (5 L) was prepared and 
split into upper (2.3 L) and lower layer (2.7 L). The EtOAc extract was dissolved in 30 
mL upper and lower layer (1:1). The CPC system was first filled with lower layer to act 
as stationary phase. Upper layer was then pumped in at flow rate of 10 mL/min and 
rotor rotation speed of 1000 rpm. The CPC system was considered in equilibrium when 
upper layer began to elute and amount of lower layer displaced recorded as void volume 
(220 mL). The entire sample was then injected and initial 200 mL eluent discarded after 
which 120 x 10 mL fractions (CPC Fr#) were collected (pressure 52 bar). After the 120th 
fraction the CPC system was rinsed with lower layer which was collected as an 
additional rinse fraction (FrR). Fractions were analyzed by TLC, combined based on 
profile, and solvent removed in vacuo.  
 CPC Fr11-30 (318 mg) was further separated by NP pHPLC (CHCl3: EtOAc, 
9:1) with subsequent fractions 3-8 (110 mg) run on RP pHPLC (H2O: acetonitrile 
(ACN), 8:2) to yield 1 (11.6 mg) from fractions 11-13 and an impure sesquiterpene 
lactone in fractions 7-9 (88.9 mg). CPC Fr31-45 (110 mg) was separated by NP pHPLC 
(CHCl3: EtOAc, 9:1) with subsequent fractions 1-8 (52 mg) run on RP pHPLC (H2O: 
ACN, 1:1) to yield 3 additional fractions. Fractions 1-2 (27.2 mg) were combined and 
fractionated by RP pHPLC (H2O: ACN, 8:2, gradient to 100% ACN) to yield 10 (8.1 
mg) and 3 (2.9 mg). Fraction 3 (13.5 mg) was combined with fractions 7-9 from CPC 
Fr11-30 RP pHPLC and purified with RP pHPLC (H2O: ACN, 6:4) to yield 2 (67.8 mg). 
CPC Fr46-65 (368 mg) was separated by NP pHPLC (CHCl3: EtOAc, 9:1, 3 mL/min, 6 
mL fractions) with 9 (127 mg) crystallized from fractions 4-16 with hexane/Et2O while 
fractions 17-20 were further purified with RP pHPLC (H2O: ACN, 1:1) to yield 3 (2.7 
mg). CPC Fr66-120 (914 mg) was separated by flash chromatography (100 g silica, CHCl3 
increasing ratio of acetone), with 100 mL fractions collected. Flash fractions 2-6 were 
combined (576 mg) and run on NP pHPLC (CHCl3: EtOAc, 7:3) with subsequent 
fractions 7-28 further separated by NP pHPLC (CHCl3: EtOAc, 9:1) to yield 8 (98 mg) 
as white needles (hexane/Et2O) from fractions 12-28. CPC FrR (478 mg) was further 
separated by flash chromatography (50 g silica) using hexane with increasing ratio of 
acetone followed by acetone with increasing ratio of ethanol. Flash fractions 4-5 (100 
116 
 
mg) were purified with RP pHPLC (H2O: ACN, 8: 2) to yield 7 (8.3 mg) from fractions 
16-17 while fractions 18-23 (22.4 mg) were again separated by RP pHPLC (H2O: ACN, 
gradient to 100% ACN) to yield 5 (16.8 mg) from fraction 9. Flash fractions 6-7 (118 
mg) were separated by RP pHPLC (H2O: ACN, 8: 2) from which fractions 1-3 were 
again separated by RP pHPLC (H2O: ACN, 9: 1) to yield 4 (8.8 mg) from fractions 22-
25 and an impure sesquiterpene lactone in the rinse fraction. The impure sesquiterpene 
lactone was re-purified under the same conditions to yield 6 (18.2 mg).     
14-(3-Methylpentanoyl)-6-deoxybritannilactone (1): amorphous colorless solid; [α]20D 
+109.5 (c 0.15, CHCl3); UV (MeOH) λmax (log ε) 212.0 (3.95) nm; IR (film) νmax 
3503.7, 2961.4, 2360.4, 2342.7, 1759.4, 1733.6, 1268.3 cm-1; 1H and 13C NMR data, see 
Table1; APCIMS m/z 347 [M - H2O]+ (100), 363 [M - H]- (100); HRESIMS m/z 
365.2321 [M + H]+ (calcd for C21H33O5 365.2328).  
14-(3-Methylbutanoyl)-6-deoxybritannilactone (2): amorphous colorless solid; [α]20D 
+112.6 (c 0.19, CHCl3); UV (MeOH) λmax (log ε) 209 (4.06) nm; IR (film) νmax 3428.1, 
2959.5, 2360.3, 2343.7, 1759.6, 1734, 1267.3, 1187.8, 996 cm-1; 1H and 13C NMR data, 
see Table1; APCIMS m/z 333 [M - H2O]+ (100), 349 [M - H]- (100); HRESIMS m/z 
351.2166 (calcd for C20H31O5 351.2172).  
 
14-(2-Methylpropanoyl)-6-deoxybritannilactone (3): amorphous colorless solid; [α]20D 
+122.9 (c 0.07, CHCl3); UV (MeOH) λmax (log ε) 204.5 (4.29) nm; IR (film) νmax 3440, 
2961.5, 2360, 2343.3, 1759.1, 1734, 1268.4, 1191.7, 1157.8, 996 cm-1; 1H and 13C NMR 
data, see Table1; APCIMS m/z 319 [M - H2O]+ (100), 335 [M - H]- (100); HRESIMS 
m/z 337.2011 (calcd for C19H29O5 337.2015). 
 
1,3-Epi-granilin (4): amorphous white solid; [α]20D +146.0 (c 0.1, MeOH); UV (MeOH) 
λmax (log ε) 226.5 (3.26) nm; IR (film) νmax 3424, 2359.8, 2343.2, 1740, 1262, 1220, 772 
cm-1; 1H NMR (MeOD, 500 MHz) δ 6.08 (1H, br s, H-13a), 5.71 (1H, br s, H-13b), 5.18 
(1H, br s, H-15a), 4.67 (1H, br s, H-15b), 4.58 (1H, td, J = 4.8, 1.6 Hz, H-8), 4.02 (1H, 
dd, J = 11.8, 5.3 Hz, H-3), 3.42 (1H, dd, J = 11.9, 4.3 Hz, H-1), 3.07 (1H, m, H-7), 2.52 
(1H, dd, J = 15.8, 1.6 Hz, H-9β), 2.09 (1H, m, H-2α), 1.80 (1H, m, H-5), 1.80 (1H, m, 
H-6α), 1.54 (1H, m, H-9α), 1.51 (1H, m, H-2β), 1.42 (1H, ddd, J = 13, 12.9 Hz, H-6β), 
0.74 (3H, s, H-14); APCIMS m/z 265 [M + H]+ (100), 263 [M - H]- (100); HRESIMS 
m/z 265.1436 [M + H]+ (calcd for C15H21O4 265.1440).  
 
11,13-Dihydro-inuchinenolide B (5): amorphous colorless solid; [α]20D -46.1 (c 0.26, 
CHCl3); UV (MeOH) λmax (log ε) 208 (4.05) nm; IR (film) νmax 3428.5, 2976.1, 2360.3, 
2343.7, 1733.8, 1239.6 cm-1; 1H-NMR (CDCl3, 500 MHz) δ 5.55 (1H, m, H-2β), 4.71 
(1H, ddd, J = 10.1, 7.2, 2.5 Hz, H-8), 2.78 (1H, m, H-7), 2.76 (1H, m, H-11), 2.66 (1H, 
m, H-9β), 2.63 (1H, br d, H-5), 2.49 (1H, dd, J = 15.9, 2.5 Hz, H-9α), 2.33 (1H, dd, J = 
13.4, 7.4 Hz, H-3β), 2.05 (3H, s, COOCH3, H-2’), ~1.88 (1H, s, OH-4α), 1.77 (1H, m, 
H-3α), 1.77 (1H, m, H-6α), 1.68 (3H, d, J = 1.6 Hz, H-14), 1.33, (1H, m, H-6β), 1.26 
(3H, d, J = 7.5 Hz, H-13β), 1.11 (3H, s, H-15); 13C-NMR (CDCl3, 125.8 MHz) δ 180.1 
(C, COOCH3, C-1’), 170.7 (C, C12), 137.6 (C, C-1), 132.4 (C, C-10), 79.4 (CH, C-8), 




(CH, C-11), 37.4 (CH2, C-9), 23.4 (CH2, C-6), 23.0 (CH3, C-15), 22.0 (CH3, C-14), 21.2 
(CH3, COOCH3, C-2’), 12.8 (CH3, C-13); APCIMS m/z 307 [M - 1]- (20); HRESIMS 
m/z 309.1701 [M + H]+ (calcd for C17H25O5 309.1702). 
 
Pulchellin C (6): amorphous yellow solid; [α]20D +119.8 (c 0.21, MeOH); 1H-NMR 
(MeOD, 500 MHz) δ 6.08 (1H, s, H-13a), 5.72 (1H, s, H-13b), 5.27 (1H, d, J = 1.2 Hz, 
H-15a), 4.71 (1H, d, J = 1.4 Hz, H-15b), 4.55 (1H, m, H-8), 3.75 (1H, br d, H-3α), 3.44 
(1H, ddd, J = 11.6, 9.2, 4.9 Hz, H-2β), 3.11 (1H, m, H-7), 2.21 (1H, dd, J = 15.6, 1.3 
Hz, H-9α), 1.98 (1H, br d, J = 12.6 Hz, H-5), 1.83 (1H, m, H-1β), 1.83 (1H, m, H-6α), 
1.61 (1H, dd, J = 15.6, 4.6 Hz, H-9β), 1.35 (IH, m, H-6β), 1.31 (1H, m, H-1α) 0.81 (3H, 
s, H-14); APCIMS m/z 265 [M + H]+ (100), 263 [M - H]- (100); HRESIMS m/z 
265.1438 [M + H]+ (calcd for C15H21O4 265.1440). 
 
6-Deacetylbritanin (7): amorphous colorless solid; [α]20D +5.2 (c 0.12, CHCl3); 1H-
NMR (CDCl3, 500 MHz) δ 6.25 (1H, br d, H-13a), 6.16 (1H, br d, H-13b), 4.91 (1H, 
ddd, J = 8.8, 6.6, 1.5 Hz, H-2β), 4.61 (1H, ddd, J = 12.1, 8.3, 4.6 Hz, H-4α), 4.28 (1H, 
ddd, J = 12.1, 9.7, 2.8 Hz, H-8), 3.76 (1H, dd, J = 9.8, 3.6 Hz, H-6β), ~2.88 (1H, m, 
OH-6α), 2.85 (1H, m, H-7), 2.35 (1H, m, H-9β), 2.05 (1H, m, H-3a), 2.04 (3H, s, 
COOCH3, H-2’), 1.90 (1H, m, H-1), 1.84 (1H, m, H-10α), 1.82 (1H, m, H-3b), ~1.79-
1.93 (1H, m, OH-4β), 1.42 (1H, m, H-9α), 0.95 (3H, d, J = 6.3 Hz, H-14), 0.95 (3H, s, 
H-15); 13C-NMR (CDCl3, 125.8 MHz) δ 170.6 (C, COOCH3, C-1’), 170.1 (C, C-12), 
139.0 (C, C-11), 123.3 (CH2, C-13), 77.1 (CH, C-6), 76.7 (CH, C-8), 75.4 (CH, C-2), 
73.8 (CH, C-4), 52.1 (CH, C-7), 51.2 (C, C-5), 51.1 (CH, C-1), 44.0 (CH2, C-9), 36.8 
(CH2, C-3), 29.7 (CH, C-10), 21.4 (CH3, COOCH3, C-2’), 20.2 (CH3, C-14), 17.7 (CH3, 
C-15); APCIMS m/z 325 [M + H]+ (100), 323 [M - H]- (95); HRESIMS m/z 325.1649 
[M + H]+ (calcd for C17H25O6 325.1651). 
 
4H-Tomentosin (10): amorphous colorless solid; [α]20D +18.4 (c 0.10, CHCl3); 1H-NMR 
(CDCl3, 500 MHz) δ 6.26 (1H, d, J = 3.2 Hz, H-13a), 5.52 (1H, d, J = 2.8 Hz, H-13b), 
5.49 (1H, dd, J = 9.2, 5.3 Hz, H-5), 4.64 (1H, ddd, J = 11.7, 8.5, 2.8 Hz, H-8), 3.78 (1H, 
m, H-4), 3.34 (1H, m, H-7), 2.45 (1H, m, H-6β), 2.37 (1H, m, H-10), 2.18 (1H, m, H-
6α), 2.14 (1H, m, 2a), 2.00 (1H, m, H-9α), 1.99 (1H, m, H-2b), 1.90 (1H, m, H-9β), 1.57 
(1H, m, H-3a), 1.46 (1H, m, H-3b), 1.33 (1H, br s, OH-4), 1.21 (3H, d, J = 6.2 Hz, H-
15), 1.14 (3H, d, J = 6.9 Hz, H-14); 13C-NMR (CDCl3, 125.8 MHz) δ 170.4 (C, C-12), 
145.7 (C, C-1), 139,2 (C, C-11), 122.2 (CH2, C-13), 120.0 (CH, C-5), 79.8 (CH, C-8), 
67.7 (CH, C-4), 42.4 (CH, C-7), 38.1 (CH2, C-3), 36.8 (CH2, C-9), 35.2 (CH, C-10), 
33.0 (CH2, C-2), 26.9 (CH2, C-6), 24.0 (CH3, C-15), 21.1 (CH3, C-14); APCIMS m/z 
251 [M + H]+ (100), 249 [M - H]- (100); HRESIMS m/z 251.1642 [M + H]+ (calcd for 
C15H23O3 251.1647). 
 
Cell lines and Cell Culture  
The NCI-H460, DLD1, and U87 cell lines were purchased from the American 
Type Culture Collection (ATCC), while COR-L23 and COR-L23/R cell lines were 
purchased from European Collection of Cell Cultures (ECACC). Human normal 
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keratinocytes – HaCaT were obtained from Cell Lines Service (CLS). NCI-H460/R 
cells were selected originally from NCI-H460 cells and cultured in a medium containing 
100 nM doxorubicin (Pešić et al., 2006). DLD1-TxR and U87-TxR cells were selected 
from DLD1 and U87 cells, respectively, and cultured in a medium containing 300 nM 
paclitaxel (Podolski-Renić et al., 2011). All cell lines were sub-cultured at 72 h intervals 
using 0.25% trypsin/EDTA and seeded into a fresh medium at the following densities: 
8,000 cells/cm2 for NCI-H460, DLD1, DLD1-TxR, COR-L23 and COR-L23/R, 16,000 
cells/cm2 for U87 and NCI-H460/R, and 32,000 cells/cm2 for U87-TxR and HaCaT. 
Cytotoxicity assays 
Cells grown in 25 cm2 tissue flasks were trypsinized, seeded into flat-bottomed 
96-well tissue culture plates, and incubated overnight. Treatment with all compounds 
(10 μM) lasted 72 h. The cellular proteins were stained with Sulforhodamine B assay 
(SRB), following a slightly modified protocol (Skehan et al., 1990). To further assess 
the cytotoxic effects of the most potent sesquiterpene lactones in NCI-H460 and NCI-
H460/R cells, beside SRB assay, the MTT assay based on the reduction of 3-(4,5-
dimethyl-2-thizolyl)-2,5-diphenyl-2H-tetrazolium bromide into formazan dye by active 
mitochondria of living cells was applied as well. The cells were incubated with 
indicated compounds for 72 h. Afterwards, 100 μl of MTT solution (1 mg /ml) was 
added to each well and plates were incubated at 37°C for 4 h. Formazan product was 
dissolved  in 200 μl of DMSO. The absorbance of obtained dye after SRB or MTT 
assay was measured at 540 nm using an automatic microplate reader (LKB 5060-006 
Micro Plate Reader, Vienna, Austria). 
Appendix 
Detailed LC-MS conditions, NMR parameters, 1H-NMR data for compounds 6 
and 7, and NMR spectra of all isolated compounds are available in the chapter 6 
appendix.  
Results and Discussion  
An EtOH extract from dried I. britannica flowers was partitioned between 
EtOAc and H2O. The EtOAc fraction was further purified with CPC followed by 
combination of flash chromatography and pHPLC to yield 10 sesquiterpene lactones. 
Three of these compounds were new 1,10-seco-eudesmanolides assigned the trivial 
names; 14-(3-methylpentanoyl)-6-deoxybritannilactone (1), 14-(3-methylbutanoyl)-6-
deoxybritannilactone (2), and 14-(2-methylpropanoyl)-6-deoxybritannilactone (3). In 
addition, a new stereoisomer of granillin, 1,3-epi-granillin (4), and a new 
pseudoguaianolide, 11,13-dihydro-inuchinenolide B (5), were isolated. Five known 
sesquiterpene lactone compounds; pulchellin C (6) (Serkerov and Mir-Babaev, 1988; 
Adekenov et al., 1990), 6-deacetylbritannin (7) (Dzhazin and Adekenov, 1996; Yang et 
al., 2010), gaillardin (8) (Kupchan et al., 1965; Kupchan et al., 1966; Ito and Iida, 




(10) (Bohlmann et al., 1978; Kim et al., 2004) were also isolated, with 10 being 
reported in I. britannica for the first time.   
Chemical structures (1 – 10) 
 
Compounds 1-3 were isolated as amorphous colorless solids. Complete 1H and 
13C-NMR assignments are shown in table 1. Carbon atom multiplicity was confirmed 
with 13C-APT and HSQC. Complete HMBC correlations are shown in table 2. 
Similarity of 1H and 13C-NMR with literature (Zhou et al., 1993; Bai et al., 2006; Qi et 
al., 2008) suggested that 1-3 contained a 1,10-seco-eudesmanolide skeleton. A mass of 
364 was suggested by the APCIMS spectrum of 1. The molecular formula C21H32O5 
was established for 1 by HRESIMS (obsd 365.2321, calcd 365.2328, [M + H]+). The IR 
suggested the presence of a hydroxyl group (3507.7 cm-1), a γ unsaturated lactone 
(1759.4 cm-1), and an ester (1733.6 cm-1). The terminal methylene functionality of the 
α-methylene-γ-lactone was confirmed by the pair of 1H doublets appearing at δH 5.64 
and 6.27, both attached to δC 122.0 (C-13). Furthermore the carbonyl carbon at δC 170.5 
(C-12) and the quaternary carbon at δC 140.1 (C-11) correlated in HMBC to H-13. 
Correlations in COSY between H-13a and H-13b with δH 3.23 (H-7) were observed. 
The rest of the spin system connectivity was easily deduced by COSY showing 
correlations between H-7 with δH 4.90 (H-8), 2.25 (H-6), and 2.09 (H-6) as well as 
correlations in COSY between H-8 with δH 2.43 (H-9) and 2.62 (H-9). HSQC was used 
to unambiguously assign proton containing carbons on the bicyclic ring and HMBC 
confirmed connectivity of the entire spin system. The dd splitting pattern of protons at 
position 6 and 9 indicated that carbons at C-5 and C-10 were quaternary. Through 
analysis of HMBC spectra 2 alkene region quaternary carbons at δC 139.6 and δC 129.2 
were assigned as C-5 and C-10 respectively (C-5→ 2H-6, 2H-9; C-10→ 2H-6, H-8, 2H-
9). An additional HMBC correlation from C-5 to the methyl protons at δH 0.97 (CH3-
15) confirmed connectivity of side chain. Connectivity of C-5 to C4, C-15 to C4, C-4 to 
C-3, C-3 to C-2, and C-2 to C-1 was established through analysis of COSY, HSQC 
spectra, and confirmed by HMBC. The chemical shift of protons at position 1 (δH 3.98) 
and carbon (δC 64.0) confirmed the presence of hydroxyl functionality at position 1. 
Alkyl ester substitution connected to C-14 was suggested by the IR, remaining C6H11O2, 
and the deshielded protons and carbon at C-14 (δC 61.4; δH 4.13, 4.19). Connectivity 
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from C-1’ (δC 173.7) to C-2’ (δC 41.6, CH2) and C-3’ (δC 32.1, CH) was established by 
HMBC. The methine at H-3’ (δH 1.86) COSY spectrum showed correlations to H-2a’ 
(δH 2.29), H-2b’ (δH 2.09), CH3-6’ (δH 0.92), H-4a’ (δH 1.34), and H-4b’ (δH 1.22). The 
remaining methyl group was assigned to 5’ (δH 0.88) and confirmed with COSY. The 
ester substituent was thus identified as a 3-methylpentanoyl group. The cis and axial 
relative configuration of protons H-7 and H-8 was confirmed by correlation in NOESY 
spectrum (Figure 1). Correlations were observed between H-7 and both H-6 as well as 
between H-8 and both H-9 (not shown in figure 1) and thus could not be used to 
establish their relative configuration. However due to the cis configuration of H-7 and 
H-8 as well as a cross peak between H-13b and H-6 (δH 2.09) confirmed β 
configuration. A NOESY correlation from H-6β (δH 2.09) to H-9β (δH 2.62) confirmed 
β configuration of H-9β. A NOESY correlation between H-6 (δH 2.25) and H-9 (δH 
2.43) was also observed and confirmed α configuration of these protons. Compound 1 
was therefore identified as 14-(3-methylpentanoyl)-1-hydroxy-1,10-seco-5(10),11(13)-
eudesadien-12,8β-olide.    
The same 1,10-seco-eudesmanolide skeleton as 1 was recognized in 
compounds 2 and 3 by 1H-NMR, COSY, 13C-APT, HSQC and HMBC spectra. A mass 
of 350 was suggested by APCIMS of 2. The molecular formula C20H30O5 was 
established for 2 by HRESIMS (obsd 351.2166, calcd 351.2172, [M + H]+). The 
difference between 1 and 2 was therefore due to a different functional group at the C-14 
position. Alkyl ester substitution was again suggested from IR (1734 cm-1) and 
remaining C5H9O2. Connectivity from the carbonyl C-1’ (δC 177.5) to 2’-H (δH 2.17) 
and 3’-H (δH 2.08) was determined by HMBC and 2’ correlated in COSY with 3’. The 2 
overlapping methyl groups (δH 0.94) showed correlations in COSY with 3’ and were 
assigned at the 4’ and 5’ positions. The substituent was therefore established as a 3-
methylbutanoyl group. The relative configuration was the same as 1, confirmed by 
NOESY. Therefore compound 2 was identified as 14-(3-methylbutanoyl)-1-hydroxy-
1,10-seco-5(10),11(13)-eudesadien-12,8β-olide.  
The mass of compound 3 was suggested to be 336 based on APCIMS. 
Confirmation of the molecular formula as C19H28O5 was established by HRESIMS 
(obsd 337.2011, calcd 337.2015, [M + H]+). Alkyl ester substitution at C-14 was 
suggested by IR (1734 cm-1) and remaining C4H7O2. In HMBC correlations between 
carbonyl C-1’, 2’-H (δH 2.53) and 2 overlapping methyl groups (δH 1.16). Connectivity 
between 2’-H and the methyl groups at 3’ and 4’ was confirmed by coupling constant (J 
= 7.0 Hz) and COSY. The substituent was therefore established as a 2-methylpropanoyl 
group. NOESY established that the relative configuration for 3 was the same as in 1 and 





Table 1. 1H and 13C-NMR data for compounds 1 – 3 (CDCl3)  
 1 2 3 
position δC type δH (J in Hz) δC type δH (J in Hz) δC type δH (J in Hz) 
1 64.0, CH2 3.98, m 64.0, CH2 3.98, m 64.1, CH2 3.97, m 
2 27.0, CH2 1.32, m 27.0, CH2 1.31, m 27.0, CH2 1.32, m 
  1.42, m  1.41, m  1.41, m 
3 30.8, CH2 1.16, m 30.7, CH2 1.15, m 30.7, CH2 1.17, m 
  1.31, m  1.29, m  1.30, m 
4 33.6, CH 2.76, m 33.5, CH 2.76, m 33.6, CH 2.77, m 
5 139.6, C  139.4, C  139.6, C  
6α 29.0, CH2 2.25, dd (15.0, 
6.6) 
28.9, CH2 2.24, dd (15.0, 
6.7) 
29.0, CH2 2.25, dd (15.0, 
7.1) 
6β  2.09, m  2.08, m  2.09, dd (15.0, 
4.5) 
7 37.5, CH 3.23, m 37.5, CH 3.23, m 37.5, CH 3.24, m 
8 77.1, CH 4.90, m 77.1, CH 4.90, m 77.1, CH 4.91, m 
9α 31.8, CH2 2.43, dd (15.3, 
4.4) 
31.8, CH2 2.42, dd (15.4, 
4.3) 
31.8, CH2 2.43, dd (15.0, 
4.4) 
9β  2.62, dd (15.3, 
4.6) 
 2.61, dd (15.3, 
4.6) 
 2.64, dd (15.0, 
4.5) 
10 129.2, C  129.2, C  129.2, C  
11 140.1, C  140.1, C  140.1, C  
12 170.5, C  170.5, C  170.5, C  
13b 122.0, 
CH2 
5.64, d (2.3) 122.9, 
CH2 
5.64, d (2.3) 122.0, 
CH2 
5.65, d (2.3) 
13a  6.27, d (2.7)  6.27, d (2.7)  6.28, d (2.7) 
14 61.4, CH2 4.13, d (11.9) 61.3, CH2 4.13, d (11.9) 61.5, CH2 4.14, d (12) 
  4.19, d (11.9)  4.19, d (11.9)  4.19, d (12) 
15 19.5, CH3 0.97, d (6.8) 19.5, CH3 0.97, d (6.8) 19.5, CH3 0.98, d (6.8) 
1’ 173.7, C  173.4, C  177.5, C  
2’ 41.6, CH2 2.09, m 43.5, CH2 2.17, d (7.1) 34.16, CH 2.53, septet (7) 
  2.29, dd (14.7, 
6.1) 
    
3’ 32.1, CH 1.86, m 25.8, CH 2.08, m 19.2, CH3 1.16, d (7) 
4’ 29.8, CH2 1.22, m 22.5, CH3 0.94, d (6.6) 19.2, CH3 1.16, d (7) 
  1.34, m     
5’ 11.4, CH3 0.88, t (7.5) 22.5, CH3 0.94, d (6.6)   
6’ 19.4, CH3 0.92, d (6.7)     
OH  ~1.51, br s  ~1.50, br s  ~1.43, m 
 




Table 2. HMBC correlations 1 - 3 
position 1 (C→ H#) 2 (C→ H#) 3 (C→ H#) 
1  2, 3 2, 3 
2 1, 3 1, 3 1, 3 
3 1, 15 1, 2, 4, 15 1, 15 
4 6β, 15 2, 3, 6, 15 6β, 15 
5 6, 9, 15 3, 6, 9, 15 6, 9, 14, 15 
6 8, 13a 8, 13 8, 13a 
7 6, 9, 13 6, 9, 13 6, 9, 13 
8 6, 9 6, 9 6, 9 
9 6, 14 4 14 
10 6, 8, 9, 14 6, 8, 9 6, 8, 9, 14 
11 6, 13a 13 13a 
12 8, 13 8, 13 8, 13 
13    
14 9 9 9 
15  3  
1’ 2’, 3’ 2’, 3’ 2’, 3’, 4’ 
2’ 4’, 6’ 3’, 4’, 5’ 3’, 4’ 
3’ 2’, 5’ 2’, 4’, 5’ 2’, 4’ 
4’ 2’, 5’ 2’, 3’, 5’ 2’, 3’ 
5’ 4’ 2’, 3’, 4’  
6’ 2’, 4’   
 
A mass of 264 was suggested from the APCIMS spectrum of 4 and HRESIMS 
(obsd 265.1436, calcd 265.1440 [M + H]+) confirmed C15H20O4 as the molecular 
formula. Compound 4 had very similar 1H-NMR and IR spectra as that of granilin 
(Nikonova and Nikonov, 1972; Maruyama and Shibata, 1975; Vichnewski et al., 1976). 
However differences were noted in the δ and J values for protons at position 1, 2, and 3 
suggesting a different relative configuration of the hydroxyl groups. The spin system 
connecting 2H-13 to H-7, H-7 to 2H-6 and H-8, H-8 to 2H-9, H-6 (δH 1.42) to H-5, and 
H-5 to 2H-15 was confirmed by COSY. Protons at δH 3.42 and δH 4.02 were assigned to 
H-1 and H-3 respectively due to deshielding from hydroxyl groups and for H-3 a 
correlation in COSY with methylene protons 2H-15. Connectivity between H-1 to 2H-2 
(δH 2.09; δH 1.51) to H-3 was confirmed by COSY. In the NOESY spectrum a 
correlation between H-7 and H-8 was observed confirming a cis and axial configuration 
(Figure 4). Further correlations in NOESY between H-7 and H-6 (δH 1.80) as well as H-
8 and H-9 (δH 1.54) confirmed α configuration for these protons. Both H-6β (δH 1.42) 
and H-9β (δH 2.52) correlated in NOESY with the methyl group at position 14 (δH 0.74) 
confirming β configuration. The α configuration of H-1 was confirmed by a correlation 
in NOESY with H-9α. Further correlations from H-1 to H-2α (δH 2.09) and H-2α to H-3 
confirmed the hydroxyl groups at 1 and 3 as β oriented. Finally a correlation from H-2β 
(δH 1.51) to the β oriented methyl group at C-14 was also observed in the NOESY 





Figure 2. NOESY correlations of 4. 
 
 
Figure 3. NOESY correlations of 5. 
 
 
The molecular formula of compound 5 was established as C17H24O5 by 
HRESIMS (obsd 365.2321, calcd 365.2328 [M + H]+). The 1H and 13C-NMR spectra of 
5 resembled inuchinenolide B, previously reported from I. Britannica (Ito and Iida, 
1981), however the methylene H-13 doublets were lacking and an additional methyl 
group (δH 1.26) was present. The connectivity of the spin system H-2 (δH 5.55) and 2H-
3 (δH 2.33; 1.77) was confirmed with COSY. Correlations in COSY from H-8 (δH 4.71) 
to 2H-9 (δH 2.66; 2.49), H-8 to H-7 (δH 2.78), H-7 to 2H-6 (δH 1.77; 1.33), and H-6 (δH 
1.33) to H-5 (δH 2.63) were observed. The methyl groups at positions 14 (δH 1.63), 15 
(δH 1.11), and 2’ (δH 2.05) were assigned based on typical δH from neighboring 
functional groups and similarity with inuchinenolide B (Ito and Iida, 1981). The 
remaining methine proton and methyl group were assigned to H-11 (δH 2.76) and 3H-13 
(δH 1.26) respectively with correlation in COSY confirming connectivity. Carbon 
resonances containing protons were unambiguously assigned with 13C-APT and HSQC. 
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Remaining quaternary carbons were assigned based on similarity to inuchinenolide B 
(Ito and Iida, 1981). This data confirmed that 5 was the 11,13-dihydro version of 
inuchinenolide B. A correlation in NOESY between H-7 and H-8 was observed 
confirming axial and cis configuration (Figure 3). Correlations in NOESY from H-7 to 
H-6 (δH 1.77) and H-5 as well as H-8 to H-9 (δH 2.49) and H-5 confirmed α 
configuration of these protons. Both H-6β and H-9β correlated with 3H-13 in NOESY 
confirming the methyl group was in β orientation. Correlations in NOESY from H-6β to 
3H-15 confirmed the methyl group was β orientated and hydroxyl group at position 4 α 
orientated. The methyl group at 15 also correlated with H-3 (δH 2.33) and H-2 
confirming their β configuration. Therefore compound  5 was identified as 2α-acetoxy-
4α-hydroxy-1(10)-guaiadien-12,8β-olide.  
Figure 4. NOESY correlations of 6.  
 
Previously literature concerning 6 did not complete all proton assignments 
(Serkerov and Mir-Babaev, 1988; Adekenov et al., 1990). By measuring 6 in MeOD 
with 1H-NMR, COSY, and NOESY all protons and their relative configuration was 
completed (see experimental) (Figure 4). For 7 it was noted that no 13C-NMR data was 
available (Dzhazin and Adekenov, 1996). Using 13C-APT and HSQC carbon resonances 
for 7 were assigned. Close inspection of previous NMR data regarding 10 (Bohlmann et 
al., 1978; Kim et al., 2004) compared with 1H-NMR, COSY, HMBC, and NOESY 
spectra obtained revealed incorrect assignments of 2H-2 and 2H-6 (Figure 5). 
Furthermore no complete 13C-NMR assignments were found for 10. Therefore the 
corrected proton assignments, relative configuration based on NOESY, and 13C-NMR 




Figure 5. HMBC (C → H) and NOESY correlations of 10. 
 
 
MDR cancer cell lines with P-gp over-expression (NCI-H460/R, DLD1-TxR 
and U87-TxR) have been developed from their sensitive counterparts (NCI-H460, 
DLD1 and U87, respectively) by continuous exposure to increasing concentrations of 
chemotherapeutic drugs (Pešić et al., 2006; Podolski-Renić et al., 2011). COR-L23/R 
cell line is an MDR cancer cell line with MRP1 over-expression originating from 
corresponding sensitive cancer cell line (COR-L23/R). P-gp and MRP1 are ABC-type 
transporters (ATP-dependent drug efflux pumps) for xenobiotic compounds with broad 
substrate specificity. Isolated compounds were screened for their activity against non-
small cell lung carcinoma (NCI-H460 and COR-L23), colorectal adenocarcinoma 
(DLD1), glioblastoma (U87), and their respective MDR cancer cell lines. Initially, 10 
μM of each compound was tested by Sulforhodamine B assay (SRB) (Table 3). 
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Compound 2 was not assayed due to low purity (86%), as determined by HPLC at 230 
nm. All other compounds were > 90% pure (data not shown). Compounds that achieved 
more than 50% inhibition (7-10) on the majority of cell lines after 10 μM application 
were selected for further testing. To compare their effects (the IC50 values) toward 
sensitive (NCI-H460) and MDR (NCI-H460/R) cancer cell lines as well as non-cancer 
cell line (HaCaT), SRB and MTT assays were applied (Table 4). Doxorubicin, a known 
anti-cancer drug, was used as a positive control. The results obtained by MTT and SRB 
assays were similar. Doxorubicin had approximately 100 times weaker activity against 
NCI-H460/R compared to corresponding sensitive NCI-H460 and 3 to 4 times stronger 
activity against NCI-H460 compared to non-cancer cell line – HaCaT. Contrary, no 
selectivity towards NCI-H460, NCI-H460/R or HaCaT was observed for 7-10, 
suggesting that these compounds are generally cytotoxic. In addition, this data suggests 
that sesquiterpene lactones exhibit cytotoxic effects regardless of the presence of P-
gp/MRP1.   
Table 3. The percentage of cell growth inhibition induced by 10 µM (SRB assay) 
Cell Lines 1 3 4 5 6 7 8 9 10 
NCI-H460 25±9 35±5 n 20±5 13±9 32±6 71±15 83±13 81±6 
NCI-H460/R 52±11 5±2 n n no 9±5 47±3 90±9 86±1 
DLD1 14±6 12±5 n n 26±9 25±5 86±4 78±2 87±9 
DLD1-TxR 28±3 40±13 n n 52±5 53±6 87±10 80±7 86±7 
U87 24±6 20±4 10±4 25±10 26±6 67±4 74±6 63±6 66±2 
U87-TxR 36±5 26±2 33±2 21±5 17±4 54±5 68±1 71±5 73±8 
COR-L23 44±8 17±7 n 9±1 58±7 66±10 78±10 74±13 78±6 
COR-L23/R 48±8 15±7 n 9±5 5±3 41±4 59±1 72±3 67±12 





Table 4. The IC50 values (µM) of 7-10 in NCI-H460, NCI-H460/R and HaCaT  
compounds 
NCI-H460* NCI-H460/R** HaCaT*** 
MTT SRB MTT SRB MTT SRB 
7 15.0±0.1 10.6±0.6 20.2±0.5 17.0±0.2 9.3±0.1 16.5±3.3 
8 3.8±0.1 3.6±0.2 15.1±0.4 12.1±0.3 4.1±0.1 5.8±0.2 
9 4.7±0.1 1.9±0.2 3.3±0.3 7.3±0.1 8.3±0.1 9.5±0.8 
10 8.2±0.1 5.7±0.5 4.5±0.1 14.3±0.2 8.0±0.1 19.4±0.1 
dox 0.036±0.001 0.037±0.003 4.42±0.17 2.04±0.05 0.146±0.01 0.09±0.01 
*NCI-H460 were seeded at 1000 cells/well, **NCI-H460/R were seeded at 2000 
cells/well, ***HaCaT were seeded at 4000 cells/well 
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Appendix Chapter 6 
LC-MS  
LC-MS with an Agilent 1100 series HPLC with a G1379A degasser, a 
G1312A binary pump, a G1367A WPALS (automated liquid sampler), a G1315B DAD 
detector, and a G1956 LC/MSD SL single quadropole mass spectrometer equipped with 
an atmospheric pressure chemical ionization probe (APCI) was used for initial mass 
determination. A 150 x 4.6 mm Luna 5 micron C18 (2) 100A column equipped with a 
guard column containing C18 4 x 3 mm cartridges was used for separation 
(Phenomenex Inc, Torrance, California, USA). Gradient elution with a flow of 0.5 
mL/min consisted initially of 80% H2O and 20% ACN which increased to 100% ACN 
in 20 min and remained at 100% ACN for 5 min. The DAD detector was set at 210 and 
254 nm with a UV spectrum scan from 190-390 nm. Mass spectra were acquired in both 
positive and negative mode with a mass range of 50-500 amu and a fragmentor voltage 
of 150. The APCI spray chamber gas temperature was set to 350 °C, a vaporizer 
temperature of 325 °C, a drying gas flow rate of 5 L/min, and a nebulizer pressure of 40 
psig. The VCap was set to 4000 V for positive scans and 3000 V for negative scans 




High resolution mass spectrometry was performed on an LC-LTQ-Orbitrap 
FTMS system, (Thermo Scientific, Waltham, Massachusetts, USA) with an Accela 
HPLC, an Accela photodiode array detector, connected to a LTQ/Orbitrap hybrid mass 
spectrometer equipped with an electrospray (ESI) source. Chromatographic separation 
used a Phenomenex Luna C18(2) analytical column (150 x 2.0 mm, 3 µm particle size). 
Both H2O and acetonitrile contained 0.1 % v/v formic acid, were run at a flow rate of 
0.19 mL/min, and a column temperature of 40 °C. A linear gradient from 5 to 75% 
acetonitrile in 45 min was applied, which was followed by 15 min of washing and 
equilibration. FTMS full scans (m/z 100−1200) were recorded with a resolution of 
60.000, whereas for MSn scans a resolution of 15.000 was used. The FTMS was 
externally calibrated in negative mode using sodium formate clusters in the range m/z 
150-1200 and automatic tuning was performed on m/z 384.93.  
 
Typical NMR parameters 
 
1H-NMR: Solvent CDCl3, Temperature 298.0, Pulse Sequence zg30, 
Experiment 1D, Number of Scans 128, Receiver Gain 181, Relaxation Delay 1.0000, 
Pulse Width 7.3000, Acquisition Time 3.1719, Spectrometer Frequency 500.13, 
Spectral Width 10330.6, Lowest Frequency -2090.8, Nucleus 1H, Acquired Size 32768, 
Spectral Size 65536; 1H-1H COSY: Parameter Value (f2, f1), Solvent CDCl3, 
Temperature 298.0, Pulse Sequence cosygpqf, Experiment COSY, Number of Scans 4, 
Receiver Gain 256, Relaxation Delay 1.4869, Pulse Width 7.3000, Acquisition Time 
0.2048, Spectrometer Frequency (500.13, 500.13), Spectral Width (5000.0, 5000.0), 
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Lowest Frequency (-263.4, -263.2), Nucleus (1H, 1H), Acquired Size (1024, 512), 
Spectral Size (1024, 1024); 13C-APT: Solvent CDCl3, Temperature 298.0, Pulse 
Sequence jmod, Experiment JMOD, Number of Scans 10240, Receiver Gain 23170, 
Relaxation Delay 2.0000, Pulse Width 9.5000, Acquisition Time 1.0912, Spectrometer 
Frequency 125.77, Spectral Width 30030.0, Lowest Frequency -2421.9, Nucleus 13C, 
Acquired Size 32768, Spectral Size 65536; HSQC: Parameter Value (f2, f1), Solvent 
CDCl3, Temperature 298.1, Pulse Sequence hsqcetgp, Experiment HSQC, Number of 
Scans 4, Receiver Gain 20642, Relaxation Delay 1.5000, Pulse Width 7.3000, 
Acquisition Time 0.4096, Spectrometer Frequency (500.13, 125.77), Spectral Width 
(5000.0, 20833.3), Lowest Frequency (-312.0, -1044.5), Nucleus (1H, 13C), Acquired 
Size (2048, 512), Spectral Size (2048, 2048); HMBC: Parameter Value (f2, f1), Solvent 
CDCl3, Temperature 298.0, Pulse Sequence hmbcgplpndqf, Experiment HMBC, 
Number of Scans 4, Receiver Gain 23170, Relaxation Delay 1.5000, Pulse Width 
7.3000, Acquisition Time 0.2925, Spectrometer Frequency (500.13, 125.77), Spectral 
Width (7002.8, 26411.8), Lowest Frequency (-1315.3, -642.0), Nucleus (1H, 13C), 
Acquired Size (2048, 512), Spectral Size (2048, 2048); NOESY: Parameter Value (f2, 
f1), Solvent CDCl3, Temperature 298.0, Pulse Sequence noesygpphpp, Experiment 
NOESY, Number of Scans 4, Receiver Gain 1626, Relaxation Delay 1.5000, Pulse 
Width 7.3000, Acquisition Time 0.2048, Spectrometer Frequency (500.13, 500.13), 
Spectral Width (5000.0, 5000.0), Lowest Frequency (-163.0, -163.5), Nucleus (1H, 1H), 
Acquired Size (1024, 400), Spectral Size (1024, 1024). 
 
Gaillardin (8): white needles; [α]20D -2.1 (c 0.09, CHCl3); APCIMS m/z 307 [M + H]+ 
(35), 305 [M - H]- (5); HRESIMS m/z 307.1543 [M + H]+ (calcd for C17H23O5 
307.15455). 
 
Britannin (9): clear crystals; [α]20D -15.1 (c 0.11, CHCl3); APCIMS m/z 367 [M + H]+ 






Table A1. 1H-NMR and COSY data for compounds 8 and 9 
 8  9 
1H δH (J in Hz) COSY 1H δH (J in Hz) COSY 
  
 1α 1.94, m*  2β 
1β 2.46, br d 2β, 5, 9, 14 
   2β 5.34, m 1, 3α,β 2β 4.9, br dd 1, 3α 
3α 2.03, d (15.4) 3β 3α 2.07, m 2, 3β, 4 
3β 1.93, dd (15.4, 4) 2β, 3α 3β 1.83, m 3α, 4 
  
 4α 4.12, ddd 
(11.5, 8.2, 3.5) 
3α,β, OH 
5α 2.17, td (12.2, 3) 1, 6α,β 
   6α 2.56, m 5, 6β, 7 
   6β 1.41, m 5, 6α, 7 6β 5.06, d (8.3) 7 
7 2.62, m 6α,β 8, 13a,b 7 3.03, m 6, 8, 13a,b 
8 4.5, br d 7, 9, 14 8 4.53, m 7, 9α,β 
9 5.94, br s 1, 8, 14 9α 2.45, m 8, 9β, 10 
  
 9β 1.44, dt  8, 9α, 10 
  
 10β 1.91, m* 9α,β, 14 
13a 6.23, d (3.3) 7 13a 6.17, d (3.5) 7 
13b 5.55, d (3.1) 7 13b 5.37, d (3.2) 7 
14 1.83, br s   14 0.99, d (5.9) 10 
15 1.26, s   15 1.02, s   
Ac 2.11, s   Ac 2.05, s   
  
 Ac 2.25, s   
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Abstract  
 
 Nuclear factor E2-related factor 2 is a transcription factor known to activate 
cytoprotective genes which may be useful in the treatment of neurodegenerative 
disease. In order to better understand the structure activity relationship of phenolic 
diterpenes from Salvia officinalis L., we isolated carnosic acid, carnosol, epirosmanol, 
rosmanol, 12-methoxy-carnosic acid, sageone, and carnosaldehyde using polyamide 
column, centrifugal partition chromatography, and semi-preparative high performance 
liquid chromatography. Isolated compounds were screened in-vitro for their ability to 
active the antioxidant response element and general cellular toxicity using mouse 
primary cortical cultures. All compounds except 12-methoxy-carnosic acid were able to 
activate the antioxidant response element. Rosmanol was able to dose dependently 
activate the antioxidant response element without cellular toxicity at the doses tested 
(12.5, 25, and 50 μM) and thus represents an interesting compound for further studies 
against neurodegenerative disease.  
 




 Ethnobotanical investigations of English herbal texts, Indian Ayurvedic 
medicine, and Chinese traditional medicine report that S. officinalis has memory 
enhancing properties (Perry et al., 1999). Rosmarinus officinalis also has a reputation 
for treatment of nervous system related disorders in European traditional medicine 
(Heinrich et al., 2006). The essential oil of Salvia species including S. officinalis, S. 
fruticosa, and S. lavandulaefolia displays acetylcholinesterase inhibitory activities 
(Savelev et al., 2004), which may explain their effects on memory in healthy volunteers 
(Moss et al., 2010) and mild improvements in cognition shown in a small open labeled 
trial on patients with Alzheimer’s disease (Perry et al., 2003). Extracts of S. officinalis 
have also been shown to improve memory and attention in older (> 65 years of age) 
healthy volunteers (Scholey et al., 2008).  
A number of Salvia species and R. officinalis are well known to produce the 
phenolic diterpenes carnosic acid (1) and carnosol (2) (Abreu et al., 2008). Compounds 
1 and 2 are strong antioxidants possessing anti-microbial, anti-cancer, anti-
inflammatory, and lipid lowering properties (Bonito et al., 2011; Johnson, 2011). 
Recently a number of investigations have demonstrated that these compounds also 
exhibit biological activity which may be useful against neurodegenerative diseases. 
Protective effects of 2 on dopaminergic neuronal cell lines against rotenone induced 
toxicity and sodium nitroprusside toxicity in glial cells have been reported (Kim et al., 
2006; Kim et al., 2010). Carnosic acid protects against glutamate toxicity in primary rat 
cortical cultures and against cerebral ischemia in mice by activating the nuclear factor 
E2-related factor 2 (Nrf2) / Kelch-like ECH-associated protein 1 (Keap1) pathway 
(Satoh et al., 2008a).  
 Nrf2 is a transcription factor known to induce a promoter sequence called the 
antioxidant response element (ARE) which leads to expression of various cytoprotective 
and antioxidant enzymes such as NQO1. Nrf2 localization and degradation is regulated 
by its cytoplasmic repressor protein Keap1. In conditions of oxidative stress or 
disruption by small molecules Nrf2 is freed from Keap1 and enters the nucleus 
activating the ARE (Itoh et al., 2004). Since many neurodegenerative diseases may be 
caused or exacerbated by oxidative stress, activation of the ARE is a potential 
therapeutic strategy (de Vries et al., 2008; Calkins et al., 2009).  
Little information is available on the structure activity relationship of phenolic 
diterpenes for Nrf2/Keap1 activation. Comparisons have been made between 1, 2, and a 
series of alkyl-ester derivatives at carbon 11 and 12 of 1 in HT22 cell lines (Satoh et al., 
2008b; Tamaki et al., 2010). Therefore in order to gain further insights into the structure 
activity of phenolic diterpenes for Nrf2/ARE activation we isolated 1, 2, epirosmanol 
(3), rosmanol (4), 12-methoxy-carnosic acid (5), sageone (6), and carnosaldehyde (7) 
from S. officinalis (Figure 1). Compounds were screened for Nrf2/ARE activation using 
transgenic primary mouse cortical cultures modified to express human placental 
alkaline phosphatase (hPAP) as a reporter gene for ARE.  Potential toxicity of the 




yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) 2H tetrazolium inner salt (MTS) 
assay.      
Figure 1. Chemical structures of 1-7 
 
Materials and Methods 
Plant material 
 Dried aerial parts of Salvia officinalis were purchased from De Groene Luifel 
BV, Sluis, Netherlands. A voucher specimen was deposited in the economic botany 
collection of the National Herbarium Nederland in Leiden under the following barcode: 




Plant material (100 g) was extracted with 2 L acetone for 2 hours to yield 9 g 
crude extract. The extract was extracted 2 times with 100 mL warm hexane and hexane 
solution added to polyamide column (100 g). The column was eluted with additional 
300 mL of hexane to give 2 g hexane fraction and further eluted with 650 mL MeOH to 
give 2 g MeOH fraction.  
CPC 
 The MeOH and hexane fractions were further purified using a Fast Centrifugal 
Partition Chromatograph with a 1 L internal volume rotor (Kromaton Technologies, 
Angers, France). The MeOH fraction was separated by using a two phase solvent 
system composed of 5 L heptane: acetone: H2O (3: 5: 2). The MeOH fraction was 
dissolved in 30 mL 1:1 mixture of upper and lower layers of the solvent system. The 
CPC system was filled with the lower layer and the phase held in place with a rotor 
speed of 1000 rpm while the upper layer was pumped into the CPC at a flow rate of 10 
mL/min in ascending mode. Equilibrium between the layers was reached when the 
upper layer began to elute from the CPC (lower layer displaced = 230 mL), after which 
the sample was immediately injected. After 250 mL of the mobile phase eluted 120 
fractions (10 mL each) were collected. The system was then rinsed with 1 L of the 
remaining lower layer and the eluent collected as an additional rinse fraction. Pressure 
was stable between 63-65 bar throughout the run. The hexane fraction was separated 
using a 2 phase solvent system composed of 2.5: 6: 1.5 heptane: acetone: H2O. All other 
CPC conditions were the same as for the MeOH fraction except the volume of the lower 
layer displaced during equilibration was 260 mL, the pressure 48 bar, and 80 (10 mL) 
fractions were collected. Fractions were analyzed by silica gel TLC (hexane: ethyl 
acetate: acetic acid, 7: 3: 0.1, vanillin/sulfuric acid reagent) and combined based on 
similarity of profile. Combined fractions from CPC experiment on MeOH fraction are 
referred to as CPC-M Fr# and fractions from CPC on hexane fraction as CPC-H Fr#.   
Semi-preparative HPLC 
 Final purification was performed on a Shimadzu semi-preparative HPLC. A 
Luna C18 (2) 100 A 5 micron 250 x 10 mm column was used for separations 
(Phenomenex, Torrance, CA, USA). H2O (A) and MeOH (B) were used as mobile 
phase. Flow rates were 5 mL/min, 10 mL fractions were collected, and UV detector set 
to 230 and 280 nm. Samples were injected manually using a Rheodyne injector 
equipped with a 5 mL injection loop.  
CPC-M Fr40-75 (660 mg) was dissolved in 10 mL 70% aqueous MeOH and run 
twice using gradient from 70% B to 85% B in 60 min. Fractions 5, 8-15, and 18-20 
were separately combined and MeOH removed under reduced pressure at 40 °C. 
Combined fractions were then dissolved in 100 mL H2O and 150 mL EtOAc. The 
EtOAc layer was collected and solvent removed to yield 12.6 mg 2 from fraction 5, 




fraction (242 mg) was purified using gradient from 50% B to 100% B in 120 min. 
Solvent was removed from fractions 7, 9, and 24-25 to yield 2.1 mg 3, 2.6 mg 4, and 
20.3 mg 2 respectively. CPC-H Fr26-40 (164 mg) was dissolved in 5 mL 70% aqueous 
MeOH and run with gradient from 70% B to 100% B in 120 min. Fractions 9-10 yielded 
11.2 mg 6 and fractions 17-18 yielded 5.8 mg 7. CPC-H Fr41-80 (50 mg) was purified 
under the same conditions as Fr26-40 to yield an additional 1.4 mg 6.     
Structure elucidation  
 The structure of isolated compounds was determined by 1H-NMR and COSY 
on a Bruker DMX 500 MHz NMR (Karlsruhe, Germany). An Agilent single quadropole 
mass spectrometer equipped with an atmospheric pressure chemical ionization probe 
(APCI) was used for mass confirmation. A 150 x 4.6 mm Luna 5 micron C18 (2) 100A 
column was used for separation (Phenomenex Inc).  Solvent system was composed of 
MeOH and H2O plus 0.1% formic acid. The flow rate was 0.5 mL/min. Gradient of 70% 
MeOH to 100% MeOH in 20 min with 10 min hold at 100% MeOH was used. Mass 
spectra were acquired in both positive and negative mode with a mass range of 50-500 
amu. APCI spray chamber gas temperature was set to 350 °C, a vaporizer temperature 
of 325 °C, a drying gas flow rate of 5 L/min, and a nebulizer pressure of 40 psig. The 
VCap was set to 4000 V for positive scans and negative scans while the corona current 
was 5 µA for positive scans and 15 µA for negative scans.   
Cell cultures 
 Primary cortical neuronal cultures were derived from ARE-hPAP reporter mice 
as previously described (Johnson et al., 2002; Kraft et al., 2004). In brief cortices from 
E15 mouse pups were pooled in 10 mL ice-cold Ca2+ and Mg2+ free HBSS (Life 
Technologies, Carlsbad, CA, USA). Tissue was then minced, centrifuged, and digested 
in 0.05% trypsin containing no EDTA in HBSS for 15 min at 37 °C. Cells were rinsed 3 
times with HBSS following digestion. Then cells were washed with CEMEM 
(minimum essential media with Earle’s salts); (Life Technologies) 2 mM glutamine, 1% 
penicillin/streptomycin, 10% heat inactivated fetal bovine serum, and 10% horse serum 
(Atlanta Biologicals, Inc., Lawrenceville, Georgia, USA). Cells were triturated to a 
single-cell suspension and strained through a 70 µM cell strainer (BD Biosciences, San 
Jose, California, USA). Cells were counted, assayed for viability using trypan blue, and 
plated on poly-D-lysine coated plates at a density of 3 x 105 cell/cm2. Cells were kept in 
CEMEM for 45 min, after which medium was changed with CEMEM. After two days, 
medium was changed from CEMEM to NBM (Neurobasal media; Life Technologies), 
supplemented with B27 with antioxidants, and 2 mM glutamine. These mixed cultures 
(~ 40% astrocytes and 60% neurons) were incubated at 37 °C in a tri-gas incubator with 
5% O2, 5% CO2, and 90% N2.  
Bioassay 
 After 6 days in culture compounds were dissolved in 100% DMSO (final 
concentration DMSO 0.1%) and administered to cells for 48 hours. After 48 hours, Nrf2 
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activation was determined by measuring for hPAP activity as previously described 
(Kraft et al., 2004). In brief, cells were lysed in TMNC lysis buffer (50 mM Tris, 5 mM 
MgCl2, 100 mM NaCl, 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS)) and freeze-thawed at -20 ºC. To inactivate endogenous 
alkaline phosphatase activity extracts were incubated with 200 mM diethanolamine 
(DEA) buffer at 65 ºC. The hPAP activity was quantified in 200 mM DEA with 0.8 mM 
CSPD ((disodium 3-(4-methoxyspiro (1,2-dioxetane-3,2’-(5’-chloro)tricycle(3.3.1.1 
3,7)decan)-4-yl)phenyl phosphate) (Life technologies), 2x Emerald, and 5 mM MgCl2). 
Using one second intergration luminescence was measured on a Berthold Orion 
microplate luminometer (Berthold Technologies GmbH & Co., Bad Wildbad, 
Germany). Baseline signals from hPAP negative control culture samples (n = 5 for each 
compound) were subtracted from all values. Cell viability was assayed using the MTS 
assay following the manufacturer’s suggested protocol (Promega, Madison, WI, USA).   
Data analysis 
 All data are represented as mean ± SEM (n = 5). Statistical analysis was 
performed using one-way ANOVA followed by Newman-Keuls multiple comparison 
(GraphPad Prism, version 4). A P value < 0.05 was considered statistically significant.  
Results and Discussion  
Isolation 
Phenolic diterpenes 1-7 were isolated from an acetone extract of S. officinalis 
by first partitioning hexane soluble material over polyamide, followed by centrifugal 
partition chromatography, and finally with reverse phased semi-preparative HPLC. 
Isolated compounds were identified by comparison of 1H-NMR with literature, 
confirmed with COSY, and LC-MS (Pukalskas et al., 2005; Cuvelier et al., 1994; Tada 
et al., 1994). Compound 7 is reported in S. officinalis for the first time. All compounds 
were > 95% pure, except 7 (91%) according to HPLC at 230 nm. Detailed structural 
data is available in the appendix.  
Bioassay hPAP 
The hPAP expressing primary cortical cultures used in this study have been 
previously validated as a model system for studying activation of the Nrf2/ARE 
pathway (Johnson et al., 2002). The positive control tert-Butylhydroquinone (tBHQ) 
has been demonstrated to show Nrf2/ARE dependant neuroprotective effects on such 
cultures (Kraft et al., 2004). Results of hPAP assays are expressed as the fold increase 
in hPAP activity over basal levels (Figure 2). The entire hPAP and MTS assay were 
performed twice with two separate batches of primary cortical cultures in order to 
understand batch to batch variation in activity. In general the trend in hPAP activity was 
the same between batches. However in the first batch cells appeared more responsive 
towards hPAP activation compared with the second batch. This observation could be the 




Figure 2. Fold activation of hPAP levels (compounds 1-7). Top first batch, bottom 
second batch. 
 
Compounds 2 and 7 were the most potent activators in both hPAP assays 
(Figure 2). In the first assay, 2 at 25 μM showed > 100 fold increase in hPAP activity 
and in the second assay at 50 μM > 100 fold increase. Compound 7 had similar levels of 
hPAP activity at 12.5 and 25 μM. A sharp decrease in hPAP activity was observed at 50 
μM for 2 and 7 in the first experiment. Due to poor stability of 7 we were unable to 
assay this compound in the second batch of cultures. Compound 4 had a similar pattern 
of hPAP activation as the positive control, tBHQ in both assays. Compounds 1 and 3 
had similar and weak patterns of hPAP activation while 5 and 6 were inactive.   
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Results from the MTS assay are expressed as % cell viability (Figure 3). 
Significant decrease in cell viability < 100% indicates cellular toxicity while > 100% 
indicates cell proliferation. Compounds 6 and 7 showed dose dependent decreases in 
cell viability in the first assay. In the second hPAP and MTS assay 6 was tested at lower 
doses, 3.13 and 6.25 μM. Although toxicity went away no significant hPAP activity was 
observed. Compound 2 caused a significant decrease in cell viability to 48% at 50 μM 
in the first culture batch (Figure 3). The sharp decreases in hPAP activity observed in 
compounds 2 and 7 at 50 μM in the first batch of cultures are explained by the MTS 




viability were observed at 25 and 50 μM of 1 in the second batch while a non-
significant decrease in viability (94%) at 50 μM was observed in the first batch. 
Therefore 1 and 2 at lower doses tended to increase or have no effect on cell 
proliferation while at higher doses decrease cell proliferation or cause toxicity. 
Compounds 6 and 7 were generally cytotoxic according to MTS results. Both the 
positive control tBHQ and 4 consistently had significant > 100% cell viability which 
tended to increase with dosage suggesting the compounds were inducing cell 
proliferation. Compound 3 was non-toxic in both assays and induced a strong increase 
in cell viability which decreased at higher doses in the first assay. This effect was not 
observed in the second assay for 3. The hPAP inactive compound 5 had a similar 
pattern of activity as 3 in the MTS assay either dose dependently decreasing cell 
proliferation or having no effect on cell viability. 
Structure activity relationship 
 Previous studies suggested that the mechanism of action of 1 to activate the 
Nrf2/ARE pathway was due to the catechol moiety initially acting as an antioxidant 
against reactive oxygen species. Upon oxidation 1 converts into an ortho quinone whose 
C-14 position can act as an electrophile, reacting with biological thiols such as the 
cysteine residues of Keap1 thus activating Nrf2 (Satoh et al., 2008a). Another study 
demonstrated that ester derivatives at both the C-11 and C-12 eliminated activity of 1 
(Satoh et al., 2008b). In our experiments a methoxy group at position 12 as in 5 
eliminated activity in the hPAP assay, confirming the importance of the catechol moiety 
for Nrf2/ARE activation. The lack of hPAP activity of 6 could be due to conjugation of 
the aromatic ring with the 1-carbonyl-5,10-diene functionality which would likely alter 
the oxidative products formed.  
Replacement of the carboxylic acid functionality in 1 with an aldehyde as in 7 
caused a dramatic increase in hPAP activity although this was accompanied by dose 
dependent loss in cell viability. Carnosol and 4 were also much more active than 1 in 
the hPAP assay. Compound 3, a stereoisomer of 4, had weaker activity suggesting that 
the stereochemistry of the hydroxyl group at position 7 is important. Together these 
results suggest that an electronegative functionality at the C-7 position can increase 
Nrf2/ARE activation compared to 1. However, depending on the functionality it can 
either increase cell proliferation with higher doses as in 4 or decrease cell viability with 
higher doses as in 2. It has been reported that 1 can induce nerve growth factor in 
human astrocytes and glioblastoma cells regulated by Nrf2 which may explain the 
potential increases in cell proliferation observed in our experiments (Mimura et al., 
2011; Yoshida et al., 2011). A previous comparison of Nrf2/ARE mediated 
neuroprotection between 1 and 2 in HT22 cells demonstrated more potent activity of 1 
compared with 2 (Satoh et al., 2008b). The differences in results are most likely due to 
differences in the cellular models used. Primary cortical cultures contain a mixture of 
astrocytes and neurons which are known to display differing patterns of Nrf2/ARE 
activation (Kraft et al., 2004). Immortalized neuronal cell lines such as HT22 may 





 In conclusion phenolic diterpenes isolated from S. officinalis can activate the 
Nrf/ARE pathway in mouse primary cortical cultures with varied potency. The balance 
between loss of cell viability and Nrf/ARE activation needs to be carefully considered 
when studying these compounds as drugs against neurodegenerative diseases. 
Compounds 1, 2, and 7 had a narrow window between doses that activated Nrf/ARE 
and doses that reduced cell viability. In contrast 4 showed dose dependent increases in 
Nrf2/ARE activity accompanied by dose dependent increases in cellular proliferation up 
to 50 μM. These results suggest that 4 is a compound worth further exploration as an 
agent against neurodegeneration. Finally our results in comparison with literature 
suggest that different cellular models of Nrf2/ARE activity may lead to different results. 
Therefore future studies should aim to test a range of active phenolic diterpenes in a 
variety of models used to study Nrf2/ARE mediated neuroprotection both in vitro and in 
vivo.  
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Appendix Chapter 7 
 
Table A1. 1H-NMR data [δH (J, Hz)] CDCl3 500 MHz (compounds 1, 5, 7) 
1H carnosic acid 12-methoxy-carnosic acid carnosaldehyde 
1α 1.25-1.3 m 1.23 m 1.13 m 
1β 3.31 dt (3.6, 13.8) 3.56 m 3.22 m 
2α 1.76 dddd (3.5, 8.7, 
13.5, 17.1) 
2.19 qt (4.5, 14.6) 1.48-1.59* m 
2β 1.49 br d (13.3) 1.59 m 1.48-1.59* m 
3α 1.57-1.65 m 1.54 m 1.15-1.36* m 
3β 1.3-1.36 m 1.30 m 1.15-1.36* m 
5 
1.59 dd (1.7, 12.7) 
1.56 m 1.62 dd (1.7, 
12.7) 
6α 1.88 m 1.85 m 2.03 m 
6β 2.34 tdd (7.0, 10.8, 
12.9) 
2.28 tdd (6.5, 11.1, 12.9) 1.86 tt (8.7, 13.2) 
7α 2.83 m 2.84 m 2.87 dd (3.6, 8.5) 
7β 2.83 m 2.84 m 2.87 dd (3.6, 8.5) 
14 6.57 s 6.53 s 6.60 s 
15 3.19 hept (6.9) 3.17 hept (6.9) 3.23 m 
16 
1.21 d (6.9) 
1.21 d (6.9) 1.21 d (6.9) 
17 
1.22 d (6.9) 
1.21 d (6.9) 1.21 d (6.9) 
18 1.01 s 0.98 s 1.04 s 
19 0.92 s 0.89 s 0.9 s 
20 
 
 9.9 d (1.5) 
OH ~7.09 br s 
 
7.13 s 
OH ~5.71 br s ~6.11 br s 5.78 s 
O-Me 
 
3.73 s  








2 2.69 t (7) 
3 1.94 t (7) 
6 2.39 dd (5.9, 8.1) 
7 2.54 dd (5.9, 8) 
14 6.58 s 
15 3.29 hept (6.9) 
16 1.24 d (6.9) 
17 1.24 d (6.9) 
18 1.27 s 
19 1.27 s 
OH 9.44 s 
OH 6.16 s 
 
Table A3. LC-MS data, APCI ion (percent abundance) 
compound APCI positive [M+H] APCI negative [M-H] 
carnosic acid not detected 331 (100) 
carnosol 331 (80) 329 (100) 
epirosmanol 347 (10) 345 (100) 
rosmanol 347 (10) 345 (100) 
12-methoxy-carnosic acid not detected 345 (100) 
sageone 301 (100) 299 (100) 
carnosaldehyde 317 (55) 315 (100) 
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Table A4. 1H-NMR data [δH (J, Hz)] MeOD 500 MHz (compounds 2-4) 
1H 
carnosol epirosmanol rosmanol 
1α 2.81 br dd (1.4, 14.3) 2.78 br d (14.3) 1.97 td (5.3, 14.1) 
1β 2.57 td (4.4, 14) 2.57 td (4.4, 14) 3.30 * 
2α 1.9 m 1.85 dtd (3.1, 10.8, 13.8) 1.62 m 
2β 1.6 ddt (3.3, 7.2, 13.8) 1.6 m 1.52 m 
3α 1.52 br dd (1.2, 13.1) 1.49 br d (13.2) 1.26 m 
3β 1.32 td (3.3, 13.6) 1.32 dt (6.9, 13.6) 1.45 m 
5 1.7 dd (5.7, 10.7) 1.38 d (4.1) 2.26 s 
6α 1.85 m 4.3 dd (4.2, 4.3) 4.52 d (3.3) 
6β 2.19 m 
 
 
7α 5.42 br d (2.9) 5.13 d (4.5)  
7β  
 
4.59 d (3.3) 
14 6.69 s 6.77 s 6.84 s 
15 3.24 hept* 3.26 hept* 3.22 hept (7.1) 
16 1.20 d (6.2) 1.22 d (6.1) 1.22 d (6.9) 
17 1.19 d (6.5) 1.21 d (6.5) 1.19 d(6.9) 
18 0.88 s 1.03 s 1.03 s 
19 0.87 s 0.91 s 0.91 s 
OH ~7.87 br   
OH ~4.57 br   







































Conclusions and Future Perspectives 
 
Throughout this thesis numerous aspects of terpenoid chemistry as it relates to 
medicine were explored. In chapter 2 Lavandula angustifolia, Thymus vulgaris, 
Matricaria recutita, Salvia officinalis, Eucalyptus globulus, and Melissa officinalis were 
tested in the Volcano vaporizer. These results confirmed that the vaporizer is capable of 
volatilizing the main essential oil components from L. angustifolia, T. vulgaris, M. 
recutita, and S. officinalis in a reproducible manner. Plants producing essential oils in 
secretory cavities such as E. globulus and those containing low amounts of essential oils 
such as the batches of M. officinalis used in the study are not useful to administer in the 
vaporizer. However, vaporizers such as the Volcano contain a wire-mesh which allows 
pure terpenoids or essential oils to be used in the device and heated in the same manner 
as with plant material. Therefore such devices allow many possibilities for designing 
clinical protocols. This could improve study design when assessing potential therapeutic 
effects of essential oil bearing plants.  
 
A more detailed analysis of the vaporizer was performed in chapter 3 using 
Cannabis sativa (cannabis) as a model plant. The cannabis vapor produced by the 
Volcano did not contain pyrolytic degradation products found in cannabis smoke 
confirming that the vaporizing is a safer administration method. Furthermore the in-
vitro CB1 binding of ∆9-THC was not altered by impurities found in the vapor, smoke, 
or between the strains. Any additional potential biological effects of other components 
in cannabis besides ∆9-THC would be difficult or impossible to study in-vitro. The 
question of whether or not herbal cannabis contains more active ingredients than ∆9-
THC is still an ongoing discussion (Russo, 2011). This question of multiple active 
ingredients, which is a common question when studying a herbal drug, can only truly be 
answered with properly designed clinical trials in humans using standardized and 
chemically defined plant sources.  
  
 In chapter 4, cannabis was used as a model plant to determine if the chemical 
profile could distinguish different varieties. A targeted metabolic profiling approach 
was developed and validated to chemically classify 11 cannabis varieties according to 
the terpenoid and cannabinoid content. Indeed the results demonstrated that cannabis 
varieties can be distinguished based on cannabinoid and terpenoid profiles. Interestingly 
cannabis varieties with similar levels of ∆9-THC could be differentiated based on mono 
and sesquiterpenoid content. Cannabis varieties of the same genotype, grown in 
multiple batches under the same environmental conditions had reproducible chemical 
profiles. Although alterations in growth period (number of days vegetative or flowering) 
seemed to increase quantitative differences in a variety’s profile, the differences were 
minor and qualitatively they were the same. These results would be expected if 
terpenoid and cannabinoid production in cannabis is genetically regulated and 




Figure 1. PCA plot (top) and loading plot (bottom) from Hazekamp and Fischedick, 
2012 reprinted with permission. Amnesia samples represented as black triangles, white 
widow samples as black circles.  
 
 
The approach outlined in chapter 4 for analyzing cannabis was extended to 
evaluate two common cannabis varieties sold in Dutch coffeeshops, known as ‘white 
widow’ and ‘amnesia’. In this study two 1 gram samples of each variety purchased in 2 
separate visits to each coffeeshop (10 coffeeshops total) spread throughout the 
Netherlands were obtained. By analyzing quantitative data for the terpenoid and 




BV were clearly distinguished from each other by PCA (Figure 1). These results again 
demonstrated that cannabis varieties containing similar ∆9-THC levels could be 
distinguished by terpenoid profile (Hazekamp and Fischedick, 2012).  
 
Overall the results from chapters 3 and 4 demonstrate that it is possible to 
standardize a plant producing volatile terpenoids and its administration form. Although 
cannabis was chosen as a model example due to its complex chemical profile and 
ongoing clinical research it is in theory possible to take such an approach with any plant 
or herbal product as long as certain criteria can be met. These criteria include: 
 
1. Standardization of the plant source material or extract 
2. Appropriate chemical characterization of the product 
3. Standardization of the plant or extracts administration form  
 
Standardization of plant material would be more difficult with plants that 
cannot be cultivated or propagated asexually. In these cases homogenization of the used 
plant material or production of standardized extracts would be an alternative. Obviously 
if an herbal drug is administered as a tea or eaten whole as opposed to inhaled, chemical 
characterization should utilize an appropriate analytical method such as NMR or HPLC 
to standardize the procedure. If cannabis is used as an example the following clinical 
protocol could be envisioned; as treatments two or more cannabis varieties with unique 
chemical profiles, the isolated essential oil of each variety, equivalent doses of ∆9-THC 
as a positive control, and a negative control with no drugs. Administered to humans 
with a relevant illness one could then conclusively address the question over whether 
herbal cannabis is more or less therapeutically effective compared with pure ∆9-THC for 
that particular illness.  
 
The second half of this thesis (chapters 5-7) focused on sesquiterpene lactones 
and phenolic diterpenoids as lead compounds for drug development. In chapter 5, 
eleven sesquiterpene lactones from Tanacetum parthenium were screened for their 
ability to activate the Nrf2/ARE pathway in mouse primary cortical cultures. The 
structure activity relationship of the compounds confirms the importance of the α-
methylene-γ-lactone moiety for activity. Although the data also suggests that other 
functional groups and the shape or flexibility of the molecule contribute to the activity 
as well. This observation is consistent with literature concerning the structure activity 
relationship of sesquiterpene lactones and cytotoxicity (Ghantous et al., 2010). The 
considerable toxicity of sesquiterpene lactones on primary cortical cultures in-vitro as 
well as available toxicity information in the literature demonstrates that further research 
is needed to assess the toxicity and selectivity of these compounds in-vivo.  
 
In chapter 6, the structure of 5 new sesquiterpene lactones is described along 
with the structure of 5 known sesquiterpene lactones isolated from Inula britannica. 
Screening the compounds on cancer cell lines, multi-drug resistant cancer cell lines, and 
human keratinocytes demonstrated again that biological activity was mainly dependent 
on the presence of α-methylene-γ-lactone moiety. Although no strong trends in 
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selectivity against any of the cell lines were observed the sesquiterpene lactones were 
capable of inhibiting drug resistant cancer cell lines. One of the main complications of 
cancer treatment is the development of resistance of cancer cells to the 
chemotherapeutic agents. Drugs such as taxol can induce cancer cells to overexpress 
membrane transporter permeability-glycoprotein-1 which increases the cells ability to 
pump out the drug and or inhibit its uptake (Podolski-Renić et al., 2011). There is 
evidence that constitutive activation of NF-κB contributes to resistance of cancer cell 
lines against anti-cancer drugs (Sethi et al., 2012). Inhibition of NF-κB by parthenolide 
was demonstrated as a mechanism by which parthenolide was able to potentiate the 
ability of taxol to induce cell death in lung cancer both in-vitro and in-vivo (Zhang et 
al., 2009). Therefore the relationship between the mechanisms by which anti-cancer 
drugs induce resistance in cancer cells and the mechanisms by which sesquiterpene 
lactones may be able to prevent or reverse this process is a promising area for further 
research.  
 
Figure 2. Dimethylamino-parthenolide. 
 
 
It is important to realize that for over 40 years it has been known that the 
cytotoxic activity of sesquiterpene lactones is often dependent on the α-methylene-γ-
lactone moiety (Kupchan et al., 1971). Furthermore, no sesquiterpene lactones with the 
α-methylene-γ-lactone moiety have been approved as drugs to date. This is likely due to 
their lack of selective biological activity and toxicity concerns. In fact as mentioned in 
chapter 1 sesquiterpene lactones that do not contain the α-methylene-γ-lactone, yet 
contain other functional groups such as ester side chains or an endoperoxide moiety, 
such as thapsigargin and artemisinin respectively, are actively being investigated as 
anticancer drugs. Parthenolide, which shows promising antitumor activity in-vivo, 
suffers from poor pharmacokinetic properties such as low water solubility and poor 
bioavailability. In order to overcome this problem analogues of parthenolide have been 
synthesized, such as dimethylamino-parthenolide which shows improved 
pharmacokinetic properties and maintains antitumor activity in-vivo (Figure 2) 
(Shanmugam et al., 2011).  
 
For these reasons future research into sesquiterpene lactones should avoid 




this thesis will continue to hinder drug development of these compounds. Bioactivity 
guided fractionation into plant families that often contain sesquiterpene lactones, such 
as the Asteraceae, may be biased towards sesquiterpene lactones due to the reactivity of 
the α-methylene-γ-lactone moiety. Researchers analyzing plant families rich in 
sesquiterpene lactones should aim early on in a bioactivity guided fractionation study to 
determine if they are present in a plant extract. Column material with active thiols or 
addition of biological thiols such as cysteine to the extract could potentially be used to 
remove or inactivate the α-methylene-γ-lactone moiety. This would make it easier for 
researchers to better assess if other components in the plant material have biological 
activity. Another area of future research is to chemically modify sesquiterpene lactones 
that have other interesting functional groups. For example tanaparthin-β-peroxide 
isolated in chapter 5 contains an endoperoxide moiety. Tanaparthin-β-peroxide was 
shown to potently activate the Nrf2/ARE pathway in mouse primary cortical cultures, 
but it was also toxic. Perhaps chemically reducing or modifying the α-methylene group 
would lead to a compound with more selective biological activity. Unfortunately the T. 
parthenium used in this study only produced low levels of tanaparthin- β-peroxide 
making such synthetic studies difficult. However, it has been reported that certain 
chemotypes of T. parthenium produce much larger amounts of tanaparthin peroxides 
(Begley et al., 1989).  
 
In chapter 7, seven phenolic diterpenoids isolated from S. officinalis were 
screened for their ability to activate the Nrf2/ARE pathway in mouse primary cortical 
cultures. The catechol moiety was demonstrated as being necessary for activation of the 
pathway. Carnosaldehyde and sageone were toxic towards the cultures indicating 
structural features that are not desirable such as presence of an aldehyde at C-20 
position. The presence of a functional group at the C-7 position also had an influence on 
activity, increasing hPAP activation in the case of carnosol and rosmanol when 
compared to carnosic acid. However further experiments are needed to determine which 
phenolic diterpenoids represent the most promising candidates for drug development. 
These experiments include determining if phenolic diterpenes are actually increasing 
cortical cell proliferation or if the MTS assay is giving false positives. Furthermore a 
direct demonstration of neuroprotection from the most promising compounds in our 
initial screening, carnosol and rosmanol, should be performed in both in-vitro and in-
vivo experiments. At the time of this writing the follow up in-vitro experiments are 
being performed. 
 
Finally many other Salvia species contain abietane diterpenoids with catechol 
moieties. Some examples include 16-hydroxycarnosic acid from S. apiana (Dentali and 
Hoffmann, 1990), euphraticol from S. euphratica (Ulubelen, 1989), and 
demethylcryptojaponol from S. phlomoides (Hueso-Rodríguez et al., 1983) (Figure 3). 
Another group of diterpenoids found in Salvia species that contain catechol moieties are 
the icetexanes, which include brussonol from S. broussonetii and przewalskin C from S. 
przewalskii (Figure 4) (Simmons and Sarpong, 2009). Future research should aim to 
investigate these and related compounds as potential neuroprotective agents as well. As 
discussed in previous chapters much of the research performed with Salvia species has 
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focused on the essential oil due to acetylcholinesterase inhibitory activity. Perhaps the 
phenolic diterpenoids in Salvia species may be essential for truly understanding the 
potential memory enhancing and neuroprotective effects of this valuable medicinal 
plant.  
 
Figure 3. Abietane diterpenoids from Salvia species. 
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The purpose of this thesis was to investigate aspects of terpenoid chemistry 
relevant to medicine. Specifically, to test vaporizing as a viable administration form for 
volatile terpenoids, to determine if the chemical profile of Cannabis sativa volatiles is 
useful for chemotaxonomy and reproducible, and to screen sesquiterpene lactones and 
phenolic diterpenes as drug leads. In chapter 2 the gas chromatographic analysis of the 
vapor’s produced by the volcano vaporizing device from Lavandula angustifolia, 
Thymus vulgaris, Matricaria recutita, Salvia officinalis, Eucalyptus globulus, and 
Melissa officinalis plant material is described. Lavandula. angustifolia, T. vulgaris, M. 
recutita, and S. officinalis vapor contained >0.1 mg/g of major essential oil components 
which increased in concentration with increased temperature. Chapter 3 compared the 
vapor, smoke, and ethanol extracts with gas chromatography of three medicinal 
cannabis varieties produced by Bedrocan BV. The varieties Bedrocan, Bedrobinol, and 
Bediol produced cannabinoids and mono-terpenoids as major components of their 
smoke and vapor. Pyrolytic breakdown products were detected in cannabis smoke while 
none were observed in the vapor. No statistically significant differences in CB1 binding 
affinity in-vitro between pure ∆9-THC, smoke, and vapor were observed at equivalent 
concentrations of ∆9-THC.  
 
In chapter 4 a quantitative gas chromatography flame ionization detection 
method is described as well as its validation for analysis of cannabis monoterpenoids, 
sesquiterpenoids, and cannabinoids. The method was used to quantitatively analyze 11 
cannabis varieties. In total 36 compounds were quantified in the 11 varieties and multi-
variant data analysis was used to analyze the quantitative data. By using principal 
component analysis the cannabis varieties could be chemically distinguished from each 
other. Furthermore, a number of the cannabis varieties were grown in multiple batches 
to test the reproducibility of the volatile chemical profile. Cannabis varieties that were 
grown under the same environmental conditions and were of the same genetic stock had 
a reproducible chemical profiles. Minor deviations in growth period had minor effects 
on the quantitative levels of volatile compounds.    
 
 Chapters 5 and 6 focused on the isolation, structure elucidation, and 
bioactivity screening of sesquiterpene lactones from Tanacetum parthenium and Inula 
britannica respectively. Centrifugal partition chromatography was used as the main 
fractionation technique. Solvent systems composed of heptane: ethyl acetate: methanol: 
and water proved effective in separating sesquiterpene lactones from both plants. From 
T. parthenium, 11 sesquiterpenes were isolated and identified by NMR and high 
resolution mass spectrometry. These compounds were screened in-vitro on mouse 
primary cortical cultures for the ability to activate the Nrf2 pathway. Sesquiterpene 
lactones with the α-methylene-γ-lactone moiety were able to activate the Nrf2 pathway 
however they were also toxic towards the cultures. From I. britannica, 10 sesquiterpene 
lactones were isolated and identified by NMR, high resolution mass spectrometry, and 
infrared spectroscopy. Five of these compounds were never reported previously. 
Isolated compounds were screened for cytotoxic activity in-vitro on human cancer cell 
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lines, their derived multi-drug resistant cell lines, and normal human keratinocytes. 
Cytotoxic activity was generally mild, in the micromolar range, and the activity was 
similar between the different cell types.  
 
 In chapter 7 the isolation of phenolic diterpenoids from Salvia officinalis is 
reported. In total 7 compounds were isolated with polyamide and centrifugal partition 
chromatography as the main fractionation methods. Carnosic acid, carnosol, 
epirosmanol, rosmanol, 12-methoxy-carnosic acid, sageone, and carnosaldehyde were 
identified by NMR and mass spectrometry. Isolated compounds were screened in-vitro 
on mouse primary cortical cultures for the ability to activate the Nrf2 pathway. Carnosic 
acid, carnosol, epirosmanol, and rosmanol were able to activate the Nrf2 pathway with 
minimal or no observed toxicity. 12-Methoxy-carnosic acid was inactive while sageone 
was inactive and toxic. Carnosaldehyde was active but toxic.  
 
 The conclusions and future perspectives of this thesis are discussed in detail in 
chapter 8. The main conclusions are that vaporizing is a promising administration form 
for volatile terpenoids. The volatile chemical profile of cannabis can be used for 
discriminating between varieties and that if grown under controlled conditions the 
chemical profile cannabis is reproducible. Sesquiterpene lactones display many 
biological activities however they often lack the specificity and are generally cytotoxic 
due to the reactive α-methylene-γ-lactone moiety. Finally, carnosic acid, carnosol, and 
rosmanol from S. officinalis represent interesting lead compounds for development as 







Het doel van dit proefschrift was onderzoek te doen naar biochemische 
aspecten van terpenen die relevant zijn voor de medicinale toepassing en ontwikkeling 
van deze stoffen. 
Meer in het bijzonder richtte het onderzoek zich op verdampen als efficiente 
toedieningsvorm van vluchtige terpenen, op het analyseren van het terpeen profiel van 
Cannabis sativa als methode voor chemotaxonomie en kwaliteitscontrole, en tenslotte 
op het screenen van sesquiterpeen-lactonen en fenolische diterpenen als leads voor 
nieuwe medicijnen. 
 
In hoofdstuk 2 wordt beschreven hoe de vluchtige stoffen van de 
plantensoorten Lavandula angustifolia, Thymus vulgaris, Matricaria recutita, Salvia 
officinalis, Eucalyptus globulus, en Melissa officinalis werden vrijgemaakt met behulp 
van de Volcano® verdamper, en geanalyseerd door middel van gas chromatografie 
(GC). Damp afkomstig van L. angustifolia, T. vulgaris, M. recutita, en S. Officinalis 
bevatte > 0.1 mg terpeen componenten per gram plant materiaal, en deze hoeveelheid 
nam toe bij toenemende verdamptemperatuur. 
 
In hoofdstuk 3 worden de damp, (verbrandings)rook, en ethanol extracten van 
drie verschillende typen medicinale cannabis, geproduceerd door Bedrocan BV, met 
elkaar vergeleken op basis van GC analyse. Cannabinoiden en monoterpenen waren 
hoofdbestanddelen in de rook en damp van alle drie de geanalyseerde cannabis 
varietëiten ‘Bedrocan’, ‘Bedrobinol’ en ‘Bediol’. Pyrolitische afbraakproducten waren 
wel detecteerbaar in cannabis rook na verbranding, maar niet in de onderzochte damp. 
In een daaropvolgende in vitro assay voor bindingsaffiniteit voor de CB1 receptor werd 
geen significant verschil gevonden tussen zuivere THC, en rook of damp afkomstig van 
cannabis met een equivalente concentratie aan THC. 
 
In hoofdstuk 4 wordt een kwantitatieve GC-FID methode beschreven en 
validatie voor de analyse van Cannabis monoterpenen, diterpenen en cannabinoiden. De 
ontwikkelde methode werd vervolgens gebruikt voor de analyse van 11 verschillende 
cannabis variëteiten. Hierbij werden in totaal 36 verschillende componenten 
gekwantificeerd, waarna de data werd geanalyseerd met behulp van multi-variate 
analyse software. Door toepassing van Principle Component Analysis (PCA) konden de 
verschillende variëteiten tenslotte efficient van elkaar worden onderscheiden op basis 
van hun chemisch profiel. Een aantal van de bestudeerde variëteiten werden bovendien 
geteeld in meerdere batches, met als doel om de reproduceerbaarheid van het 
terpeenprofiel tijdens de teelt vast te kunnen stellen. Cannabis variëteiten die werden 
gekweekt onder gelijke kweekomstandigheden en die afkomstig waren van dezelfde 
genetische basis vertoonden inderdaad een reproduceerbaar en herkenbaar chemisch 
profiel. Kleine afwijkingen in de teeltomstandigheden bleken geen significante invloed 




Hoofdstukken 5 en 6 richten zich op de isolatie, structuuropheldering en 
bioactiviteitscreening van sesquiterpeen lactonen afkomstig van Tanacetum parthenium 
and Inula britannica. Centrifugale partitie chromatografie (CPC) werd daarbij gebruikt 
als de belangrijkste methode van fractioneren. Oplosmiddelsystemen bestaande uit 
specifieke mengsels van heptaan, ethylacetaat, methanol en water toonden zich daarbij 
het beste voor de scheiding van sesquiterpeen lactonen van beide plantensoorten. Uit T. 
Parthenium konden 11 sesquiterpenen worden geïsoleerd, en vervolgens geïdentificeerd 
door middel van NMR en hoge resolutie massaspectrometrie. Deze stoffen werden in 
vitro gescreend in muis primary cortical cultures op hun vermogen om de Nrf2 pathway 
te aktiveren. Sesquiterpeen lactonen met een α-methylene-γ-lacton structuur toonden 
een interessante activiteit, maar bleken tevens toxisch te zijn voor de gebruikte 
celcultures. Uit I. Britannica werden 10 sesquiterpeen lactonen geïsoleerd en 
geïdentificeerd met behulp van NMR, hoge resolutie massaspectrometrie en infrarood 
spectrometrie. Vijf van deze stoffen bleken nooit eerder gerapporteerd. De geïsoleerde 
verbindingen werden gescreend voor cytotoxische activiteit in vitro op humane 
kankercellijnen, daarvan afgeleide multi-drug resistente cellijnen, en op normale 
humane keratinocyten. De gevonden cytotoxische aktiviteiten waren over het algemeen 
beperkt, in de micromolair range, en de relatieve activiteit was vergelijkbaar tussen de 
verschillende cellijnen. 
 
In hoofdstuk 7 wordt de isolatie van fenolische diterpenen uit Salvia 
officinalis beschreven. In totaal konden 7 verschillende verbindingen worden geïsoleerd 
met polyamide kolom chromatografie en CPC als belangrijkste methoden van 
fractioneren. Carnosic acid, carnosol, epirosmanol, rosmanol, 12-methoxy-carnosic 
acid, sageone, en carnosaldehyde konden worden geïdentificeerd door middel van NMR 
en massa spectrometrie. De geïsoleerde verbindingen werden in vitro gescreend in muis 
primary cortical cultures op hun vermogen om de Nrf2 pathway te aktiveren. Carnosic 
zuur, carnosol, epirosmanol, en rosmanol toonden zich hierbij aktief met minimale of 
geen toxische werking op de cellen. 12-Methoxy-carnosic zuur en sageone waren niet 
aktief, en sageone was bovendien toxisch. Carnosaldehyde was actief maar toxisch. 
 
De conclusies en perspectieven van dit proefschrift worden in detail besproken 
in hoofdstuk 8. Enkele van de belangrijkste conclusies daarbij zijn; dat verdampen een 
veelbelovende methode is voor het (medicinaal) toedienen van vluchtige terpenen; dat 
het terpeen profiel van cannabis kan worden benut voor het onderscheiden van 
verschillende variëteiten en dat gestandaardiseerde teelt van cannabis resulteert in een 
reproduceerbaar terpeen profiel; dat sesquiterpeen lactonen met een α-methylene-γ-
lacton structuur verschillende interessante biologische aktiviteiten vertonen, maar dat ze 
vaak te weinig specifiek zijn en tegelijkertijd te toxisch zijn; en tenslotte dat carnosic 
zuur, carnosol, en rosmanol uit S. Officinalis interessante stoffen zijn voor het 
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